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Cryopreservation of pancreatic islets
Nikola Doležalová
Pancreatic islet transplantation is a curative treatment for diabetes but access to this
therapy is limited by the availability of islets. Long-term cryopreservation of islets could
partially address this limitation but current cryopreservation protocols, which use the toxic
cryoprotectant dimethyl sulphoxide (DMSO), achieve suboptimal cryosurvival and are not
clinically used. The aim of this project was to develop an improved and clinically-relevant
method for cryopreservation of islets. The project examined the efficacy of the non-toxic
cryoprotectant trehalose in combination with (1) membrane-permeabilising biopolymers
PP-50 and PP-75 to increase intracellular uptake, and (2) antioxidants MitoQ and salidroside
to reduce cryopreservation-induced oxidative stress.
Due to the complex architecture of pancreatic islets, human mononuclear cells were
first used to optimise the use of permeabilising polymers. Current methods of viability
assessment were critically examined and improved, followed by systematic screening of
cryopreservation conditions. The efficacy of promising cryopreservation protocols were
subsequently confirmed for mouse pancreatic islets using viability and functional assays.
PP-50 and PP-75 polymers were shown to be unsuitable for trehalose-based cryopreser-
vation of mononuclear cells and islets due to potential toxicity and need for long incubation.
Investigation of diffusion kinetics demonstrated that a minimal incubation time of 6 h at 37 °C
is required to enable diffusion of solutes into the islet core. This finding implies that current
clinical viability assessment protocols only survey the periphery of islets. A range of imaging
modalities were used to confirm that islet core viability can be dramatically different from
the islet periphery. Using these insights, a novel cryopreservation protocol was developed in
which islets are pre-incubated for 6 h at 37 °C with trehalose and antioxidants, followed by
addition of DMSO, resulting in significantly greater viability of cryopreserved islets.
In conclusion, this study identified important limitations of the current cryobiological
viability assessment of mononuclear cells and pancreatic islets. Permeabilising biopolymers
did not improve trehalose-based cryopreservation in primary cells. An improved method for
cryopreservation of pancreatic islets was developed which combines DMSO and trehalose in
a novel manner and can be further improved by addition of antioxidants.
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Pancreatic islet transplantation is a curative treatment for diabetes but access to this therapy
is limited by the availability of islets. Long-term cryopreservation of islets could partially
address this limitation but current cryopreservation protocols, which use the toxic cryopro-
tectant dimethyl sulphoxide (DMSO), achieve suboptimal cryosurvival and are not clinically
used. The aim of this project was to develop an improved and clinically-relevant method for
cryopreservation of islets. The project examined the efficacy of the non-toxic cryoprotec-
tant trehalose in combination with (1) membrane-permeabilising biopolymers PP-50 and
PP-75 to increase intracellular uptake, and (2) antioxidants MitoQ and salidroside to reduce
cryopreservation-induced oxidative stress.
Due to the complex architecture of pancreatic islets, human mononuclear cells were
first used to optimise the use of permeabilising polymers. Current methods of viability
assessment were critically examined and improved, followed by systematic screening of
cryopreservation conditions. The efficacy of promising cryopreservation protocols were
subsequently confirmed for mouse pancreatic islets using viability and functional assays.
PP-50 and PP-75 polymers were shown to be unsuitable for trehalose-based cryopreser-
vation of mononuclear cells and islets due to potential toxicity and need for long incubation.
Investigation of diffusion kinetics demonstrated that a minimal incubation time of 6 h at 37 °C
is required to enable diffusion of solutes into the islet core. This finding implies that current
clinical viability assessment protocols only survey the periphery of islets. A range of imaging
modalities were used to confirm that islet core viability can be dramatically different from
the islet periphery. Using these insights, a novel cryopreservation protocol was developed in
which islets are pre-incubated for 6 h at 37 °C with trehalose and antioxidants, followed by
addition of DMSO, resulting in significantly greater viability of cryopreserved islets.
In conclusion, this study identified important limitations of the current cryobiological
viability assessment of mononuclear cells and pancreatic islets. Permeabilising biopolymers
did not improve trehalose-based cryopreservation in primary cells. An improved method for
cryopreservation of pancreatic islets was developed which combines DMSO and trehalose in
a novel manner and can be further improved by addition of antioxidants.
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1.1 Need for cryopreservation of cells and tissues
An effective method for long-term preservation of cells and tissues is essential in many fields,
particularly in medicine, as a way to overcome the limited time window for the clinical or
experimental use of fresh tissues. The shortage of organs for transplantation is currently one
of the most pressing challenges in medicine and contributes to significant number of deaths
worldwide. Enabling cryopreservation of cells, tissues and organs has a potential to extend
the pool of available organs, enable more accurate screening and matching, and remove some
of the logistical challenges of transplantation [1].
Freezing of tissues is now routinely performed in fertility treatments, umbilical cord
blood stem cell banking or haematopoietic stem cell (HSC) transplantation, but significant
advances are needed to enable cryopreservation of other tissues and whole organs. An
essential step for the future use of regenerative therapies is development of methods for
banking of immunophenotyped embryonic stem cells (ESCs), induced pluripotent stem cells
(iPSCs) or other regenerative cellular therapies [2].
Pancreatic islet transplantation is another area in which there is an urgent and current
unmet need for an effective cryopreservation strategy. Often it is not possible to obtain
sufficient islet cell mass for pancreatic islet transplantation from one donor. Islets from
multiple donors are therefore combined to achieve insulin independence in the recipient.
However, pancreatic islets can only be cultured for a few days [3], making simultaneous
transplantation of fresh islets pooled from several donors an unresolved challenge. This




1.2.1 Pancreatic islet morphology and function
The islets of Langerhans, or pancreatic islets, are small distinct cell clusters within the
pancreas (constituting about 4.5 % of the adult human pancreas volume [4], found in higher
density in the tail region of the pancreas [5]) that are able to secrete endocrine hormones.
Pancreatic islets consist of several endocrine cell types, summarised in Table 1.1.
Table 1.1 Main cell types in pancreatic islets
Cell type Hormone
secretion




a-cells Glucagon Increasing blood glucose levels 30 – 40 15 – 20
b -cells Insulin Decreasing blood glucose levels 50 – 60 70 – 80
d -cells Somatostatin Inhibition of insulin and
glucagon release
5 – 15 5 – 10
PP-cells Pancreatic
polypeptide
Reduction in appetite - -
e-cells Ghrelin Stimulation of appetite, increased
fat deposition
- -
*Percentages of a , b and d -cells in mouse and human islets are derived from Brissova et al. [6].
The organisation of these cell types in islets differs between species: in mouse, most
b -cells populate the central part of the islet and the rest of the cell types predominate on
the periphery, while in human islets, the different cell types are more evenly distributed [6].
Although islets significantly vary in size (diameter ranges from 50 – 250 µm), the diameter
of a human islet is on average 109 µm [4] and contains between 1,000 – 10,000 cells [7]. In
both mouse and human islets, the distribution of islet sizes is similar with relatively high
number of small islets and low numbers of large islets [8] (Figure 1.1). In mouse islets, very
high proportion of the islets contains b -cells, regardless of the islet size. Conversely, in
human islets, the proportion of b -cells decreases with the islets size [8] in all head, body and
tail of the pancreas [5].
1.2.2 Regulation of insulin secretion in b -cells
Pancreatic b -cells constantly express a glucose transporter GLUT-2 on their surface, enabling
them to continuously sense glucose concentrations in the blood stream. Uptake of glucose by
these transporters initiates metabolic and signalling pathways that ultimately lead to release
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Fig. 1.1 Islet size distribution and cellular composition in mouse and human pancreas. Grey bars
represent the frequency of islet size, green, red and blue lines represent the frequency of b , a and d
cells, respectively. Reproduced from Kilimnik et al. [8] with permission from Taylor & Francis.
of insulin from storage granules, as depicted in Figure 1.2. Insulin release can be further
amplified in the presence of incretin hormones such as glucagon-like peptide 1 (GLP-1) or
glucose-dependent insulinotropic polypeptide (GIP). These are released by gut cells after
food intake and are bound to receptors on the membrane of b -cells which leads to synthesis
of cyclic adenosine monophosphate (cAMP) by adenylyl cyclase and subsequent downstream
signalling leading to an increase in insulin degranulation [11].
Insulin release can be inhibited by signalling molecules, including somatostatin, adrenaline
and noradrenaline, which target different parts of the secretion pathway (through inhibitory
G-proteins or hyperpolarisation of the membrane) [11]. In turn, insulin acts as an inhibitor of
glucagon secretion by a-cells [12].
1.2.3 Regulation of blood glucose levels
As mentioned above, elevated blood glucose levels lead to secretion of insulin by b -cells.
Insulin receptors are present on the membrane of skeletal muscle and adipose cells, as well as
hepatocytes. These cell types have membrane glucose transporters (GLUT-4 in muscle and
fat cells, GLUT-2 in liver cells) stored in recycling endosomes inside the cells. Unlike b -cells
which constantly express GLUT-2 transporters on their membrane, these receptors are only
exposed on the membrane of muscle cells, hepatocytes and adipocytes after exocytosis of the
endosomes is triggered by insulin binding to its receptor. Glucose taken up by these cells
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Fig. 1.2 Regulation of insulin secretion in b -cells and regulation of blood glucose levels. (A) Diagram
of glucose sensing and insulin secretion by b -cells. Glucose is taken up by GLUT-2 transporter and is
catabolised through glycolysis and Krebs cycle, accompanied by synthesis of ATP. ATP-sensitive K+
channels are closed upon the ATP release, causing depolarisation and opening of voltage-dependent
Ca+ channels. Increased intracellular Ca+ concentration then leads to degranulation of the insulin
granules and release of insulin into the blood stream. This pathway is necessary for initiation of the
insulin secretion in b -cells. G-protein coupled receptors (GPCRs) on the surface of b -cells can bind
incretin hormones (i.e. GLP-1, GIP) which can in turn stimulate adenylyl cyclase to produce cAMP.
This pathway is important for maintaining and amplifying the insulin secretion [9]. (B) In adipose,
skeletal muscle and liver cells, GLUT-4 or GLUT-2 transporters would normally be stored in recycling
endosomes inside the cells. When insulin is released from b -cells and binds to an insulin receptor of
these cells, signalling cascade induces fusion of these endosomes with cellular membrane, exposing
the glucose transporters and enabling glucose uptake. In adipose cells, intracellular glucose would be
stored in the form of triglycerols, whereas in muscle cells and hepatocytes it is stored in glycogen
molecules. During fasting, these storage molecules can be broken down to glucose and ATP. The
detailed signalling pathways and regulation mechanisms differ between cell types. Adapted from
Carroll et al. [10] and Rutter et al. [11]. ATP = adenosine triphosphate; cAMP = cyclic adeno-
sine monophosphate; GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like
peptide 1; GLUT-2 = Glucose transporter type 2; GLUT-4 = Glucose transporter type 4; GPCR = G-
protein coupled receptor; KC = Krebs cycle (citric acid cycle).
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can then be stored as glycogen (skeletal muscle and hepatocytes) or triacylglycerol (adipose
cells). Thus, concentration of glucose in the blood stream (and in the intracellular space of
these cells) is decreased in response to glucose [10].
During fasting, glucagon is secreted by pancreatic a-cells and induces breakdown of
glycogen in hepatocytes. Similarly, during physical activity, released adrenaline stimulates
catabolism of glycogen in skeletal muscles for use as an energy source. This results also in
an increased release of glucose into the blood stream [13].
1.2.4 Pancreatic islets in diabetes treatment
Diabetes mellitus is a group of medical conditions characterised by increased blood glucose
levels, either because of reduced insulin production by b -cells (type 1 diabetes) or due to
acquired resistance to insulin (type 2 diabetes). The treatment for type 2 diabetes initially
involves changes in lifestyle, and in more advanced cases the administration of drugs, which
can include insulin [14]. Treatment of type 1 diabetes entails tight regulation of blood
glucose levels by insulin therapy. Whole pancreas transplantation [15] or pancreatic islet
transplantation [16, 17] can also be used for management of selected cases and can partly or
fully normalise glucose levels.
Whole pancreas transplantation has the disadvantage of being a very invasive procedure
with high risk of post-transplant complications. Due to these risks, majority of patients are
transplanted with pancreas simultaneously with or subsequently after kidney transplantation
as a treatment for end-stage diabetic renal failure. Solitary pancreas transplantation is
more unusual as the benefits do not always justify the risk of the transplantation procedure
and requirement of immunosuppression [18]. Transplantation of isolated pancreatic islets
avoids some of these issues by removing the exocrine portion of the pancreas and by
the use of less invasive infusion of the transplanted tissue into the portal vein. However,
successful islet transplantation was not clinically attainable for a long time and was only
achieved after the optimisation of the isolation procedure [19, 20] and creation of the
Edmonton protocol which introduced steroid-free immunosuppression regimen and serial
islet transplantations to achieve critical islet mass [18]. According to the Edmonton protocol,
10,000 islet equivalents (IEQ) per kilogram of body weight are administered during pancreatic
islet transplantation [21]. Reports suggest that 6,000 to 9,000 islets per kilogram of body
weight are sufficient to achieve insulin independence [20]. This means that between 420,000
and 700,000 islets are needed for the transplantation into a 70 kg patient, however, the typical
islet mass gained from one pancreas is 400,000 islets [20]. As a consequence, patients often
receive islets from more than one donor on multiple occasions in order to benefit from the
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transplant. In a recent clinical trial, 45.8 % patients received a single islet infusion, 52.1 %
received two infusions and 2 % received three infusions [22].
Although pancreatic islet transplantation currently has worse long-term graft survival
than whole pancreas transplantation (52 % 5-year pancreas graft survival versus 48 % 5-year
islet graft survival in the United Kingdom) [23], there is potential for optimisation of the
transplantation site, immunosuppressive regimen and dose of islets to further improve out-
comes. Indeed, when islet transplantation patients receive an additional islet transplantation
from a second or third donor, the 5-year graft survival rises to 60 % [23].
1.2.5 Cryopreservation in pancreatic islet transplantation
The need to transplant islets from multiple donors currently leads to subjecting patients to
multiple surgeries. In addition, it is preferable for patients to receive their multiple islet
transplants in a limited time window after a first pre-conditioning with T cell-depleting
therapy (personal communication with Dr. Shareen Forbes). Cryopreservation of islets
from multiple donors and subsequent pooling would enable transplanting the appropriate
dose of islets at one time, potentially decreasing the risk of complications coming from the
transplantation procedure and increased amount of immunosuppression. It would also allow
creation of biobanks and enable effective HLA matching of the islets, which is currently not
performed, even though it has been shown to contribute to development of donor-specific
antibodies and subsequent rejection of the graft [24].
Early after the introduction of the Edmonton protocol, two diabetic patients were trans-
planted with a combination of fresh and cryopreserved pancreatic islets and one of these
patients remained insulin independent at one year after transplantation. Patients who were
transplanted only with fresh islets from a single donor, did not remain insulin independent
one year after transplantation due to insufficient dose of transplanted islets [25]. This case
report provides a proof of principal in human showing that cryopreserved pancreatic islets
can be used to improve transplantation outcome, at least when used in combination with
fresh islets.
Protocols using cryopreserved pancreatic islets, however, were never permanently intro-
duced into clinical practice due to low post-thaw survival and the use of fetal calf serum [26].
Better cryopreservation protocols are therefore needed but research on this topic is limited by
the low availability of human islets for research and high complexity of cryopreservation pro-
tocols due to the fact that islets are multicellular aggregates. For the purposes of this project,
human mononuclear cells and mouse pancreatic islets were therefore used for optimisation
of the cryopreservation protocols.
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1.3 Mononuclear cells
1.3.1 Sources and use of mononuclear cells
Mononuclear cells are the fraction of cells from peripheral blood (or other sources) which
contain a single spherical nucleus as opposed to red blood cells (no nucleus) or granulocytes
(nucleus with multiple lobes). They can be isolated from the whole blood by centrifugation
on a density gradient. These cells include primarily immune cells such as lymphocytes and
monocytes. Granulocytes and red blood cells are excluded by the gradient separation but
some contamination with these cells may remain in the mononuclear fraction.
Mononuclear cells are widely used in immunological and haematological research, as
well as in research into blood borne diseases and cancer. There is also increasing interest
in development of therapies based on regulatory T lymphocytes or trans-differentiation of
blood cells into other cell types using the iPSC technology. Clinically, they can be used for
isolation of haematopoietic progenitors which are later used in HSC transplantation.
Mononuclear cells for therapeutic use are routinely obtained from bone marrow (BM),
umbilical cord blood (UCB) or mobilised peripheral blood. Alternatively, they can be found
in spleen, but the frequency of the therapeutic haematopoietic progenitors is considerably
lower, which then presents a challenge of gathering sufficient number of cells to achieve
engraftment after transplantation [27, 28].
1.3.2 Haematopoietic progenitors and their cryopreservation
The cell type in the centre of existing clinical therapies derived from mononuclear cells
is haematopoietic progenitor cell. Long-term HSCs (LT-HSCs) are thought to be the true
multipotent self-renewing population with a generally accepted phenotype of CD34+ CD38 
CD90+ CD45RA  [29]. Through many developmental stages, including short-term HSCs
(ST-HSCs) and lineage-committed progenitors, LT-HSCs give rise to all lineages of the
haematopoietic tree (Figure 1.3). For the purposes of transplantation, mononuclear cells
are typically enriched for the CD34+ population by magnetic separation [31]. In this thesis,
CD34+ cells will be further referred to as haematopoietic progenitors and these two names
will be used interchangably.
HSCs are used for treatment of haematological or other diseases and typically have to
be cryopreserved prior to use, except for certain cases of allogenic transplantations that are
completed within 72 h [32]. Avoiding prolonged periods of culture minimises the risk of
bacterial or viral contamination and differentiation of the stem cells [33]. The ability to
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Fig. 1.3 Human haematopoietic tree and associated markers. Adapted from Doulatov et al. [29]
with revision from Gorgens et al. [30]. B/NK = B cell and NK cell progenitor; EMP = erythro-
myeloid progenitor; EoBP = eosinophil and basophil progenitor; ETP = early T-lineage progenitor;
GMP = granulocyte and macrophage progenitor; LMPP = lymphoid-primed multipotent progenitor;
LT-HSC = long-term HSC; MEP = megakaryocyte and erythrocyte progenitor; MLP = multilymphoid
progenitor; MPP = multipotent progenitor; ST-HSC = short term HSC.
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cryopreserve cells allows sufficient time for quality and safety control of the cells or their
transport.
Cryopreservation of CD34+ cells is therefore a routine practice and protocols used are
summarised in Section 1.6.1. While these protocols can preserve sufficient amount of cells
to ensure clinical efficacy of HSC transplantation, improvements on these protocols can have
a rapid impact on these existing clinical protocols.
1.4 Physical aspects of freezing cells
1.4.1 Overview of freezing in biological systems
When mixed water systems cool down, ice crystals begin to form by the process of nucleation.
The ’minimal crystal’ grows during the freezing process, excluding solutes from its structure
which increases the concentration of the solutes in the remaining liquid phase. Formation of
ice crystals can be prevented by cooling the system down very rapidly (over  1000 °C/min),
which results in formation of amorphous glass in a process known as vitrification [34].
1.4.2 Theories and mechanism of cryoinjury
There is evidence that an optimal freezing rate exists for each cell type. Both exceeding and
falling behind of this optimal rate is a source of freezing injury. The two-factor hypothesis
proposed by Mazur in 1972 suggests that intracellular ice and changes in solute concentration
are the main sources of injury during cryopreservation [35].
If cells are cooled slower than the optimal rate, damage is mostly caused by osmotic
stress from the loss of water to extracellular ice formation. As ice forms in the extracellular
space, the concentration of the solutes increases, resulting in cellular dehydration to account
for the osmotic change. During thawing, the process is reversed and rapid inflow of water
into the concentrated cytoplasm represents additional stress factor [35, 36].
Conversely, excessively rapid freezing results in formation of intracellular ice and eventu-
ally irreversible damage to the cell membrane or other cellular structures [35, 37]. This risk
is present not only during the freezing but also during thawing when recrystallisation is ac-
companied by growth of crystals, especially when the warming is performed slowly [35, 36].
1.4.3 Mechanisms of cryoprotection
Many organisms living in cold areas are adapted for survival in sub-zero temperatures. Cold-
tolerant species utilise a variety of mechanisms to mitigate the detrimental effects of freezing.
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These include production of glucose, disaccharides, polyols, ice nucleators, and specialised
antifreeze proteins or glycolipids [38].
Inspired by the nature, the protective effects of the first cryoprotectants were discovered
in 1940s and 1950s, enabling cryopreservation of cells. A cryoprotectant is a substance
which, when added to the freezing medium, is capable of reducing the freezing injury to
the cryopreserved cells. The underlying mechanism of cryoprotection involves lowering
the solute concentration by increasing the intracellular osmotic pressure. This lowers the
freezing point of the system, thus reducing the incidence of ice crystal formation [34, 39].
An alternative method of preventing damage by ice crystal formation is vitrification of
the cells, which involves formation of a non-crystalline amorphous solid state. However,
achieving vitrification in many biological systems is challenging because cryopreservation is
performed in volumes too large to achieve homogenous freezing. Vitrification is not possible
without elimination of water-water interactions which is usually achieved by increasing the
concentration of the cryoprotectant, often to the point where it exerts toxic effects on the
cells [40].
1.5 Cryoprotectants
1.5.1 The ideal cryoprotectant
An effective cryoprotectant should be able to protect cells from the damage caused by
ice crystal formation, while reducing the osmotic stress, and subsequently allow cells to
return to their normal physiological state. Cell membrane integrity, cell volume, and other
morphological qualities of the cells should be preserved as well. It must also maintain the
genomic and epigenetic characteristics of the cells, their expression profile, and thus their
physiological function after thawing. It must not induce differentiation or de-differentiation
of cells. Furthermore, to be applicable in clinical and research practice, attention must be
paid to the cost of the method, the time of the pre-freeze and post-thaw processing, transport
requirements and storage space requirements. A cryoprotectant used in clinical practice must
meet additional requirements related to patient safety.
The ideal cryopreservation protocol will most likely not be identical for all cell types
because of differences in cell size, water content, intracellular structures, membrane compo-
sition, and cell density. The cryopreservation protocols must therefore be tailored to various
cell types [34]. Special attention also needs to be paid to cryopreservation of cell clusters,
since the protocol must allow the cryoprotectant to penetrate the cells located centrally within
the cluster, making diffusion kinetics a central parameter.
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1.5.2 Overview of cryoprotectants
The first study utilising glycerol as a cryoprotectant showed that addition of a protective agent
can significantly increase the survival rate of spermatozoa [41]. Further research showed
other neutral solutes with low molecular weight, such as ethylene glycol and diethylene
glycol, can have similar effects as glycerol. Sugars (glucose and xylose) and sugar alcohols
(erythritol) can also provide some, albeit reduced, level of protection, mostly because the
cell membrane is only partially permeable to them [39]. Subsequently, dimethyl sulphoxide
(DMSO) was identified as a potentially ideal cryoprotectant, preferred to glycerol because of
the higher permeability of cell membrane to DMSO [42]. Glycerol and DMSO still remain
the most commonly used cryoprotectants in clinical practice and research.
Currently available cryoprotectants can be classified into two groups based on their ability
to cross the plasma membrane: penetrating or non-penetrating. Penetrating cryoprotectants,
such as DMSO, glycerol or other alcohols, can easily enter the cell and replace a fraction
of water molecules in the intracellular space, preventing dehydration after outflow of water
during the cooling process. Conversely, non-penetrating cryoprotectants such as various
mono-, di- and polysaccharides, in most cases cannot permeate through the membrane and
thus only act extracellularly [43]. The mechanism of extracellular cryoprotection lies in
modification of the membrane permeability which helps to maintain the cell volume in a
tolerable range [44]. Examples of penetrating and non-penetrating cryoprotective substances
are shown in Table 1.2.
Table 1.2 Overview of most common penetrating and non-penetrating cryoprotectants
Penetrating cryoprotectants
Sulphoxides Dimethyl sulphoxide
Amides + imides Formamide, acetamide, propionamide etc.
Alcohols Glycerol, methanol, ethylene glycol, propylene glycol, erythritol,
mannitol, sorbitol
Non-penetrating cryoprotectants
Monosaccharides Glucose, galactose, arabinose, mannose, fructose etc.
Disaccharides Sucrose, trehalose, lactose, maltose etc.
Polysaccharides Raffinose, dextran, hydroxyethyl starch
Macromolecules Ficoll, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alco-
hol, hyaluronan
Adapted from Swain et al. [43] with revisions from Meryman [44] and Stolzing et. al [45]
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1.5.3 Mechanisms of cryoprotectant toxicity
While cryoprotectants can prevent irreversible cell damage during freezing, they may them-
selves have toxic effects. This toxicity limits the concentration of the cryoprotectant that can
be used for cryopreservation and therefore its protective potency [46]. To be considered toxic,
it must be clearly demonstrated that the cryoprotectant causes significant and irreversible
changes to cells detrimental to survival and function in relevant concentration ranges, expo-
sure times and temperatures [43, 47]. Mechanism of toxicity of cryopreservation solutions
has not been fully clarified but variety of harmful effects have been observed.
Toxic effects of cryoprotectants can be categorised as non-specific (relevant to all cry-
oprotectant) or specific (related to individual cryoprotectants or group of cryoprotectants).
Non-specific effects include cell dehydration, changes in membrane permeability, or external
environment polarity [46]. Specific toxic effects include chemical modifications of cellular
structures or enzymes, changes in cytoskeleton, changes in transcription profile, and many
others [46, 47]. Toxic effects associated with DMSO are discussed in detail in Chapter 1.8.2.
Reduction of cryoprotectant toxicity can be achieved by step-wise cryoprotectant addition
and removal which reduces the osmotic stress to the cells [43]. Use of lower concentrations
and shorter exposure times reduce the toxicity but often also the efficacy. Toxic effects of
individual cryoprotectants can also be diminished by combining several cryoprotectants in
lower and less toxic concentrations [43] or by toxicity neutralisation by other substances [48].
1.6 Current cryopreservation methods
1.6.1 HSC cryopreservation protocols
Choice of cryoprotectant
Current protocols for cryopreservation of haematopoietic progenitors in clinical and research
practice differ significantly between institutions. The predominant cryoprotectant used is
DMSO at 10 % concentration, but lower concentrations of DMSO are also used [32, 49]
with varying degrees of success [50, 51]. DMSO-containing cryopreservation solutions are
usually supplemented by serum, as this has been shown to have a beneficial effect on cell
recovery [52]. Other additives such as hydroxyethyl starch [53] or disaccharides [54, 55] are
sometimes used. Protocols that do not utilise DMSO are yet to be clinically validated.
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Freezing rate
In clinical practice, controlled-rate freezers are recommended for freezing of haematopoietic
progenitors [56]. The programmed freezing rate should reflect the specific needs of the
cell type and the cryoprotectant used. It must also compensate for the heat released during
transition from liquid to solid phase by increasing the freezing rate around the eutectic point
(temperature where all the components of a mixture freeze) [57]. Nevertheless, uncontrolled
freezing may be preferred to use of a controlled-rate freezer due to its lower cost. Moreover,
uncontrolled freezing has been shown to have comparable efficacy to controlled-rate freezing
for these cells [53, 58] with the exception of granulomonocytic colony forming units (CFU-
GM) growth efficiency where uncontrolled freezing results in slightly worse outcomes [59].
The ideal freezing rate for human haematopoietic progenitors cryopreserved in 10 % DMSO
was shown to be between 1 and 3 °C/min [60].
Cryopreservation temperature
Long-term storage of samples in mechanical freezers with temperatures of approximately
 80 °C is not ideal since the temperature is not low enough to completely stop the biochemi-
cal activity of some enzymes, which may have implications for cell viability [61]. Conversely,
storage in liquid phase of nitrogen ( 196 °C) carries the risk of contamination [62]. This can
be partly avoided by keeping the samples in the nitrogen vapour phase or in more efficient
mechanical freezers (temperatures as low as  150 °C).
Cell density
Another variable in cryopreservation protocols is cell concentration. Although cell con-
centrations below 2 ⇥ 107 cells/mL were initially preferred due to toxicity concerns [32],
later studies validated the use of higher cell densities (up to 5 ⇥ 108) for successful HSC
cryopreservation [63, 64]. Cryopreservation in higher cell densities implies lower final
volume, reducing the cost of storage and risk to the patient resulting from the amount of
cryoprotectant infused into the body as part of the clinical therapy. No significant differences
were found between storage of cells in vials and bags [65].
Thawing and post-thaw processing
Standard thawing protocols for haematopoietic progenitors used by most institutions includes
rapid thawing in 37 °C water bath although slower thawing at 20 °C does not significantly
decrease the post-thaw viability of cryopreserved haematopoietic progenitors [66]. The
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optimal rate of thawing has been shown to be dependent on the rate of freezing. Slow
warming is more damaging for rapidly frozen cells than slowly frozen cells but generally,
rapid thawing results in enhanced recovery regardless of the freezing rate [67]. Concerns
about contamination caused by thawing in water bath have been addressed by development
of a dry heat device [68].
Subsequent washing of the cells is recommended to ensure the removal of the cryopro-
tectant. It usually includes slow dilution of the cryoprotectant to reduce the osmotic shock
and removal of the supernatant after centrifugation [69]. Although this removes most of the
cryoprotectant and improves the viability and clonogenic activity of the cells, it also results in
significant cell losses (approximately 30 – 40 % [69, 70]). For clinical purposes, automated
methods of post-thaw washing have been developed [70].
1.6.2 Pancreatic islet cryopreservation protocols
Compared to single cell cryopreservation, freezing and thawing of cell clusters such as
pancreatic islets presents additional challenges. The size of the islets makes it necessary to
incubate them longer with the cryoprotectant to allow for cryoprotectant diffusion throughout
the cluster and its equilibration with the water inside cells. During the incubation and
cryopreservation, the different cell layers will be subjected to different cryoprotectant and
intracellular water concentrations and non-uniform temperature changes, which can lead
to increased ice crystal formation in some regions of the tissue [71]. Moreover, the size
variability between islets (shown earlier in Figure 1.1) makes it nearly impossible to design
an ideal incubation and freezing protocol if islets are cryopreserved in a heterogeneous batch.
Important parameters of the pancreatic islet cryopreservation are summarised below.
Addition of cryoprotectants
Most adult pancreatic islet cryopreservation protocols use DMSO as a cryoprotectant. If islets
are incubated in a single concentration of DMSO, its penetration into the centre of the cluster
is not rapid enough to allow for equilibration and avoid its high time-dependent toxicity
at the same time (Figure 1.4). Multi-step protocols were therefore designed to first allow
equilibration of low and less toxic concentrations of DMSO, followed by short incubation
in the final DMSO concentration. Step-wise addition protocols also minimise the osmotic
stress from addition of high concentrations of solutes [73].
The current standard protocol designed by Rajotte suggests incubation in 0.67 M DMSO
for 5 min at 22 °C, followed by incubation in 1 M DMSO for 25 min at 22 °C before final
incubation in 2 M DMSO for 15 min at 0 °C [74].
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Fig. 1.4 Schematic of permeation of DMSO into pancreatic islets. In pancreatic islets immersed in
DMSO solution (single concentration), DMSO diffuses into the core in a time-dependent manner.
(A) and (B) Short incubation times do not provide sufficient concentration of DMSO to provide
cryopreservation effect in the whole islet volume. (C) (D) and (E) Later, the prolonged exposure of
the peripheral cells to DMSO starts exhibiting its toxic effect. Achieving homogenous concentration
of DMSO in the whole islet volume is not possible using simple incubation in single concentration
of DMSO. The time scale on this schematic depends on the size of a particular islet; it has been
shown that an islet of 150 µm diameter can equilibrate with 1.5 mol/kg DMSO in ~10 min at room
temperature [72]
Diffusion rates and ideal incubation steps are highly likely to be different for other
cryoprotectants (e.g ethylene glycol, glycerol or non-penetrating cryoprotectants), although
many have not yet been experimentally determined. Mazur and Rajotte have provided early
evidence of permeation rates for DMSO and glycerol in fetal rat pancreas: full equilibration
with 2 M DMSO was achieved in only 10 – 15 min at 0 °C while it took 10 – 30 times longer
to achieve equilibration for glycerol [75]. Evidence from other publications suggests that
the standard 45 min incubation protocol with DMSO should allow for full equilibration of
DMSO in islets [76]. Benson et al. have shown that a 150 µm diameter islet can equilibrate
with 1.5 mol/kg in ~10 min at room temperature [72].
Cryoprotectant mixtures
The current standard method uses DMSO at 2 M final concentration. Studies examining the
ideal final concentration of DMSO are limited. Lakey et al. have shown in human islets that
decreasing the concentration to 1.5 M does not negatively impact the post-thaw islet recovery
and insulin secretion [77]. Conversely, another group has performed similar experiments
with rat islets but found that decreasing DMSO concentration from 14.4 % (equivalent to
2 M) to 10 % (equivalent to 1.4 M), as well as increasing it above 14.4 % resulted in lower
viability [78].
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Taylor et al. compared DMSO and glycerol for cryopreservation of adult rat pancreatic
islets and found that DMSO was superior to glycerol in preserving post-thaw insulin secretion
patterns and ability to reverse diabetes in rats [79].
Ethylene glycol (EG) was successfully shown in a rat model to be a less toxic alternative
to DMSO [80], with EG achieving a higher recovery count and DNA content per islet, higher
glucose-stimulated insulin secretion and ability to reach insulin independence in diabetic
mice [81]. However, these results have not been replicated using human islets [82].
Beattie et al. tested addition of 11.1 mM glucose and 300 mM trehalose to a DMSO-
based cryopreservation medium. They cryopreserved adult and fetal-like pancreatic islets and
observed a significant increase in recovery when trehalose was added together with DMSO
for both tissue types compared to glucose addition. However, they did not directly compared
the protocol to the original one proposed by Rajotte et al. [83].
Freezing and thawing rate
Slower freezing rates are considered to be beneficial in slow-cooling (as opposed to vitri-
fication) since they allow sufficient time for water to escape the cells which then prevents
formation of intracellular ice [35]. Rajotte noticed that freezing rate for cell clusters tends to
be slower than for single cells and suggested the freezing rate of  0.25 °C/min for pancreatic
islets. Rajotte’s full freezing protocol includes a seeding stage at  7.5 °C for 10 – 15 min
to allow for nucleation and release of latent heat of fusion, slow-cooling to  40 °C and
plunging to liquid nitrogen [73] (Figure 1.5). Other groups use cooling rates of  0.25 or
 0.3 °C/min [79].
Foreman et al. compared different cooling rates for islets partially or fully-equilibrated
with DMSO and found that the cooling rates from  0.3 to  1000 °C/min were equivalent as
long as the islets fully equilibrated with the cryoprotectant [76].
Regarding thawing rate, Rajotte observed that if islets were slow-cooled to  40 °C
they required rapid thawing. Conversely, slow thawing was ideal for samples slow-cooled
to  75 °C [73]. Current protocol includes thawing of cryovials in 37 °C water bath until
the last small crystal is visible which usually achieves thawing rates between 150 and
200 °C/min [84]. It has been shown that rapidly thawed islets recovered better post-thaw
compared to islets thawed slowly at room temperature [85].
Cryoprotectant removal
For human pancreatic islets, the recommended procedure for DMSO removal is dilution by
0.75 M solution of sucrose followed by equilibration for 30 min, and step-wise addition of
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Fig. 1.5 Schematic of cooling and warming rates in the standard pancreatic islet cryopreservation
protocol. Pancreatic islets are brought from the 37 °C culture to room temperature, at which point
the DMSO is added step-wise. Once the final DMSO concentration has been reached, islets are
transferred to 4 °C and further incubated for 15 min, before controlled-rate freezing commences.
Samples are cooled down to  7.4 °C/min and after allowing for nucleation and release of the latent
heat of fusion, cooling rate of  0.25 or  0.3 °C/min is used to bring the samples down to  40 °C. At
the end of this freezing programme, samples are plunged to liquid nitrogen and stored in a dewar until
thawing. Thawing is performed by immersing vials in 37 °C water bath until the last crystal is visible,
bringing the islets into physiological medium by step-wise dilution of DMSO, upon which islets can
be cultured at 37 °C again. Figure adapted from Rajotte [73]. LN2 = liquid nitrogen.
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thawing medium every 5 min. A 24 h post-thaw culture at 37 °C has also been suggested to
allow a recovery period for the islets prior to in vitro or in vivo testing [73, 86].
Different methods of thawing have been suggested for islets isolated from dogs. The
method of Lakey et al. omits the sucrose dilution and simply uses a step-wise dilution of
DMSO over 24 min. They showed that this method results in equivalent islet survival when
cryopreservation is done in glass tubes and superior to the sucrose method when freezing is
done in freezer bags [87].
1.7 Current methods of cryosurvival assessment
1.7.1 Assessment of mononuclear cell cryosurvival
Methods used in clinical transplantation and cryobiology
The most common methods used for assessment of viability of mononuclear cells (and other
single cell suspensions) are trypan blue staining and flow cytometry. Trypan blue offers a
rapid non-specific viability assessment of all cells in the mixed population of mononuclear
cells and is performed under a light microscope using haemocytometer. Flow cytometry
offers the option of labelling and distinguishing different cell types, a useful feature if a
particular sub-population is of interest. The disadvantages of flow cytometry are longer time,
higher cost and specialised equipment requirements.
Adaptation of these methods for the purposes of cryobiology has been noted in some
studies [88]. Yang et al. noticed that cryosurvival is reported inconsistently in different
publications. Reporting only the viability of the post-thaw sample overestimates the actual
efficacy of cryopreservation since it does not account for the loss of cells during the freezing
process. It does, however, give a useful evaluation of the sample quality. More accurately,
percentage survival should be reported which relates the number of viable cells after thawing
to the number of viable cells pre-freeze [89]. However, this recommended practice of
reporting viability along with absolute counts has not been rigorously followed and no
standard method for cryobiological assessment of mononuclear cells exists to date.
Survival of haematopoietic progenitors
Because of the clinical use of haematopoietic progenitors for HSC transplantation, assess-
ment of their survival has been a well explored area. The focus of the community has been
the standardisation of haematopoietic progenitor markers, flow cytometry gating strategies
and cell enumeration method between clinical centres. The widely standardised ISHAGE
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guidelines for enumeration of CD34+ cells are routinely used in clinical practice and use a
gating strategy based on light scatter properties of cells and fluorescence from anti-CD45 an-
tibody conjugated to FITC fluorochrome, anti-CD34 antibody conjugated to PE fluorochrome
and 7-AAD dead cell dye [90].
This method, however, only uses very crude determination of progenitor capacity by
using the CD34 as a marker which labels all early and late progenitors. To identify true stem
cells, additional markers should be used in flow cytometry measurement (see Figure 1.3), or
the ability to differentiate into multiple lineages should be evaluated by functional assays.
The widely used in vitro functional assay for haematopoietic progenitors is the colony
forming units (CFU) assay. It can determine the proliferation and differentiation potential of
progenitors, mainly towards the myeloid and erythroid lineages. An in vivo assay, consisting
of depletion of bone marrow cells by irradiation of mice followed by transplantation of
haematopoietic progenitors can also be used for identification of LT-HSCs [91].
1.7.2 Assessment of pancreatic islet cryosurvival
Many of the methods used for assessment of islet survival are very specific due to the fact that
these are 3D cellular clusters which vary significantly in size and shape. A variety of methods
have been developed for assessment of islets before transplantation but most have important
limitation in predicting clinical outcomes. In cryobiology research, the protocols used for
survival assessment mostly follow the methods used in clinical transplantation described
below.
Islet viability
Staining islets with a combination of membrane integrity stains and dye based on enzymatic
activity of cells is the most common method for islet viability measurement. These dyes
include propidium iodide (PI), ethidium bromide or ethidium homodimer-1 for staining of
dead cells and fluorescein diacetate (FDA), acridine orange or Syto® and Sybr® dyes for
staining of live cells [92]. Despite its wide-spread use, especially of the FDA/PI combibation,
it has been shown that viability determined by this method does not correlate with clinical
outcomes [93–95].
There is little current insight into the reasons underlying this discrepancy. Potential
reasons include inability of these dyes to detect apoptotic cells [95] and a biased method
of analysis. Currently, islets stained with viability dye are commonly manually categorised
based on the perceived viability [94]. This method of image analysis is highly subjective
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and therefore automated image analysis programmes should ideally be employed to avoid
variability between assessors.
Assays using dissociated islets are in some aspects less biased since precise methods
such as flow cytometry can be used. However, during the dissociation process, islets may be
subjected to additional damage caused by enzymatic digestion or mechanical stress (based
on the dissociation method used) and cell losses are high. After dissociation, cell death rate
also potentially increases because of the loss of inter-cellular contact and communication
which is required by many tissues, including islets [96].
Basic viability staining of both intact and dissociated islets, nevertheless, remains a
method widely used in the clinical practice due to its simplicity and because it is one of the
few assays that can be performed prospectively – i.e. before the transplantation.
Islet size
Size of islets is an important parameter in clinical transplantation and currently determines
the dose of islets given to a patient. However, it is challenging to measure, especially if
exocrine tissue is also present in the sample. A classic method of size and purity measurement
involves staining with dithizone (a dye specific for insulin producing cells due to their high
content of zinc) and manual categorisation of islet size observed under a light microscope
using a calibrated grid. The results is then expressed as islet equivalents (IEQ, one IEQ is
equivalent to an islet of 150 µm diameter) [97]. New image analysis methods and use of
novel technologies (such as large particle flow cytometry or nuclei counting) were suggested
but have not been introduced into clinical practice [95].
Islet function in vitro
Glucose-stimulated insulin secretion (GSIS) is a classical assay used for evaluation of islets’
ability to respond to varying concentrations of glucose. This assay can be done either in a
static culture or as a perifusion measurement where islets are placed in a solution flow of
changing glucose concentrations followed by continuous sampling of the secretions. The
results obtained from the static assays have been useful for predictions of transplantation
outcome in some [94] but not other studies [98, 99]. Variability in the results of this functional
assay may be caused by insulin degranulation by damaged cells, variable assay conditions or
the absence of necessary signal molecules [95].
Two methods focusing on function of mitochondria have been recently suggested to
replace current viability and functional measurements. The advantage of mitochondrial
assays is that they are able to detect dying cells at the apoptosis stage, unlike standard viability
1.8 DMSO 21
measurements. Papas et al. suggested measuring oxygen consumption rates (OCR) of intact
islets. They have shown that OCR and OCR to DNA ratio correlate with transplantation
outcomes in diabetic mice [100]. Measuring the ATP/ADP ratios has also shown promise in
accurate prediction of in vivo results [101].
Islet function in vivo
Demonstrating reversal of diabetes in vivo is the ultimate measure of pancreatic islet function.
Transplantation of pancreatic islets under the kidney capsule of immunodeficient mice has
been shown to correlate with the outcome of clinical transplantation and is therefore regarded
as the most reliable assay for assessment of islet quality. The downsides of this approach
include long duration, technical difficulty and cost of the assay as well as the necessity to
time the diabetes induction with availability of islets [95].
1.8 DMSO
1.8.1 DMSO attributes
Dimethyl sulphoxide (chemical formula (CH3)2SO) is a compound composed of a polar
sulphoxide moiety connected to two non-polar methyl moieties (Figure 1.6). This struc-
ture gives DMSO high affinity to water; one molecule of DMSO is thought to bind two
water molecules by hydrogen bonds. This interaction decreases the freezing point of the
solution [102].
Fig. 1.6 Chemical structure of dimethyl sulphoxide. Polar part of the molecule consists of sulphoxide,
attached to the two methyl groups with non-polar character.
The cell membrane is highly permeable to DMSO. This characteristic was initially
thought to be the predominant mechanism of its cryoprotective properties [42], allowing it to
equilibrate on both sides of the membrane easily and thus prevent both ice crystal formation
and dehydration [54]. Subsequently, its high cryoprotective efficiency was also attributed to
its colligative properties (dependent on the concentration of the substance, not on its specific
chemical properties) [103], but the possibility of its direct interaction with other molecules
and cellular structures was also explored. Anchordoguy and colleagues showed that the
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oxygen atom in DMSO interacts with positively charged phospholipid heads [104]. Another
mechanism of protection includes the preferential exclusion of DMSO from the vicinity
of proteins at low temperatures, which keeps proteins surrounded by water molecules and
prevents their denaturation [105].
1.8.2 DMSO toxicity
Despite of its cryoprotective properties, DMSO can exert toxic effects that are depending
on its concentration, exposure time, and temperature [33]. Although cells can tolerate even
high concentrations (25 %) of DMSO at 2 °C for up to one hour, the same exposure of
haematopoietic progenitors at 20 °C results in a significant decrease in viability and ability to
form haematopoietic colonies [106]. DMSO can exert a range of adverse cellular effects, such
as changing the dynamics of cytoskeleton [107], altering the activity of enzymes involved in
glycolysis and other biochemical processes [108] or causing protein denaturation [109]. In
regenerative medicine, there is a concern about the effect of DMSO on protein expression by
embryonic stem cells [110] or epigenetic profile of embryoid bodies [111].
Toxicity of DMSO does not only has an impact at the cellular level, but cases of
adverse effects in transplant patients have also been observed after infusion of DMSO-
cryopreserved cells. In many cases, DMSO toxicity manifests as nausea, vomiting, and
abdominal cramps [49]. However, more serious effects can also be associated with ad-
ministration of DMSO, including cardiovascular, neurological, gastrointestinal and renal
complications or allergies (reviewed by Shu et al. [112] and Cox et al. [113]). Transplant
centres are being encouraged to use lower concentrations of DMSO or to remove it before
administration to patients but this has not become standard practice [49].
1.8.3 Alternatives to DMSO
Attempts have been made to supplement or substitute DMSO with naturally occurring
protective substances such as saccharides. The disaccharides sucrose and trehalose are the
most promising candidates. They can both form ’glass’ and stabilise proteins and membranes,
although trehalose is a more effective cryoprotectant than sucrose [114]. One possible
explanation is trehalose’s larger hydration radius which enables it to better protect proteins
by preferential exclusion of the sugar from the proteins, in a manner similar to DMSO [115].
It is also more effective than sucrose in replacing water molecules in the hydration layer
of the phospholipid membrane and thus provide greater protection against damage from
dehydration [116]. Moreover, trehalose is less prone to hydrolysis than sucrose in suboptimal




The disaccharide trehalose is composed of two D-glucose units linked by an a ,a-1,1-
glycosidic bond (Figure 1.7). This link gives the disaccharide a non-reducing character and
prevents its degradation in acidic conditions or by the activity of a-glucosidase. Trehalose is
naturally produced by many lower organisms and metabolised by trehalase enzyme [118].
Although unable to synthesise trehalose, numerous higher organisms, including humans,
express trehalase in the small intestine and other organs and are therefore able to digest
the disaccharide [118, 119]. Trehalose has been shown to cause little or no toxicity in
humans [118], with the exception of very rare cases of trehalose intolerance [120].
Several hypotheses have been proposed to explain the cryoprotective effects of trehalose.
The water-replacement hypothesis suggests that trehalose replaces water molecules in binding
polar groups of molecules and other cellular structures (most importantly the cell membrane)
and therefore aids in preserving their conformation during freezing [121]. Water entrapment
or preferential hydration hypothesis suggests that trehalose does not bind directly to the
surface of proteins but instead surrounds thin layer of water molecules around the protein,
keeping it hydrated [115, 122]. The vitrification hypothesis suggests that trehalose allows the
formation of amorphous glass which minimises the mechanical damage caused by crystal
formation [123]. Additional evidence suggests that trehalose can promote stability of proteins
by lowering the oxidative stress [124, 125] which could be advantageous for highly sensitive
cells such as haematopoietic progenitors [126] or pancreatic islets [127]. These mechanisms
may all contribute to the protective effects of trehalose [118].
Fig. 1.7 Trehalose and its building blocks. (A) Monosaccharide a-D-glucose; the hydroxyl group
of the hemiacetal which takes part in forming the chemical bond in trehalose, is highlighted in blue
circle. (B) Disaccharide trehalose. Highlighted glycosidic bond is created by joining hemiacetal
hydroxyl groups of two a ,D-glucoses.
24 Introduction
1.9.2 Cryopreservation with trehalose
Trehalose has been added in some protocols as a supplement to DMSO or EG, resulting
in improvements in plating efficiency, proliferation, albumin and urea formation of hepa-
tocytes [128] or viability of bovine embryos [129]. Others that attempted to use trehalose
as the only cryoprotectant, have faced the necessity for intracellular delivery of the disac-
charide [54, 130]. Several studies have suggested that 200 mM concentration of trehalose
delivers the highest protective effect [54, 128].
Trehalose has also been investigated for cryopreservation of haematopoietic progenitors.
Using the immature haematopoietic cell line TF-1, Buchanan et al. showed that trehalose is
a suitable cryoprotectant for HSCs as it preserves their stem cell phenotype and clonogenic
potential [54]. Zhang and colleagues demonstrated improvements in colony forming ability
of UCB cells if trehalose was added to conventional cryopreservation medium [131]. Similar
results were observed by Limaye et al. who cryopreserved HSCs from UCB and foetal liver
in 10 % DMSO supplemented with trehalose [132]. Scheinkonig and colleagues investigated
using trehalose as the sole cryoprotectant. Although the viability of cells from bone marrow
and peripheral blood cryopreserved in trehalose did not reach that of DMSO-cryopreserved
cells, the number of colony forming units was higher in trehalose [130].
Cryopreserved islets demonstrated high viability and in vivo survival when the disaccha-
ride was added to the standard cryopreservation solution simultaneously with DMSO [83].
Another study reported that addition of to standard DMSO freezing protocol improved
cryosurvival of hydrogel-encapsulated islets [133]. Modified Kyoto solution containing
trehalose as a cryoprotectant has been suggested as a preservation solution for human islet
isolation that may be superior to University of Wisconsin (UW) solution [134].
1.9.3 Intracellular trehalose delivery
Trehalose should be delivered intracellularly to achieve maximal cryoprotection [54, 135,
136]. However, mammalian cell membranes do not have a transporter for trehalose and
uptake by passive diffusion only facilitates intracellular delivery of small quantities of the
disaccharide [114]. Several approaches have been explored to increase the intracellular uptake
of trehalose, including administration of genetically engineered pores into the membrane [54,
135], microinjections [137], electroporation [138], induction of thermal shock [139], delivery
during membrane phase transition [83], addition of trehalose-containing liposomes [136], and
using engineered trehalose conjugated to lipophilic groups [140]. A group of amphipathic
polymers capable of integrating into the membrane and changing its permeability has also
been developed and shown to permit trehalose uptake by erythrocytes and SAOS-2 cells
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(human osteosarcoma cell line) [141, 142], as discussed below. All these methods have their
advantages and disadvantages in different cellular and multicellular systems which were
reviewed by Stewart et al. [143].
1.10 Permeabilising polymers
1.10.1 Characteristics
PP-50 is an amphipathic pseudo-peptidic polymer developed by the Department of Chemical
Engineering and Biotechnology at the University of Cambridge. It is synthesised by grafting
L-phenylalanine (containing an aromatic group) onto a hydrophobic poly(L-lysine iso-
phthalamide) (PLP) backbone via the pendant, weakly ionisable carboxylic acid moieties
(Figure 1.8) [144]. The polymer undergoes a conformational change in different pH: the
molecule is extended at higher pH than its pKa and folded to a globular structure at lower pH.
Such hydrophobically-stabilised structure disrupts the cell membrane and allows the uptake of
molecules, such as drugs or trehalose, to which the cell membrane is normally impermeable.
These pH-dependent conformational changes also enable removal of the polymer from
the membrane by increasing the pH [141]. Lynch and colleagues have proposed a precise
mechanism of membrane disruption, in which membrane thinning localised around the
polymer incorporated into the membrane allows more frequent formation of gaps which
facilitates trehalose uptake [125].
PP-50 belongs to a whole family of pH responsive amphipathic polymers with membrane
permeabilising ability based on the PLP backbone. Potential modifications include the
amino acid grafted (L-valine in PV series, L-leucine in PL series and L-phenylalanine in
PP series) and the degree of substitution (from approximately 30 to 65 %). Composition of
some of the polymer variants is summarised in Table 1.3 [141]. These polymers are also
biodegradable [145].
Table 1.3 Composition of PLP and examples of its amino acid-grafted variants
Polymer PLP PV-50 PL-50 PP-30 PP-50 PP-60 PP-75
Molar ratio* (%) 0 50.0 50.0 30.0 50.0 60.0 75.0
Degree of substitution** (%) 0 46.9 46.9 32.4 46.2 54.6 63.2
Adapted from Lynch et al. [141]; *Molar ratio of amino acid to carboxylic moieties on PLP used
during synthesis; **Actual degree of substitution after synthesis (number of aminoacids grafted per
100 carboxylic acid groups)
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Fig. 1.8 Chemical structure of PLP and its variants. Chemical formula of the synthesised poly(L-lysine
isophthalamide) (PLP) backbone containing ungrafted repeat units (with index m1) and repeat units
grafted with aminoacids (index m2) . Aminoacids grafted onto the backbone were L-phenylalanine
(PP series, including PP-50 and PP-75), L-leucine (PL series) or L-valine (PV series) (figure adapted
from Chen et al. [144])
1.10.2 PP-50 efficacy and toxicity
Phenylalanine is the most hydrophobic amino acid at pH 7.0 and, compared to grafting with
L-lysine and L-leucine, gives the polymer the most optimal properties for permeabilising the
membrane after grafting onto the PLP backbone [144]. Moreover, PP-50 was found to be
more effective than PL-50 and PV-50 in loading of trehalose into ovine erythrocytes. The
minimal degree of L-phenylalanine substitution in PP series for effective trehalose loading
was shown to be 32.4 % [141].
Several studies tested the potential toxicity of the amphipathic polymers on erythrocytes
or nucleated cell lines. Toxicity of PLP, PL-75 and PP-75 was evaluated by propidium
iodide (PI) staining after 48 h incubation of HeLa cells with concentration of the polymers
from 0 to 2000 µg/mL. In this assay, PLP did not result in in vitro toxicity within the
concentration range and PL-75 and PP-75 were toxic at concentrations higher than 500
and 50 µg/mL respectively [144]. PP-50 did not decrease metabolic activity of SAOS-2
cells measured by MTS assay up to the concentration 200 µg/mL when incubated for 2 or
24 h [142].
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1.10.3 Trehalose and permeabilising polymers
Few studies have examined intracellular delivery of trehalose mediated by membrane-
disrupting biopolymers. Lynch et al. showed that intracellular trehalose loading by PP-50
increased cryosurvival of ovine erythrocytes compared to extracellular trehalose alone [141].
Trehalose loading into ovine erythrocytes facilitated by PP-50 has been shown to be depen-
dent on pH, incubation time, temperature, and PP-50 and trehalose concentrations. Efficient
loading was only possible at pH lower than 7.05. Increase in PP-50 concentration led to a
rise in intracellular trehalose concentration following incubation, reaching the maximum
trehalose permeability at 100 µg/mL of PP-50. Intracellular trehalose concentration reached
its maximum if 360 mM extracellular solution of trehalose was used with PP-50; it was
suggested that higher concentrations of trehalose could inhibit PP-50 interactions with the
membrane. The highest loading of trehalose was observed at a higher incubation temperature
(37 °C) and a longer incubation time (9 h) [141].
SAOS-2 cell line was also used to assess the efficacy of PP-50 in cryopreservation
with trehalose to extend the work to nucleated cells. Sharp et al. reported that addition of
PP-50 to trehalose cryopreservation medium increases cell recovery. The optimal PP-50
concentration for SAOS-2 cell line was 25 µg/mL with optimal osmolarity of the solution at
133 mOsm/L [142]. Mercado et al. reported co-localisation of fluorescent PP-50 and fluores-
cent trehalose in the supra-nuclear space in SAOS-2 cells, suggesting that PP-50 mediated
this uptake of trehalose. While addition of PP-50 significantly improved cryosurvival of
SAOS-2 cells frozen with 200 mM trehalose, this was still well below the efficacy of the
standard 10 % DMSO cryopreservation protocol [146].
Cryopreservation of primary cells, including human haematopoietic progenitors or pan-
creatic islets with trehalose and permeabilising polymers has not been previously studied.
1.11 Antioxidants
1.11.1 Oxidative stress in cryopreservation
All cells can tolerate limited exposure to the reactive oxygen species (ROS) that are naturally
generated during the process of oxidative phosphorylation and can even be key to the
homeostatic metabolic function, signalling of cells or fighting infections. ROS also arise as a
consequence of ionising radiation, ischemia, and cryopreservation. Cells express endogenous
antioxidant enzymes in amounts sufficient to protect them from damage during homeostasis.
However, when the antioxidant capacity of cells is exceeded, redox homeostasis fails and cells
are subjected to potentially damaging amounts for ROS [147]. This can have a detrimental
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impact on the mitochondrial health, integrity of DNA, function of proteins in cells and
ultimately lead to apoptosis or malignant transformation [148].
The cryopreservation process inherently causes stress to cells and it may be necessary to
target multiple pathways to prevent apoptosis and ROS-related damage to DNA, proteins
and other cellular components. ROS can arise in cryopreserved tissue for multiple reasons.
Firstly, it has been shown that osmotic stress, which is to some extent always present
during cryopreservation due to addition of cryoprotectants, can increase production of ROS.
Additionally, thawed cells initiate many repair mechanisms which increases the oxidative
metabolism, generating more ROS [149]. Majority of antioxidants previously tested in
cell cryopreservation showed improvement in the post-thaw cell quality but there is also
evidence for antioxidant resveratrol that while its addition decreased the oxidation of cellular
components, it did not achieve an improvement in function of cells (in this case, the sperm
motility) [150].
Pancreatic islet cells have decreased amounts of endogenous antioxidant enzymes (cata-
lase, glutathione peroxidase and superoxide dismutase) compared to other tissues such as
liver, which makes them more sensitive to increased levels of ROS [127]. Addition of variety
of antioxidant compounds during the isolation and culture of islets before transplantation has
been tested with encouraging results [151]. Increased levels of ROS are found during the
progression of type 2 diabetes and antioxidants have been shown to prevent hyperglycaemia
and other markers of diabetes [152]. Addition of exogenous antioxidants may therefore tilt
the balance towards survival during pancreatic islet cryopreservation.
1.11.2 Salidroside
Positive effect of natural plant-derived compounds on pancreatic islet survival and insulin
secretion has been well demonstrated [153]. Even in cryopreservation, the extract from
Curcuma longa called curcumin has been shown to improve the post-thaw viability and
insulin secretion profile in pancreatic islets [154]. Another natural antioxidant, salidroside, is
a promising candidate for improvement of cryopreservation outcome but has not yet been
tested either for islet culture or cryopreservation.
Salidroside (Figure 1.9A) is an active compound of the medicinal herb Rhodiola rosea
with demonstrated pharmacological effects [155]. Al-Otaibi et al. have shown that salidroside
improves cryopreservation of red blood cells by positively affecting their oxidative status,
manifested as a decrease in lipid peroxidation and protein carbonylation [156]. Similarly,
decreased lipid oxidation and lactate dehydrogenase activity, as well as increased expression
of proteins involved with DNA repair and cell proliferation were demonstrated for human
leukaemia cell line cryopreserved with combination of DMSO and salidroside [157]. Safety
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Fig. 1.9 Structure of antioxidants salidroside and MitoQ. (A) Chemical structure of salidroside
(B) Chemical structure of MitoQ and changes happening during oxidation and reduction.
of orally administrated R. rosea has also been demonstrated in multiple clinical trials [158].
Although the precise mechanism behind its anti-oxidative properties is currently unclear, it is
known that in red blood cells, salidroside targets signalling pathways involved in induction of
apoptosis and prevents activation of caspase-3 and increase in intracellular Ca2+ ions [155].
1.11.3 MitoQ
The majority of ROS in cells is generated during the reactions of mitochondrial respiratory
chain. Increased concentration of ROS in mitochondria causes oxidation of mitochondrial
components (mtDNA, lipids, proteins) which can then initiate a cascade of events leading to
apoptosis and ultimately the death of the cell [148].
Mitoquinone (MitoQ) is a mitochondria-targeted antioxidant composed of a lipophilic
triphenylphosphonium cation and antioxidant ubiquinone. The lipophilic part of the molecule
directs the transport of MitoQ to mitochondria, where it accumulates and therefore delivers
the antioxidative effect directly at the main source of ROS. Upon entrance into mitochondria,
the oxidised ubiquinone form is reduced by complex II of the respiratory chain to ubiquinol
which can then exhibit its antioxidant function by being oxidised back to ubiquinone. It
can then be repeatedly recycled back to the original ubichinol form which ensures that each
molecule can exhibit its effect many times (Figure 1.9B) [159].
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MitoQ has been shown to decrease oxidative damage during ischemia reperfusion injury
in kidney and heart [160, 161]. Two clinical trials have been performed using MitoQ for
the treatment of hepatitis C [162] and Parkinson’s disease [163] and demonstrated safety
of MitoQ. Additionally, MitoQ was shown to provide protection against oxidative stress in
b -cell lines in the context of type 2 diabetes progression [164]. It has been previously tested
in the context of cryopreservation in sperm [165] and heart valve tissue [166], suggesting
that it is a good candidate for ameliorating oxidative stress in cryopreservation. It has never
been tested for cryopreservation of pancreatic islets.
1.12 Project aims
The ultimate aim of this project was to improve cryopreservation methods for pancreatic islets
for the purposes of transplantation by investigating potential of novel compounds including
disaccharide trehalose, permeabilising biopolymers PP-50 and PP-75 and antioxidants MitoQ
and salidroside. Optimisation of culture, viability assessment and performance of these
compounds in a single-cell model are important steps leading to the final cryopreservation
method for cell clusters.
The specific aims of this project were to:
1. Improve the methods of viability assessment of pancreatic islets for the purposes of
cryopreservation research and transplantation
2. Use mononuclear cells from deceased organ donors as a single cell model for investi-
gation of the efficacy of trehalose and membrane-permeabilising polymers
3. Investigate the potential of trehalose, permeabilising polymers and antioxidants for
cryopreservation of pancreatic islets:
(a) In a novel DMSO-free method
(b) As additives to the existing DMSO-based method
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1.13 Experimental approach
To improve viability assessment in both mononuclear cells and pancreatic islets, the key step
was identification of the limitations of current methods. These were demonstrated using a
series of experiments and approaches to improve them were suggested.
Because function of permeabilising polymers has never been explored in primary cells,
mononuclear cells were used for optimisation of its function before proceeding to multicellu-
lar islet model. All mononuclear cell experiments were performed using human cells from
deceased human organ donors. Screening of methods for pancreatic islet cryopreservation
was performed using mouse islets and where possible, replicated using deceased human
organ donor islets.
To select suitable cryopreservation protocols, a variety of cryopreservation protocols,
cryoprotectant combinations and additives were systematically screened using flow cytometry
for mononuclear cells and live/dead staining and wide-field fluorescent microscopy for
pancreatic islets. Slow freezing was chosen over vitrification due to disadvantages of
vitrification including use of toxic concentrations of cryoprotectants and the related difficulty
of removing these from multicellular aggregates. Slow-freezing has generally been better
explored than vitrification and standard protocol exists which can be modified with available
technologies. The modifications of the cryopreservation methods considered in this project
include:
• Pre-cryopreservation culture conditions
– Culture medium composition and culture temperature
• Composition of cryopreservation medium
– Presence of DMSO
– Addition of trehalose
– Addition of permeabilising polymers for intracellular trehalose delivery
– Addition of antioxidants
– Concentration of all components (cells, DMSO, additives)
• Incubation of cells with the cryoprotectants








– Removal of cryoprotectant
The successful protocols selected by this optimisation were then validated using variety
of in vitro functional assays and in vivo testing in mice. With pancreatic islets, the focus was
to evaluate the function of critical b -cell pathways described in Chapter 1.2.2 (by glucose-
stimulated insulin secretion and cAMP production after stimulation with incretin hormones),
mitochondrial health (mitochondrial DNA oxidation and ATP/ADP ratios) and ability to
survive and function in vivo (transplantation into diabetic mice).
Chapter 2
Materials and Methods
2.1 Tissues from deceased human organ donors
2.1.1 Tissue retrieval
Tissues from deceased human organ donors after circulatory death (DCD) or brainstem
death (DBD) were collected under ethical approval (REC Ref: 15/EE/0152) after obtaining
informed consent for use in research from the donor family. Deceased donors are a potential
alternative source of haematopoietic progenitors suitable for transplantation as they retain
their function even after certain periods of hypoxia [27, 167].
Bone marrow (BM) was aspirated from vertebrae using an 11 G bone marrow biopsy
needle (JamshidiTM) and collected into a heparinised 50 mL syringe. Multiple pieces of
spleen were excised and placed on ice in a container filled with Belzer UW®Cold Storage
Solution (Bridge to Life Ltd.) within one hour of circulatory arrest. Some of the spleens were
obtained as attached to pancreases intended for transplantation and subsequently declined
by multiple transplant centres (under ethical approval REC Ref: 12/EE/0253, substituted
by 16/EE/0227). Notably, such spleen tissue will have spent a prolonged period in cold
preservation solution before being ready for processing in the laboratory (12 – 18 h). BM




Spleen was cut into small pieces of approximately 1 cm3 using a scalpel and transformed
into a single cell suspension by one of the following two methods.
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In the first method, the tissue was pushed through a 100 µm sieve using a syringe plunger,
until it was completely disintegrated, and the sieve was then washed with Dulbecco’s Modified
Eagle Medium (DMEM, Thermo Fisher Scientific) supplemented with 10 % FCS (Sigma
Life Sciences). Second method utilised the gentleMACSTM Dissociator (Miltenyi Biotec).
Sections of spleen were placed into gentleMACSTM C Tubes (Miltenyi Biotec) and covered
with DMEM + 10 % FCS. Tissue was dissociated into a single-cell suspension using a pre-set
programme on the device.
Cell suspension from either method was filtered through a 70 µm cell strainer and mononu-
clear cells were isolated by density gradient separation. 20 mL of the cell suspension was
carefully layered on top of 15 mL of LymphoprepTM (Stemcell Technologies) in a 50 mL
Falcon tube. The tubes were then centrifuged at 800 g for 25 min at 20 °C with the brake off.
The layer of mononuclear cells was collected by Pasteur pipette and washed twice by DMEM
+ 10 % FCS, centrifuged at 300 g for 7 min with the brake on. Cells were then counted using
haemocytometer and resuspended in a cryopreservation medium for freezing or in culture
medium for analysis of fresh sample.
Bone marrow
Bone marrow was filtered through a 70 µm cell strainer, separated on density gradient media
and further processed as described above for spleen.
2.1.3 Obtaining human pancreatic islets
Pancreatic islets were isolated from pancreases of human deceased organs donors by SNBTS
Islet Cell Laboratory in Edinburgh (ethical approval REC Ref: 16/WM/0093). These clin-
ically isolated islets were declined for transplantation due to low purity, viability or yield
and subsequently offered for research use. They were shipped in CMRL 1066 Supple-
mented culture media (Corning) at room temperature and further processed upon arrival.
The purity and viability of the received islets was validated upon receipt in our laboratory
using dithizone staining and fluorescein diacetate/propidium iodide staining as described in
Sections 2.6.1 and 2.6.2.
2.1.4 Information storage
Anonymised donor information was retrieved from a database managed by research assistants
at the Department of Surgery. A dedicated database of samples stored in the liquid nitrogen
dewar was managed and regularly updated, ensuring that manipulation of samples in the
dewar by all users was kept to a minimum.
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2.2 Animals and animal procedures
2.2.1 Animal provenance and husbandry
All animals were housed and maintained in University Biomedical Services facility under
specific-pathogen-free conditions. All procedures were performed under project licences
(PPL numbers 70/8702 and 80/2638) approved by the United Kingdom Home Office under
the Animal (Scientific Procedures) Act 1986.
Male C57BL/6JAX mice were purchased from Charles River, UK and subsequently used
for isolation of mouse pancreatic islets as described in Section 2.2.2. These mice were
maintained following standard husbandry procedures in the animal facility and used for
experiments between the age of 5 and 12 weeks.
Fully immunodeficient NSG (NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ, NOD scid gamma)
mice, which lack B, T and NK lymphocytes [168] were bred in-house, litters weaned at three
weeks of age and used for experiments between 6 and 13 weeks of age. Maintenance of
this strain was performed with special care, reflecting its immunocompromised background
(weekly cage changes and daily checks prior to other mouse strains, aseptic technique).
2.2.2 Isolation of mouse pancreatic islets
C57BL/6JAX mice were sacrificed by neck dislocation schedule 1 method. In a supine
position (head facing the surgeon), laparotomy was performed and diaphragm cut though and
fixed with a tape to allow space for the liver to be flipped over and uncover the gall bladder
and bile duct. Bile duct leads though the head of the pancreas and enters the duodenum at
hepato-pancreatic ampulla (white patch on the duodenum). Two clamps were placed on the
bowel, one on each side of the ampulla to prevent leaking of the perfusate into the bowel
(Figures 2.1A and B). Solution of collagenase XI (2.5 mL, Sigma Life Science, 1000 U/mL
in HBSS medium) was slowly injected into the bile duct, starting from the gall bladder, using
a 2.5 mL syringe with a 30 G beveled needle. Once the volume was injected, the pancreas
lobules were clearly separated by the injected solution (Figure 2.1C). Pancreas was then
carefully dissected out of the abdomen, placed into a 50 mL Falcon tube containing another
2 mL of collagenase XI solution and kept on ice until pancreases from all animals were
retrieved and tissue transferred into laboratory.
In the laboratory, Falcon tubes with the pancreases were incubated in 37 °C water bath
and shaken every 5 min until the tissue was digested into a fine suspension (typically for
12 to 18 min). Digestion was then terminated by adding 25 mL of ice-cold solution of HBSS
supplemented with 1 mM CaCl2 into each tube and centrifuging at 300 g for 1 min at 4 °C.
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Another two washes with HBSS + CaCl2 were performed and the digest in each tube was then
resuspended in 10 mL Histopaque 1077 Hybri MaxTM (Sigma Aldrich) at room temperature.
RPMI medium (5 mL, at room temperature) was carefully layered on top of the Histopaque
and tubes were centrifuged (Figure 2.1D). After centrifuging, the islet-enriched layer can be
found on the interface of Histopaque and RPMI, as shown in Figure 2.1E. To increase the
yield, both RPMI and Histopaque layers were collected into a new Falcon tube, topped up
with RPMI and centrifuged at 300 g for 3 min. The pellet was transferred into a 10 mm Petri
dish. Although the density gradient separation yielded reasonably pure fraction of pancreatic
islets if assessed by dithizone staining, full purification was achieved by manual handpicking
of islets under inverted microscope (Figures 2.1F and G).
Single pancreas yielded approximately 150 islets. These were subsequently cultured
in RPMI + 10% FCS + 1% Penicilin/Streptomycin at 37 °C and 5 % CO2 in humidified
atmosphere for 1 to 7 days before being used for further experiments. Viability of islets did
not decrease over this period (data not shown) and to control the quality of islets, viability
staining was always done before the start of any experiment.
2.2.3 Transplantation of islets under the kidney capsule of NSG mice
Pancreatic islets were handpicked into one 1.5 mL Eppendorf tube per each individual
injected mouse, centrifuged at 300 g for 1 min, supernatant removed and islet in each tube
resuspended in 30 µL of Matrigel (Corning). Samples were kept on ice until the injections to
prevent solidification of the Matrigel.
NSG mice were anaesthesised using mixture of isoflurane and oxygen, shaved on the
left side and cleaned with chlorhexidine. The animal was placed on a heat mat set to 37 °C,
positioned on its side. Small incision in the skin and muscle was made at the location of the
kidney. Kidney was then gently pushed outside through this opening and kept from drying
out using warmed saline. A small incision was made in the kidney capsule with a sharp 20 G
needle. Through this incision, a blunt needle attached to Hamilton syringe containing the
Matrigel suspension with islets was carefully pushed through the kidney parenchyma and
30 µL of the suspension was injected under the kidney capsule. Syringe was loaded before
each injection to prevent differences in number of received islets per mouse.
After removing the needle from the injected kidney, bleeding was stopped by applying
mild pressure on the wound with a cotton bud. Once the kidney was returned to the peritoneal
cavity, the muscle layer was closed using a continuous 5-0 vicryl sutures and the skin layer
with interrupted sutures. To ensure that the animals do not open the wound, two to three
autoclips were applied onto the stitches. After the surgery, the animals were placed into
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Fig. 2.1 Method of mouse pancreatic islet isolation. (A) Preparation of the animal before injection
with collagenase. (B) Close-up of the organs and the injection site before injection. (C) Close-up of
the organs and the injection site after injection with visible discolouring of the liver and extension of
the pancreas lobules. (D) Tube with the pancreas digest before density gradient separation. (E) Tube
with the pancreas digest after density gradient separation. Highlighted is the layer of islets in
between Histopaque and RPMI. (F) Microscopic picture of dithizone-stained pancreatic islets before
handpicking. Endocrine tissues stain pink while the exocrine acinar cells do not. (G) Microscopic
picture of dithizone-stained pancreatic islets after handpicking. AM = hepato-pancreatic ampulla;
BD = bile duct; D = duodenum; GB = gall bladdder; PN = pancreas.
individual recovery cages and monitored for several hours, then returned into their original
cages.
2.2.4 Induction of diabetes in NSG mice
Streptozotocin (STZ, Sigma Life Science) solution was prepared on the day of the injection
by dissolving STZ powder in freshly prepared citrate buffer (0.1 M citric acid + 0.1 M sodium
citrate, pH 4.2) at a concentration of 10 mg/mL and kept on ice until the injections.
NSG mice were weighed, anaesthesised using mixture of isoflurane and oxygen and
injected with 40 mg/kg STZ intraperitoneally on five subsequent days using 30 G needle.
Higher doses of STZ were initially tested which produced rapid-onset severe diabetes but
these methods were abandoned due to a rapid weight loss of the animals (Appendix E).
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In addition to their regular chow, these mice were fed mashed food with the same
composition for the duration of the experiment. Weights and blood glucose were measured
before the first injection of STZ and subsequently every 3 – 4 days until the end of the
experiment. Blood glucose was measured using iHealth Smart Gluco-Monitoring system
(iHealth Labs) by tail vein bleeds.
Mice were considered diabetic when their blood glucose reached over 13.5 mmol/L on
two consecutive measurements and used for transplantation when blood glucose reached
over 18 mmol/L. Diabetic animals were transplanted with fresh or cryopreserved islets (or
Matrigel as a control) under the kidney capsule (as described in Section 2.2.3) to assess the
function of islet cells.
Animals were culled if they lost over 20 % of the weight measured at the start of the
experiment or at 4 weeks after transplantation. Blood serum was collected at the start
of the experiment, before the islet transplantation and at the endpoint for biochemistry
measurements. At the endpoint, blood was collected for serum using inferior vena cava bleed
and transplanted kidney removed under terminal anaesthesia, embedded in paraffin and kept
for potential immunohistochemical analysis (not included in this thesis).
2.2.5 Collection and processing of mouse peripheral blood
Tail vein bleeds for regular glucose measurements
Mice were gently placed in a restrainer and tail vein was incised using a 30 G needle. Small
drop of blood was loaded into the strip of iHealth Smart Gluco-Monitoring system (iHealth
Labs) and displayed glucose concentrations were recorded. Glucose meter was validated
agains biochemistry measurements in Appendix E). Bleeding was stopped by applying mild
pressure.
Tail vein bleeds for collection of serum
Animals were placed in a 37 °C warming cabinet for 10 min to allow for dilation of blood
vessels. Once warmed, mice were gently placed into a restrainer, tail vein was incised using
a 25 G needle and 1 – 6 drops of blood were collected from a tail vein into a blood collection
tube. Bleeding was then stopped by applying mild pressure.
Inferior vena cava bleeds
Animals were anesthesised with isoflurane and oxygen and placed on a heat mat set to 37 °C.
Laparotomy was performed to reveal the abdominal organs. Bowels and liver were carefully
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moved to the side using a cotton bud to reveal the inferior vena cava (IVC). Using 1 mL
syringe with attached 25 G needle with the bevel facing up, blood was slowly drawn from
the top portion of the IVC (typically up to 700 µL). Exsanguination under anaesthesia was a
non-recovery procedure used as a killing technique.
Extraction of serum from peripheral blood and glucose quantification
Blood collected from tail vein or IVC bleeds was kept at 4 °C for 24 h after collection,
allowing for it to coagulate. Tubes were then spun in a microcentrifuge at 13000 g for 7 min.
Clear serum was collected from the top supernatant layer, transferred into a new Eppendorf
tube and stored at  20 °C until analysis.
Glucose measurements in mouse serum were done by the Core Biochemical Assay
Laboratory (supported by the MRC MDU Mouse Biochemistry Laboratory [MRC MC UU
12012/5]). Serum glucose was measured using a colorimetric assay on the Siemens Dimen-
sion EXL autoanalyser. All reagents and calibrators were supplied by Siemens.
2.3 Compound provision and synthesis
2.3.1 Synthesis of PP-50 and PP-75
The PP-50 and PP-75 polymers were synthesised and kindly provided by Dr. Krishnaa T.
Mahbubani and Alex Chen. The synthesis steps are briefly described below.
The polymer backbone (PLMEP) was synthesised by combining potassium carbonate and
L-lysine methyl ester dihydrochloride aqueous solution with iso-phthaloyl dichloride solution
in acetone. The polymers of varying length were formed at the liquid-liquid interface. After
one hour, the formed globule was thoroughly washed from organic substances. It was then
dried in a 55 °C vacuum oven overnight.
The dry globule was ground into a powder and dissolved in DMSO. Solution of sodium
hydroxide in ethyl alcohol was then added and incubated for three minutes to allow pre-
cipitation. At this step, the methyl groups of PLMEP were substituted by hydroxyl groups.
The precipitate was collected by vacuum filtration and its aqueous solution was purified by
dialysis which ensures DMSO removal. After seven days of dialysis, the pH of the purified
solution was adjusted to 7.4 by 1 M sodium hydroxide, followed by lyophilisation of PLP.
In the next step, L-phenylalanine was grafted on the PLP backbone in a reaction of PLP
with L- phenylalanine methyl ester·HCl, mixed with triethyl amine and 4-dimethylamino-
pyridine in DMSO/DMF (dimethylformamide) solution. A solution of N,N’-dicyclohexyl-
carbodiimide in DMF was then drop-wise added to the solution. After 60 h, 5 % sodium
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Fig. 2.2 Chemical structure and 1H-NMR spectra of PLP, PP-50, and PP-75. The unique proton on
the backbone benzene was denoted as a and assigned to the according peak on the NMR spectra. Five
protons on the phenyl group were denoted as b and assigned to the peak on the NMR spectra of PP-50
and PP-75. DMSO and H2O peaks at 2.5 and 3.5 ppm were removed for better visualisation of the
spectra. This figure is a courtesy of Dr. Alex Chen. 1H-NMR = Proton nuclear magnetic resonance;
ppm = parts per million.
hydroxide was added to the reaction mixture to allow precipitation. Again, the precipitate
was collected by vacuum filtration and purified by dialysis in distilled water. After ten days,
the product was collected, pH adjusted to 7.4 and it was lyophilised into a fine powder. Prior
to use, the PP-50 powder was dissolved in PBS at a concentration 20 mg/mL.
The PLP backbone and the two synthesised polymers were subjected to proton nuclear
magnetic resonance (1H-NMR) analysis by Dr. Alex Chen and the results are displayed
in Figure 2.2. The grafting percentage calculated by 1H-NMR was 46.0 % and 60.8 % for
PP-50 and PP-75 respectively.
2.3.2 Fluorescent labelling of PP-50
Fluorescent labelling of PP-50 was done with kind help of Dr Krishnaa T. Mahbubani. First,
PP-50 was dissolved in mixture of DMSO and distilled water. N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (sulfo-NHS) were
dissolved in distilled water. The EDC/Sulfo-NHS mixture was added to the PP-50 solution
and left to react for one hour at room temperature. Alexa Fluor® 647 (AF647) cadaverine
(Thermo Fisher Scientific) was dissolved in 1 M Na2CO3 and added to the activated PP-
50/EDC/Sulfo-NHS mixture to react at room temperature overnight in the dark.
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On the next day, 5 % DMSO in PBS was added to the solution to dissolve any precipitate.
The solution was then dialysed against distilled water for 1 week in 3500 Da tubing with daily
water changes. After one week, the remaining solution was transferred to a 50 mL Falcon
tube and concentrated HCl was added to precipitate the AF647-labelled PP-50. Mixture
was then centrifuged at 2500 g for 3 min and supernatant centrifuged again to recover any
remaining precipitate. Blue solid was then dissolved using NaOH and PBS, dialysed again
against distilled water for 3 h and subsequently lyophilised to yield a blue solid powder. The
powder was then dissolved in PBS at concentration of 2 mg/mL prior to use.
2.3.3 Provision of antioxidants
MitoQ was kindly provided by Prof. Michael P. Murphy in the powder form. The batch was
synthesised in 2012. Prior to use, the powder was dissolved in ethanol at concentration of
50 mM and further diluted with ethanol to make a working stock of 50 µM. Powder and
dissolved MitoQ and stock solutions were stored at  20 °C.
Salidroside was purchased from Sigma Aldrich. Stock solution was made by diluting the
salidroside powder in DMSO at 200 mM concentration. Powder form and stock solutions
were stored at  20 °C.
2.4 Cryopreservation
2.4.1 Cryopreservation of mononuclear cells
Mononuclear cells from spleen, bone marrow or peripheral blood were frozen in 1.8 mL
cryovials (Thermo Fisher Scientific) in a final volume of 1 mL under different experimental
conditions. These included DMSO control and various combinations of trehalose (solutions
made from D-(+)-trehalose dihydrate, Sigma Life Sciences) and PP-50/PP-75 polymers
in DMEM medium with or without FCS. Other variations included addition of incubation
period or changing concentrations of the components. Cryovials were then transferred to a
freezing container (Nalgene) and placed in a  80 °C freezer overnight. The samples were
then transferred into a liquid nitrogen dewar for at least one day before the thawing and
analysis.
2.4.2 Thawing of mononuclear cells
The thawing procedure was optimised during a series of experiments for different cryopreser-
vation solutions (see Results section 4.3.3), the protocol described here is the final optimised
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protocol. Sample was removed from the liquid nitrogen dewar onto dry ice and transferred to
a 37 °C water bath. Samples frozen down with DMSO were kept in the water bath only until
a small ice crystal was left, whereby the trehalose samples were incubated for 10 min. The
suspension was then transferred into a 50 mL Falcon tube. The thawing media, consisting of
DMEM + 50 % FCS and pre-warmed to 37 °C, was added slowly drop-wise to the tube up
to the volume of 20 mL (20⇥ the original volume). The tube was then centrifuged at 300 g
for 5 min. The cells were resuspended and counted using haemocytometer. Cells were then
ready for further analysis.
2.4.3 Cryopreservation of pancreatic islets
Human or mouse pancreatic islets were handpicked into a 1.8 mL cryovial and cryoprotectant
was added according to the experimental protocol. Standard cryopreservation protocol
consists of cryopreservation in 2 M DMSO in RPMI (mouse islets) or CMRL (human
islets) with 10 % FCS. Addition of 2 M DMSO was optimised (see Section 5.3.1) and the
final protocol consists of three additions of DMSO over 45 min to gradually increase its
concentration (5 min in 0.66 M DMSO at room temperature, 25 min in 1 M DMSO at room
temperature and 15 min in 2 M DMSO at 4 °C). Any variations to this standard protocol are
described in the Results section. Additionally, compounds such as trehalose (D-(+)-trehalose
dihydrate, Sigma Life Sciences), MitoQ or salidroside (Sigma Aldrich) were used during the
incubation period before the addition of DMSO. Details of cryoprotectant combinations are
described in the Results section.
Freezing was performed using the CRF-1 controlled rate freezer (Grant) set to a pro-
gramme described in Table 2.1. Briefly, islets were brought to  7.4 °C and held at that
temperature for 15 min to allow for nucleation and release of latent heat of fusion. Following
this, islets were slow-frozen to  40 °C at the rate of  0.3 °C/min, followed by plunging to
liquid nitrogen. Vials were then stored in liquid phase of liquid nitrogen until thawing.
Table 2.1 Freezing programme for pancreatic islets
Step Rate Duration Notes
+4 °C to  7.4 °C  2 °C/min 5.75 min
 7.4 °C 0 °C 15 min Hold temperature for nucleation
 7.4 °C to  40 °C  0.3 °C/min 108 min Slow freezing
 40 °C to  196 °C >  1000 °C/min 10 s Plunge to liquid nitrogen
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2.4.4 Thawing of pancreatic islets
The thawing procedure for pancreatic islets was optimised during a series of experiments for
human and mouse pancreatic islets (see Section 5.3.3), the protocols described here are the
final optimised protocols.
Cryopreserved mouse pancreatic islet samples were removed from liquid nitrogen and
transferred to water bath on dry ice. Rapid thawing in a 37 °C water bath was performed
until the last ice crystal was visible in the vial and dilution of the cryoprotectant with culture
medium (RMPI + 10 % FCS) was performed over 24 min as described in Table 2.2. The
final concentration of cryoprotectant was decreased to 10 % of the original one (i.e. final
concentration of DMSO in samples cryopreserved in 2 M DMSO after performing this
protocol was 0.2 M). Islets were then handpicked into a fresh Petri dish containing culture
medium and either used immediately or cultured at 37 °C in 5 % CO2 humidified atmosphere.
Table 2.2 Cryoprotectant removal protocol for mouse pancreatic islets
Time after thawing Addition of CM Concentration of CPA















Notes: CM = culture medium; CPA = cryoprotectant; " = same as above
Human pancreatic islets were transferred from liquid nitrogen onto dry ice and transported
to the 37 °C water bath where they were rapidly thawed until last crystal was visible.
Cryovials were then centrifuged (300 g for 1 min) and supernatant substituted for 1 mL of
0.75 M sucrose solution in CMRL + 10 % FCS. After 30 min incubation on ice, contents of
cryovials were transferred to Petri dishes at room temperature and culture medium (CMRL
+ 10 % FCS, Corning) was added every five minutes as outlined in Table 2.3 until the final
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concentration of cryoprotectants reached 2.2 % of the original concentration (i.e. 0.04 M
DMSO if cryopreserved with 10 % DMSO) and 0.15 M sucrose. Islets were then handpicked
into a fresh Petri dish containing culture medium and either used immediately or cultured at
37 °C 5 % CO2 humidified atmosphere.
Table 2.3 Cryoprotectant removal protocol for human pancreatic islets
Time after Addition of Concentration Concentration
thawing + spin CM/SUC of CPA of SUC
(min) (mL) (% original concentration) (% original concentration)
- - 100.0 0.0
0 1 (SUC) 10.0 100.0
30 1 (CM) 5.2 50.0
35 1 (CM) 3.5 33.3
40 2 (CM) 2.2 20.0
Notes: CM = culture medium; CPA = cryoprotectant; SUC = 0.75 M sucrose
2.4.5 Liquid nitrogen storage
All cryopreserved samples were stored in liquid phase of liquid nitrogen inside one of three
dewars available. The level of liquid nitrogen in these dewars was manually monitored twice
a week and filled up as necessary. Sample database described in Section 2.1.4 was consulted
prior to any deposit or removal of samples. Transferring of samples into and from the liquid
nitrogen dewar was done in a rapid fashion and sample boxes were strictly handled on dry
ice to decrease the impact of temperature fluctuations.
2.5 Assays for single cell analysis
2.5.1 Cell counting
Absolute cell number of fresh or thawed mononuclear cells was determined either manu-
ally using a haemocytometer (Improved Neubauer, Hawksley) or using TrucountTM tubes
(BD Biosciences). To count with haemocytometer, the cell suspension was diluted with
white blood cell counting fluid (2 % acetic acid supplemented with crystal violet) or Trypan
Blue solution (MP Biomedicals). Count of cells in four large squares (1 mm2 area each) was
performed for each sample and average value was then used for the calculation of absolute
cell count following this formula:
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Absolute cell count = Average count per square ⇥ dilution factor ⇥ 104 ⇥ volume in mL
To determine absolute cell count with TrucountTM tubes, known volume of cell suspen-
sion was pipetted into the Trucount tube and diluted with staining buffer (PBS + 0.1 % bovine
serum albumin + 0.1 % sodium azide). Using BD FACSCantoTM II flow cytometer (BD Bio-
sciences), at least 20,000 events were recorded. Cells were gated based on Syto13 and
7-AAD (7- Aminoactinomycin D) staining and beads were gated using the PE-Cy7 versus
APC-Cy7 dot plot, found in upper right quadrant. Absolute cell count was calculated as:
Absolute cell count =
cells in gate
beads in gate
⇥ beads in Trucount tube
⇤
µL o f sample in Trucount tube
⇥ total volume of sample in µL
2.5.2 Toxicity assays for mononuclear cells
Fresh human splenocytes resuspended in DMEM + 10 % FCS were aliquoted into wells of
96-well plates and incubated with 0 – 1000 µg/ml of PP-50/PP-75 or 0 – 800 mM trehalose at
37 °C with 5 % CO2 for 2, 24 or 48 h. Cells were washed off after the incubation period with
PBS and viability of the cells was analysed immediately with Syto13 (Invitrogen, 1:500,000
dilution) and 7-AAD Viability Staining Solution (eBioscience, 1:20 dilution). Absolute cell
count was determined using BD TrucountTM tubes (BD Biosciences).
2.5.3 Culture assays for mononuclear cells
Fresh human splenocytes were resuspended in 200 mM trehalose (in DMEM + 10 % FCS)
and 500 µL were aliquoted into 1.5 mL Eppendorf tubes (one for each condition). Each tube
was then incubated at a different temperature (3 °C in the fridge, 20 °C at room temperature
and 37 °C in the water bath). At each time point measured, the vial was well mixed and small
known volume of the suspension was taken out into a Trucount tube. The cells were then
stained with Syto13 (Invitrogen, 1:500,000 dilution) and 7-AAD (eBioscience, 1:20 dilution)
using no-wash procedure and data collected on a flow cytometer. Absolute counts of alive
nucleated cells were normalised to absolute counts of alive nucleated cells at time 0.
2.5.4 Flow cytometry of mononuclear cells
Human cells (fresh or thawed) were resuspended in staining buffer (PBS + 0.1 % bovine
serum albumin + 0.1 % sodium azide) and treated with human or mouse FcR blocking agent
(Miltenyi Biotech, 1:20 dilution) for 15 min at 4 °C prior to staining. After one washing step
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Table 2.4 Antibodies and stains used for the analysis of fresh and thawed mononuclear cells
Antibody/stain Conjugate Supplier Dilution used
7-AAD - eBioscience 1:20
Annexin V APC Thermo Fisher Scientific 1:200
CD19 APC-Vio770 Miltenyi Biotech 1:20
CD19 PE BioLegend 1:200
CD19 PE-Vio770 Miltenyi Biotech 1:20
CD3 PE-Cy7 BioLegend 1:400
CD34 PE eBioscience 1:20




Syto13 - Thermo Fisher Scientific 1:500,000
Notes: For the antibodies, fluorochrome conjugates are indicated. Suppliers and dilutions used
(determined by titration for each of the reagents) are stated for all reagents
(centrifugation at 200 g for 4 min), cells were stained by fluorochrome conjugated antibodies
(each was titrated to ensure the correct concentration, see Table 2.4) in staining buffer for
15 min at 4 °C protected from light. The viability stain used was either 7-AAD or eFluor 780,
for the latter the staining was done subsequently in PBS for 20 min at 4 °C, protected from
light. Staining for annexin V was done in annexin binding buffer (50 mM HEPES, 700 mM
NaCl, 12.5 mM CaCl2, pH = 7.4) for 15 min in dark at room temperature. Information about
the antibodies and stains used for mononuclear cells is summarised in Table 2.4. The choice
of antibody panels used for the experiments is justified in Appendix B.
The analysis of the stained samples was done using a 6-colour flow cytometer BD
FACSCantoTM II and computer equipped with the BD FACSDivaTM software (BD Bio-
sciences, version 6.1.3). For each analysis, unstained control and single stained compensation
controls were included and automatic compensation was performed. After recording data
from the samples, FCS files were exported and further analysed by the FlowJo software
(version 10.1). The gating strategy for determining the viability of cells and enumerating the
haematopoietic progenitors is shown in Appendix B.
2.5.5 Fluorescence activated cell sorting (FACS)
Thawed human mononuclear cells were counted and stained with fluorochrome-conjugated
antibodies (Table 2.5) for 30 min at 4 °C. Single stained compensation beads (BD CompBeads,
BD Biosciences) were used as compensation controls, except for the viability stain (Zombie
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AquaTM, Biolegend) where cells were used for compensation setup. FACS was performed
using BD FACSAriaTM Fusion or BD FACSAriaTM III cell sorter (provided by NIHR
Cambridge BRC Cell Phenotyping Hub) and the desired number of cells of target population
from each sample was collected into a 1.5 mL Eppendorf tube. Cells were kept on ice during
the whole procedure.
The target population collected for the colony forming units assay was Zombie Aqua ,
CD3 , CD19 , CD235a , CD11b , CD34+. The gating strategy is shown at Figure 2.3A.
Table 2.5 Antibodies and stains used for the fluorescence cell sorting of mononuclear cells
Antibody/stain Conjugate Supplier Dilution used
CD11b APC-Cy7 BioLegend 1:300
CD19 Alexa700 BioLegend 1:300
CD235a PE BD Biosciences 1:1000
CD3 FITC BD Biosciences 1:500
CD34 APC BD Biosciences 1:200
CD38 PE-Cy7 BioLegend 1:100
Zombie AquaTM - BioLegend 1:2000
Notes: For the antibodies, fluorochrome conjugates are indicated. Suppliers and dilutions used
(determined by titration for each of the reagents) are stated for all reagents
2.5.6 Haematopoietic colony forming unit (CFU) assay
Aliquots of 2.5 mL MethoCultTM medium (H84435, StemCell Technologies) were thawed at
4 °C. Eppendorf tubes containing CD34+ cells from bone marrow after the cell sorting were
centrifuged at 500 g for 5 min and supernatant aspirated to leave approximately 50 µL of
medium in the tube. The cells were resuspended and the whole volume was then transferred
into a tube of MethoCultTM. The suspension was mixed by aspirating up and down several
time using 1 mL syringe with 18 G needle. Tubes were allowed to stand for 15 min to let
any bubbles rise to the top. Using the syringe and needle, the suspension was drawn from a
MethocultTM tube and plated in duplicates into the wells of a 6-well plate (SmartDishTM,
Stemcell Technologies), 1 mL into each well (Figure 2.3B). The 6-well plates were then
placed into a larger container together with two 35 mm Petri dishes containing sterile PBS to
keep the culture hydrated and incubated at 37 °C and 5 % CO2 for 14 days.
On days 11 and 14, the colonies of haematopoietic cells were counted by STEMvisionTM
(Stemcell Technologies) automated colony counter. Images of the colonies were acquired
using the STEMvisionTM Acquisition application (Figure 2.3D). The automatic count of
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three colony types (Figure 2.3C) by STEMVisionTM Analyser application was then manually
validated and adjusted using the STEMvisionTM Marker software (Figure 2.3E). The colony
counts from all conditions were normalised to the number of CD34+ cells seeded.
After the colonies were counted on day 14, cells from the dishes were washed with PBS +
3 % FCS, the suspension was harvested, combining the duplicate cultures, and washed twice
to remove the MethocultTM medium. Flow cytometry was then performed, using the markers
for erythrocytes (Glycophorin A/CD235a), myeloid cells (CD33), monocytes/macrophages
(CD14) and granulocytes (CD15) (Table 2.6). Gating strategy is shown at Figure 2.3F. The
stained samples were transferred into BD TrucountTM tubes (BD Biosciences) to determine
the absolute count of the harvested cells.
Table 2.6 Antibodies and stains used for the analysis of cells harvested from the colonies of
haematopoietic cells grown for the CFU assay
Antibody/stain Conjugate Supplier Dilution used
7-AAD - eBioscience 1:20
CD235a FITC Miltenyi Biotech 1:20
CD33 PE Miltenyi Biotech 1:50
CD14 PE-Vio770 Miltenyi Biotech 1:100
CD15 APC Miltenyi Biotech 1:20
Notes: For the antibodies, fluorochrome conjugates are indicated. Suppliers and dilutions used
(determined by titration for each of the reagents) are stated for all reagents
2.5.7 Total protein assay
Fresh mononuclear cells were incubated in 96-well plate (106 cells per well) with a range
of polymer concentrations for 4 h at room temperature. After the incubation, cells were
centrifuged (at 300 g for 5 min) and resuspended in NP-40 cell lysis buffer (Invitrogen)
supplemented with cOmpleteTM Protease inhibitor (Roche). Lysates were diluted and 25 µL
was transferred into a new flat-bottomed 96-well plate for the assay. Same volume of pre-
diluted bovine serum albumin (BSA) standards were also transferred into separate wells of
the new plate. Total protein measurement was performed using the BCA Protein Assay Kit II
(BioVision) according to manufacturer’s instructions. Briefly, 200 µL of prepared detection
mix was added to each well with standard or sample and the plate was incubated at 37 °C
for 30 minutes. Measurement was then performed using the FLUOstar Optima plate reader
(BMG Labtech), excitation 480 nm, emmision 560 nM.
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Fig. 2.3 Colony forming units assay. (A) Gating strategy for fluorescence activate cell sorting. Gate
P1 = cell population, P2 = singlets, P3 = Zombie Aqua  (viable cells), P4 = CD19  cells, P5 = CD3 
CD11b  cells, P6 = CD19  CD235a  cells, P7 = CD34+ cells. Target population for sorting is
Zombie Aqua , CD3 , CD19 , CD235a , CD11b , CD34+. (B) SmartDishTM with duplicate
cultures seeded with CD34+ cells; after 14 days of culture red and white haematopoietic colonies are
visible. (C) Haematopoietic colonies were classified into three categories: red BFU-E (burst-forming
unit erythroid), white CFU-GM (granulocyte-macrophage colony forming unit) and mixed CFU-
GEMM (granulocyte-erythrocyte-monocyte-megakaryocyte colony forming unit). (D) Reconstructed
dark-field image of one SmartDishTM well with haematopoietic colonies after 14 days of culture
photographed by STEMVisionTM. (E) Automated recognition of colonies by the STEMVisionTM
Analyser software. Different colony types are marked by different colour rings: red for BFU-E,
yellow for CFU-GM and blue for CFU-GEMM. (F) Gating strategy for analysis of cells from colonies
after 14 days of culture. First of all, cells, singlets and alive cells were selected by gating (as shown
in (A)). Myeloid and erythroid cells were then distinguished based on their expression of CD235a
and CD33. CD33+ myeloid cells were further distinguished as CD14+ monocytes/macrophages and
CD15+ granulocytes. Results were then expressed as percentage of erythroid cells, myeloid cells,
macrophages or granuloces from the total cell count.
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Fig. 2.4 A fresh sample of human pancreatic islets stained by dithizone dye. (A) Example of very
pure batch of islets containing almost solely islets (red colour) and no acinar tissue (grey colour).
Human islet size is typically very variable and this image shows a particularly large islet. (B) Example
of pancreatic islet sample containing large percentage of acinar tissue. Both images were taken at 4x
objective magnification.
2.6 Assays for pancreatic islets
2.6.1 Assessment of purity by dithizone staining
On arrival of fresh human pancreatic islets, the purity of the batch was validated by dithizone
staining. The stock of dithizone was prepared at the concentration of 0.2 mg/mL and pH 7.4
and aliquots were stored at  20 °C. Thawed aliquot of dithizone was filtered through 0.22 µm
syringe filter before staining. An aliquot of approximately 200 IEQ was obtained from the
islet suspension stock and resuspended in 2 mL of the dithizone stain. After 10 – 12 min of
incubation islets were immediately imaged on a glass slide with cover slip using bright field
illumination on the Olympus IX81 inverted fluorescence microscope. The pancreatic islets
stain red as the dye binds to the zinc ions in the secretory granules of b -cells. The acinar
tissue is not stained by this dye (Figure 2.4). The purity of the islet sample was visually
assessed as a percentage of red-staining tissue in the whole sample.
2.6.2 Assessment of viability by fluorescent imaging
Islets were handpicked and placed in 300 µL of PBS. Fresh mastermix of 1:10 dilution of
propidium iodide (PI) stock (0.5 mg/mL, Sigma-Aldrich) and 1:100 dilution of fluorescein
diacetate (FDA) stock (5 mg/mL, Sigma-Aldrich) were prepared and used for staining within
30 min. 20 µL of the mastermix was added to the islet sample and immediately imaged by an
Olympus IX81 inverted fluorescence microscope (FDA using the FITC filter and PI using
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Fig. 2.5 Image analysis of islet viability staining. Example of analysis using a cryopreserved mouse
islet stained with FDA and PI. (A) Images taken in TRITC channel were used for analysis of PI-stained
cells within islet. First, the original image was converted to RGB stack, followed by applying the
threshold to include only the positive areas while everything else is converted to a blue background.
(B) Analogical analysis pipeline for the FITC channel containing FDA staining. (C) Table generated
after applying the code above to a folder of images cryopreserved under a certain condition. The
table contains the Image ID (Label), the positive area measurement (Area) and the lowed and upper
threshold values (MinThr, MaxThr). All microscope images were taken at 10x objective magnification.
FDA = fluorescein diacetate; PI = propidium iodide.
the TRITC filter). Each channel was taken as a separate image and the parameters of the
microscope (exposure time, gain) were kept the same throughout each experiment to enable
unbiased quantification. The FDA positive (alive) and PI positive (dead) area was measured
using ImageJ. Briefly, the images were converted to RGB stack and threshold was applied
to select only the positive area in the appropriate colour channel (Figure 2.5A and B). The
top threshold was always kept at the maximum (255) while the lower threshold value was
determined by manually selecting ideal threshold value for three random images from each
experiment. This threshold was then applied to all images from the experiment.
A simple macro code was written to perform the batch analysis and its annotated version
is shown below for both FDA and PI images (FDA image analysis required an additional line
to switch to the appropriate colour channel).




## Only for FDA images - switching to the FITC channel
Stack.setChannel(2);




## Measurement and closing of image
run("Measure");
close();
Using this code, a table was generated which contained the positive area measurement for
each image (Figure 2.5C). These values were then transferred to Microsoft Excel. Viability
of each imaged islet was calculated using following formula:
Percentage islet viability =
FDA positive area
FDA positive area + PI positive area
⇥100.
2.6.3 Assessment of viability by flow cytometry
Sufficient amounts of pancreatic islets (approximately 2000 IEQ produces around 106 cells)
were trypsinised by 5 min incubation in 0.05 % trypsin 0.53 mM EDTA (Sigma-Aldrich).
Trypsinised islets were then pipetted several times through p1000 and p200 pipette tips for full
disintegration. Trypsin reaction was then stopped by addition of culture medium containing
FCS. Cells were counted using TrucountTM tubes (BD Biosciences) and stained for viability
with combination of FDA (alive cells) and PI (dead cells). The cells were incubated with
the stains (with the exception of PI) for 25 min at 37 °C and washed twice in staining
buffer before analysis. Samples and appropriate controls were run on FACSCantoTM II
flow cytometer equipped with BD FACSDivaTM software (BD Biosciences, version 6.1.3).
Subsequent analysis was done in FlowJo software (version 10.1).
2.6.4 Diffusion assays for pancreatic islets
Fresh mouse pancreatic islets were pre-stained with 400 µg/mL Hoechst 33342 nucleic
acid stain (ThermoFisher) under different conditions (variations in temperature, DMSO
concentration and g force). At the end of the incubation time, islets were washed with PBS
and handpicked with minimal volume of medium ( 10 µL) into a Peel-A-Way embedding
conical mold (Polysciences, Inc.). 60 – 80 µL of Optimal Cutting Temperature Compound
(OCT) was carefully mixed with the handpicked islets in the bottom of the mold to avoid any
bubbles and the drop was frozen on dry ice. Once rigid, it was covered with more OCT to
create a block which is easy to cryosection, again frozen on dry ice and stored at  80 °C
until sectioning.
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Fig. 2.6 Gating strategy for pancreatic islet flow cytometry. (A) FSC/SSC view of the recorded
cytometry events (singlets only). Counting beads shown in green, FDA+ (live) cells in blue and PI+
(dead) events in red. (B) Gating on counting beads which can be done in multiple combinations of
different fluorescent channels. Channels unused by any fluorochromes were used for this analysis.
(C) Gating on FDA+ events in the FSC/FITC channel view. (D) Gating on PI+ events in the FSC/PerCP-
Cy5.5 channel view. FDA = fluorescein diacetate; FCS = forward scatter; PI = propidium iodide;
SSC = side scatter.
Cryosectioning of temperature-equilibrated OCT blocks was done using Hacker Bright
OTF5000 cryostat (Hacker Instruments and Industries Inc.) at a thickness of 11 µm. Sections
were transferred to a room temperature microscope slide and frozen immediately on dry ice
to avoid dehydration. Prior to imaging, coverslips were mounted onto the slides using a dry
mount method. Wet mounting was not suitable since it allowed movement of dye molecules
across the samples. Therefore, dry mounting was used in which two thin strips (2 – 3 mm) of
double-sided tape were stuck on sides of each glass coverslip (Figure 2.7A). Frozen slides
were rapidly thawed, coverslip mounted on top using the tape and frozen again to avoid any
dehydration. Slides were kept on dry ice and were only removed while being imaged.
Imaging was performed using the Leica Sp5 (Leica Microsystems) inverted confocal
microscope (NIHR Cambridge BRC Cell Phenotyping Hub) as outlined in Section 2.7.1.
Bright field and fluorescent images of 3 – 10 islet sections were taken for each experimental
condition (Figure 2.7B). Only sufficiently round islets were included in the analysis as the
image analysis method was not suitable to analyse irregularly shaped or elliptical islets.
Image analysis was done in ImageJ plugin Concentric Circles as outlined in Figure 2.7C).
2.6.5 Toxicity assays for pancreatic islets
For each tested condition, 3 wells of 15 – 20 islets were handpicked into a 24-well flat-
bottomed plate, covered with 500 µL tested solution and incubated at 37 °C, 5 % CO2
humidified atmosphere. For every experiment, a culture medium control was included (RMPI
+ 10 % FCS 1 % Penicillin/Streptomycin for mouse islets or CMRL + 10 % FCS + 1 %
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Fig. 2.7 Method used for assessing dye diffusion into the centre of pancreatic islets. (A) Dry mount
method of mounting a coverslip using a double-sided tape. (B) Example of an image taken on
a confocal microscope showing a section of an islet pre-stained with Hoechst 33342 nuclear dye.
(C) Concentric circles plugin in ImageJ used for calculating the average fluorescent intensity along
each concentric circle. Using these values, a staining profile of each islet can be generated. Multiple
parameters can be changed to adjust for the size and position of the islet on the image. In real analysis,
the circles were drawn 5 pixels apart (30 – 80 circles per islet depending on the size of the islet).
Penicillin/Streptomycin for human islets). These three wells were then used to measure
viability at three different time points (2 h, 24 h and 48 h). At the end of each time point,
the content of the respective wells (medium + islets) were transferred into a fresh tube for
fluorescent viability staining (described in Section 2.6.2). Viability of islets at at beginning
of experiment was measured and used as a 0 h control for all conditions.
2.6.6 ATP/ADP assay
Fifty pancreatic islets for each experimental sample (fresh or thawed) were handpicked
into a 1.5 mL Eppendorf tube and adenonucleotides were extracted by adding 1 mL of
ice-cold perchloric acid (3 % v/v HClO4, 2 mM Na2EDTA, 0.5 % Triton X-100) followed by
vortexing. Extracted samples were stored at  80 °C until ATP and ADP quantification using
luciferase-based assay described by Strehler [169].
Briefly, samples for ATP and ADP standard curves were prepared from 20 mM stock
solutions of ATP and ADP sodium salts (Sigma) serially diluted in the perchloric acid
extractant. In the next step, 400 µL of each experimental and standard curve sample was
pH-neutralised using ice-cold KOH solution (2 M KOH, 2 mM Na2EDTA, 50 mM MOPS)
until white KClO4 precipitate formed. Samples were then centrifuged (17000 g, 1 min, 4 °C)
and supernatant used for further measurements.
250 µL of experimental sample supernatant was prepared for quantification of ADP by
degradation of endogenous ATP (Figure 2.8A). This was done by incubating the supernatant
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Fig. 2.8 ATP/ADP ratio assay reactions. (A) Degradation of endogenous ATP: ATP sulfurylase
catalyses reaction of ATP and sulfate to form pyrophosphate and adenosine 5’-phosphosulfate (APS),
which depletes ATP present in the sample. (B) Conversion of ADP to ATP: In the presence of
phosphoenolpyruvate, pyruvate kinase converts ADP to ATP along with a pyruvate by-product.
(C) Luciferase step: Firefly luciferase catalyses D-luciferin oxygenation accompanied by emission of
light in the presence of ATP and oxygen. The amount of emitted light correlates with the amount of
ATP in the sample (or ADP converted to ATP in (B)).
with 250 µL ATP sulfurylase assay buffer (20 mM Na2MoO4, 5 mM GMP, 0.2 U ATP
sulfurylase (New England Biolabs), in Tris-HCl buffer (100 mM Tris-HCl, 10 mM MgCl2
(pH 8.0))) for 30 min at 30 °C while shaking, followed by heating to 100 °C for 5 min and
cooling on ice.
100 µL of standards, one 100 µL sample for ATP measurement and two 200 µL samples
for ADP measurement were mixed in luminometer tubes with 400 µL Tris-acetate buffer
(100 mM Tris, 2 mM Na2EDTA, 50 mM MgCl2, pH adjusted to 7.75 with glacial acetic acid).
To one of the ADP measurement samples, 10 µL pyruvate kinase solution (100 mM PEP,
6 U pyruvate kinase suspension (Sigma)) was added and incubated for 30 min at 25 °C in the
dark to convert ADP to ATP (Figure 2.8B). The other ADP measurement sample remained
unconverted and served as a blank.
For all standard curve and experimental samples, 100 µL Luciferase/Luciferin Solution
(7.5 mM DTT, 0.4 mg/ml BSA, 1.92 µg luciferase/ml (Sigma), 120 µM D-luciferin (Sigma),
in Tris-acetate buffer (25 % v/v glycerol)) was auto-injected and luciferase luminescence
measured using Berthold AutoLumat Plus luminometer three times for 1 min (Figure 2.8C).
2.6.7 Static glucose stimulation assay
Salts for Krebs-Ringer Bicarbonate buffer (KRB, composition in Table 2.7) were dissolved
in ddH2O, filter-sterilised and stored at room temperature for a maximum of one month. On
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the day of the experiment, working KRB solutions were prepared by adding 10 % FCS and
1.65 M glucose stock solution to reach 3.3 mM (low glucose KRB) or 16.7 mM (high glucose
KRB) glucose concentration. Sufficient amount of 3.3 mM and 16.7 mM KRB were warmed
up to 37 °C.








Fresh or thawed pancreatic islets were thoroughly washed from any leftover cryopro-
tectant (to avoid an effect of remaining trehalose on the insulin secretion). The islets were
handpicked into a Petri dish containing 5 mL pre-warmed 3.3 mM KRB and incubated for
30 min at 37 °C, 5 % CO2. For each tested condition, either 70 (parallel set-up, Figure 2.9A)
or 40 (serial set-up, Figure 2.9B) islets were handpicked. After 30 min, all islets were
handpicked into a fresh Petri dish with 5 mL or pre-warmed 3.3 mM KRB to wash any
insulin produced during the incubation.
Each condition was tested in triplicates: 8 – 10 islets from each condition were handpicked
into each of three 1.5 mL Eppendorf tubes and covered with 500 µL of either 3.3 mM or
16.7 mM KRB (as outlined in Figure 2.9). All tubes were then incubated for 1 h in a
shaking incubator (100 rpm at 37 °C). At the end of the incubation, all tubes were mixed
and spun in a microcentrifuge (300 g for 30 s) and all supernatant transferred into a new
Eppendorf tube and stored at  20 °C prior to insulin measurement. In the serial setup of the
experiment (Figure 2.9B), the islet previously incubated at 3.3 mM KRB were now covered
by 500 µL of 16.7 mM KRB and incubated for another hour at 37 °C while shaking, then
mixed, centrifuged and the supernatant taken out into a new Eppendorf tube. At the end of
the experiment, all islet pellets were frozen at  80 °C for potential DNA quantification for
the purposes of normalising the insulin data to the amount of cells.
Insulin concentrations from the supernatant were measured by the Core Biochemi-
cal Assay Laboratory (supported by the MRC MDU Mouse Biochemistry Laboratory
[MRC MC UU 12012/5]) using an electrochemiluminescent sandwich immunoassay from
MesoScale Discovery.
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Fig. 2.9 Glucose stimulation assay protocol. Each black circle represents ⇠10 pancreatic islets; low
glucose (3.3 mM) KRB shown in blue, high glucose (16.7 mM) KRB shown in red. (A) Parallel
set-up of the glucose stimulation assay: starting with ⇠70 islets, 8 – 10 islets are picked into triplicate
tubes with 3.3 mM KRB and triplicate tubes with 16.7 mM KRB and incubated in parallel. (B) Serial
set-up of the glucose stimulation assay: starting with ⇠40 islets, 8 – 10 islets are first picked into
triplicate tubes with 3.3 mM KRB and after retrieving supernatant post-incubation, the same islets are
reused for the incubation in 16.7 mM KRB. KRB = Krebs-Ringer Bicarbonate buffer.
In Appendix D, insulin concentrations were normalised to DNA content. DNA from
the pellets was extracted using the GenEluteTM Mammalian Genomic DNA Miniprep Kit
(Sigma-Aldrich) according to manufacturer instructions and DNA stored at  20 °C until
quantification. Quantification was done using Quant-iTTM PicoGreenTM dsDNA Assay Kit
(ThermoFisher Scientific) in 96-well flat-bottomed black polystyrene microplate (Corning)
and the absorbance measured using FLUOstar Optima plate reader (BMG Labtech) using
480 nm excitation and emitted light detected at 520 nM wavelength. DNA concentrations
were determined based on a standard curve in each experiment. Insulin concentrations in
Chapter 5 were not normalised to DNA based on optimisation in the Appendix D.
2.6.8 Mitochondrial DNA oxidation assay
Using quantitative Polymerase Chain Reaction (PCR) targeting mitochondrial DNA (mtDNA),
the level of oxidative damage (such as strand breaks, oxidised bases or abasic sites) within
mitochondria can be measured. Such damage to DNA stops polymerase from progressing
along the DNA strand, thus reducing the amplification of long target (⇠10 kbp) measured
by the quantitative PCR. To control for the mtDNA copy number, a second short target
( 200 bp) is amplified in a parallel reaction and used for normalising the data.
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DNA was isolated from fresh or thawed pancreatic islets using GenEluteTM Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich) according to manufacturer instructions and
DNA stored at  20 °C until the assay. Before the assay, the samples were thawed on ice and
DNA concentration measured using NanoDropTM 8000 Spectrophotometer (ThermoFisher
Scientific). Samples were then diluted to 3 ng/mL for the assay.
Table 2.8 Components of the PCR mixture
Component Stock Final concentration Supplier
Buffer 10⇥ 1⇥ TaKaRa
BSA 10 mg/mL 100 ng/mL New England Biolabs
dNTPs 10 mM 200 µM TaKaRa
Forward primer 10 µM 200 pM Sigma
Reverse primer 10 µM 200 pM Sigma
Mg(OAc)2 25 mM 1 mM TaKaRa
LA Taq polymerase 25 U 1 U TaKaRa
Notes: Primer sequences for mouse: Forward (5’-GCC AGC CTG ACC CAT AGC CAT AAT-3’),
Reverse for short target (5’- GCC GGC TGC GTA TTC TAC GTT A -3’) and Reverse for long target
(5’-GAG AGA TTT TAT GGG TGT AAT GCG G-3’).
For PCR, a mastermix of all components was prepared as per Table 2.8, with the exception
of the polymerase which was added separately. Reaction was performed in PCR tubes and
each reaction consisted of 5 µL (15 ng) of DNA template from samples, 35 µL of PCR
mastermix and 1 U of TaKaRa LA Taq polymerase. Reactions were performed in duplicates
for each sample and one of the control samples was also amplified at 50 % concentration
to check whether the final concentration of amplified DNA lies in a linear range and non-
template control was included. Reactions were then performed using programmes outlined
in Table 2.9. Number of cycles for short and long target were optimised for our tissue type.
PCR products were quantified using Quant-iTTM PicoGreenTM dsDNA Assay Kit (Ther-
moFisher Scientific) according to manufacturer’s instructions. Size of the PCR product was
also checked by running a 0.8 % agarose gel. For the analysis, all samples were corrected to
the non-template control and normalised to amplification of the short target.
2.6.9 Cyclic AMP release assay
Fresh or thawed pancreatic islets (150 – 200 islets per condition) were dissociated into single
cells using 5 min incubation with 0.05 % trypsin + 0.53 mM EDTA (Sigma-Aldrich) and
mechanical disruption with p1000 pipette. Dissociation was stopped by addition of complete
medium containing FCS and cells were counted using hemocytometer.
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Table 2.9 PCR programmes for long and short targets
Cycles Denaturation Annealing Extension
Short target
1 – 21 94 °C for 30 s 64 °C for 45 s 72 °C for 45 s
22 94 °C for 10 min
Long target
1 94 °C for 1 min
2 – 24 94 °C for 15 s 64 °C for 12 min
25 94 °C for 10 min
Measurements of cAMP were performed with the help of Dr. Kerry Barkan at the
Department of Pharmacology, University of Cambridge, using LANCE® cAMP Detection Kit
(PerkinElmer) in accordance with the manufacturer’s instructions. The principle of the assay
is explained in Figure 2.10. Duplicate or triplicate wells were prepared for each condition and
each point on the standard curve. Correct amounts of single cell suspensions (4000 cells per
well) were resuspended in the appropriate volume of antibody mix (Alexa Fluor® 647(AF647)
anti-cAMP antibody in stimulation buffer (HBSS, 5 mM HEPES, 0.5 mM IBMX, 0.1 %
BSA, pH 7.4) and seeded in a white 384-well Optiplates (PerkinElmer). Forskolin, GLP-
1(7-26)amide, cAMP standard or DMSO control were diluted in stimulation buffer to the
appropriate concentration.
For samples, 5 µL per well of cell suspensions with antibody were added to the wells, to-
gether with 5 µL of tested compound (DMSO for blank, 10-4 M forskolin, 10-5 or 10-6 M GLP-
1(7-36)amide) and incubated for 30 min at room temperature. 10 µL of detection solution
containing europium-labelled streptavidin and biotin-cAMP in detection buffer was then
added in each well and samples were further incubated for 60 min at room temperature.
After 60 min, measurement was taken using a Mithras LB 940 microplate reader (Berthold
Technology); excitation 340 nm and emission 665 nm.
2.7 Imaging
2.7.1 Confocal microscopy
Imaging of whole pancreatic islets or islet sections stained with combinations of fluorescent
dyes or loaded with fluorescent compounds was performed using the Leica Sp5 (Leica
Microsystems) inverted confocal microscope (NIHR Cambridge BRC Cell Phenotyping Hub).
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Fig. 2.10 Cyclic AMP assay principle. (A) In the absence of free cAMP, europium-labelled strep-
tavidin bound to biotin-cAMP tracer binds to the cAMP-specific antibody, conjugated to AF647.
Europium compound acts as an energy donor and upon excitation, transfers the excitation energy
through FRET onto the AF647 fluorophore, which then emits fluorescence at wavelength of 665 nm.
(B) In the presence of free cAMP produced by cells, the europium-labelled streptavidin bound to
biotin-cAMP is competing with the free cAMP for binding to the AF647-conjugated anti-cAMP anti-
body. This prevents the FRET and results in decrease of fluorescence emission at 665 nm depending
on the concentration of free cAMP. AF647 = Alexa Fluor® 647 fluorescent conjugate; cAMP = cyclic
AMP; Eu = europium; FRET = fluorescence resonance energy transfer; l Ex = excitation wavelength;
l Em = emission wavelength.
Detection band widths were set for each fluorochrome according to its spectral properties
and the effect of spectral overlap was minimised by choice of compatible fluorochrome
combinations, avoiding simultaneous detection of several fluorochromes and decreasing the
detection band widths if necessary. Collection of images and some simple pre-processing
steps were performed using the LAS X software (Leica Microsystems).
2.7.2 Multi-photon microscopy
Pancreatic islets stained with a combination of fluorescent dyes were imaged using the
TriM Scope II (LaVision BioTec) upright 2-photon scanning fluorescence microscope by
Kevin O’Holleran at the Cambridge Advanced Imaging Centre (University of Cambridge).
Different dyes were detected by using appropriate set of wide bandpass emission filters.
2.7.3 Light sheet fluorescence microscopy
Imaging on a light sheet microscope was done in collaboration with Till Moreth from the
Goethe University in Frankfurt. Pancreatic islets stained with combination of fluorescent
dyes were embedded in 1 % low melting agarose and drawn into a glass capillary. Once the
agarose solidified, the capillary was inserted into the holder of the microscope and imaged
using the Zeiss Lightsheet Z.1 (Zeiss). The excitation/emission wavelengths were 405/415
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for Hoechst 33342, 488/498 for FDA and 561/571 for PI. Images were processed by Till
Moreth.
2.7.4 Raman spectroscopy
For a calibration curve, solutions of increasing trehalose concentrations were prepared from
D-(+)-trehalose dihydrate (Sigma Life Sciences) in distilled water by serial dilutions.
Human osteosarcoma SAOS-2 cell line was used for the proof-of-concept Raman mea-
surements of intracellular treahalose concentration. The cells were cultured in culture-treated
T25 and T75 flasks (ThermoFisher) in complete medium consisting of DMEM + 10 % FCS
+ 1 % Penicillin/Streptomycin at 37 °C, 5 % CO2 humidified atmosphere. Confluence of
cells was checked regularly and medium was exchanged every 2 – 3 days. When confluence
reached about 80 %, cells were passaged (every 3 – 4 days). This was done by washing cells
in preheated PBS twice and incubation with 0.05 % trypsin-EDTA (Sigma Aldrich) for 5 min
at 37 °C. Once the cells had detached, the trypsin activity was stopped by adding an equal
volume of complete culture medium. Cells were split in 1:4 ratio and brought into fresh
complete culture medium.
SAOS-2 cells were used for the Raman spectroscopy experiment in an early passage. At
a confluence stage, the cells were seeded into a 6-well culture-coated plate (ThermoFisher)
with Quartz substrate glass slide on the bottom for the cells to grow on. Cells were cultured
until 70 % confluence was reached on the Quartz slides. The culture medium was then
exchanged for the tested solution (200 mM trehalose, 200 mM trehalose + 100 µg/mL PP-50,
control culture medium) and incubated for 6 h at 37 °C. At the end of this incubation, the
cells were washed twice with PBS to remove any extracellular trehalose and fixed using
4 % paraformaldehyde solution for 15 min. After the fixation, cells were covered with PBS
and kept at 4 °C until analysis.
Ramans spectra were measured using Acton SpectraPro SP 2300 spectroscope (Princeton
Instruments), connected to WiTec alpha300 M+ Raman confocal microscope (WiTec) using
the 782.92 nm excitation laser. Averaged Raman spectra across 10 cells were recorded for
each condition (each consisting of 30 individual Raman spectra). The optimal Raman band to
identify trehalose is at 844 cm-1 and all subsequent analysis was performed using this band.
Analysis was performed using Origin Software (OriginLab). All Raman measurements and
data analysis was performed by Dr. Jakub Surmacki at the Cavendish Laboratory, University
of Cambridge.
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2.8 Statistical analysis
Statistical analysis was performed using the GraphPad Prism software (version 8.0.1). Power
analysis was not performed for in vitro experiments since it was expected that each optimisa-
tion step would provide only an incremental increase in the sample viability and therefore
the recommended sample size for such small effect size would be very high and impractical
(regarding the limited availability of human tissue and mouse pancreatic islets). The aim
was to use sample size of 3-5 for these optimisation experiments and then perform a full
power calculation for the final comparison of the standard and fully optimised protocol. For
in vivo experiments, pilot experiments were performed which ascertained likely effect size
and variance, upon which power calculations were performed to confirm group sizes.
For in vitro datasets with a sample size smaller than 5, samples of the same type from
multiple experiments (for example all splenocyte DMSO samples with the incubation time
of 0 h and cell density of 107 cells/mL) were pooled together for test of consistency with
Gaussian distribution. By such method, datasets with sample size between 7 and 10 were
created, which were suitable for performing a normality test. Nevertheless, I am aware that
the with such small sample size there is a risk that some deviations from normality will
not be detected. Normality of the distribution was assessed by Shapiro-Wilk test on a three
dataset of the flow cytometry of splenocytes which have all passed the normality test for
the cryoprotectant DMSO, trehalose alone and trehalose with PP-50. Based on this result,
Gaussian distribution was assumed for all the smaller datasets which could have not been
tested. For large sample sizes the normality tests were performed using Shapiro-Wilk test.
For normally distributed data, two-tailed paired t-test was used for comparison of two
groups. To compare three or more groups, one-way or two-way ANOVA (analysis of
variance), followed by Tukey’s honestly significant differences (HSD) test (controlling for
multiple comparisons) was used if three or more groups were compared to each other, Sidak’s
correction if two groups in two-way ANOVA were compared to each other and Dunnett’s
test if groups were compared to a single control group. Results were considered statistically
significant if p-value  0.05.
Results obtained from viability staining of pancreatic islets at 24 h after thawing followed
bimodal distribution. Although more exact model could be developed, for the purposes of
this thesis, calculation of means using standard methods was used as an approximation to
determine average viability of each sample. Once multiple experimental repeats were pooled
together, these means then followed Gaussian distribution and were analysed using standard
methods described above.
Chapter 3
Viability assessment of mononuclear cells
and pancreatic islets
3.1 Introduction and aims
Reporting the viability of cell samples is crucial in good research practice. Standard viability
assessment methods for both single cells and multicellular aggregates can be accurate
but also present a risk of over- or underestimation of viability if important details are
neglected. Particularly in cryobiology where the comparison of post-thaw survival of multiple
cryopreservation protocols is performed, it is critical for the viability assessment to be
accurate, unbiased and reproducible.
Section 3.2 focuses on identification of the requirements for a reliable cryosurvival
assessment method with regards to the field-specific needs of cryobiology. These parameters
are then taken into consideration to modify viability assessment method for mononuclear
cells in Section 3.3. Special attention is paid to flow cytometry and its adaptations to allow
for unbiased enumeration of cells and cell subsets in cryobiological samples.
Viability assessment of multicellular aggregates such as pancreatic islets is more complex,
given their larger size, complicated architecture and unknown parameters of the staining pro-
cess. Clinical assessment of pancreatic islet viability is done by rapid two-colour fluorescent
staining and imaging on a wide-field microscope. It has been long known that islet viability
measured using this method does not correlate with their in vitro and in vivo function [92]
and in Section 3.4, some of the possible reasons for this were identified by studying diffusion
properties of islets and investigating different imaging methods.
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3.2 Suitable viability assessment method for cryobiology
For single cells, the choice of viability assessment method is often trypan blue staining or
flow cytometry. Majority of research fields focus on identification and characterisation of
cells which are alive and excluding dead cells from the flow cytometric analysis is entirely
acceptable as long as the cell death rate is low. In cryobiology, however, ignoring dead cells
and debris is not appropriate. Different cryopreservation protocols produce different ratios
of alive cells, dead cells and debris and these proportions should be quantified in studies
pursuing freezing methods comparison.
Quantification of dead cells and debris, however, is problematic. As cells die, they can
disintegrate into many fragments of debris. One potential solution is to report absolute
numbers of live cells in comparison with other samples within the same experiment, or better,
with the absolute number of cells in the sample before freezing (Figure 3.1). Reporting
absolute numbers/aggregate sizes and comparison with pre-freeze sample provides essential
information about the potential clinical application of the cryopreservation method, because
specific target number of (viable) cells are needed to achieve a therapeutic effect in a patient.
In some cases, mixed populations of cell types are cryopreserved (B cells, T cells,
haematopoietic progenitors in BM mononuclear cells; a ,b ,d -cells in pancreatic islets
etc.). Cryosurvival of certain cell type may be of particular interest (e.g. CD34+ for bone
marrow transplantation) but not all freezing protocols will be equally efficient for all cell
types. A cryopreservation method most suitable for progenitors may not, for example, be the
right choice if we are looking to preserve T cells for CAR-T cell therapies. An ideal viability
assessment method can detect the differences in survival of cell subsets and hence inform
optimisation of cell subset-specific freezing protocols.
Finally, the cryobiology field would benefit from standardisation of cryosurvival reporting
method. Currently, comparison of publications from different groups are often hindered by
the fact that some groups report viability as percentage of all cells, some percentages of
certain cell subsets, some as absolute numbers.
Taking all these considerations into account, key cryobiology-specific needs for both
single cell and multicellular aggregates viability assessment method therefore include:
1. Accurate identification of not only live cells, but also dead cells and debris
2. Unbiased method of cell/cell cluster enumeration
3. Accurate comparison of the cell samples before freezing and after thawing
4. Information about survival of cell subsets within mixed cell populations
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Fig. 3.1 Viability assessment considerations for single cells and multicellular aggregates. Live cells
are shown in green, dead cells in red, debris in black. (A) A schematic of flow cytometric analysis
of mononuclear cell viability in fresh sample and two cryopreserved samples (C1, C2). Reporting
percentage of viability as the only outcome can be misleading as the amount of debris is often ignored.
In this example, the C1 and C2 protocols produce the same ratio of live and dead cells but in C2, many
cells have been disintegrated into debris which was not accounted for in the viability measurement.
Appropriate way would be to report the absolute cell counts in each sample and to compare the
outcome to the same sample before freezing. (B) A schematic of microscopic analysis of pancreatic
islets stained with dual viability stain. In this case, the Abs parameter must take into account both the
number of cell clusters and their size. In some cryopreservation methods, the size of islets would be
largely unchanged but viability is affected (C1) while other protocols will be be more prone to islet
disintegration but will preserve viability well (C2). Abs = Absolute number of cells in the sample;
FSC = forward scatter; SSC = side scatter; Viability = % viable cells of all cells; Adjusted survival =
Viability ⇥ Abs.
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5. Replicable protocols enabling comparison of cryopreservation protocols between labs
3.3 Cryosurvival assessment for mononuclear cells
In this project, flow cytometry was chosen over trypan blue staining as a viability assess-
ment method for its adaptability, accuracy and possibility to identify subsets in mixed cell
populations. Classical flow cytometry protocols can be easily adapted to provide not only
percentages of dead and surviving cells but also their absolute numbers, simplifying the
comparison of multiple groups.
3.3.1 Gating using light-scattering properties versus fluorescence
In flow cytometry, population of interest often has characteristic shape and position when
plotted in forward scatter (FSC) against side scatter (SSC) view. Some studies consider
gating based only on light scatter characteristics sufficient for selection of viable cells,
an approach which has been shown inadequate or even impossible in many cases [170].
Common recommendation in flow cytometry is to also apply a forward scatter threshold to
eliminate debris from the analysis.
There are several issues with assessing cryopreserved cells based on light scatter proper-
ties. During freezing, cells undergo substantial osmotic and thermal stress which can change
their size [88], intrinsic morphology and cell membrane characteristics. All these parameters
have influence on light scattering parameters of the cells, and gating based solely on FSC
and SSC characteristics, such as in the case of ’classical’ gating strategy (Figure 3.2A, B and
C), could therefore result in unwanted exclusion of viable cells from the analysis and loss of
information about dead cells and debris. Partial overlap of live cells, dead cells and debris in
their light scatter properties can also make their clear discrimination impossible [170].
To avoid these issues, fluorescence can be used to accurately gate on the cell population of
interest. Membrane integrity stains (such as 7-AAD) are traditionally used for determination
of cell viability. Syto®13 dye which binds to nucleic acids, can be used to stain all nucleated
cells (both alive and dead). Combination of Syto13 and membrane integrity dye, can therefore
be used to effectively exclude debris and erythrocytes from the analysis, as suggested by
Reardon et al. [88].
In this project, this strategy of combining a viability dye and a nuclear dye was adopted.
Minimal FSC threshold was set on the flow cytometer to prevent loss of information about
any events, including debris. The suggested gating strategy is shown on the example of
mononuclear cells in Figure 3.2D, E and F. The identified population of alive nucleated (AN)
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Fig. 3.2 Comparison of gating strategies for viability assessment of different cryopreservation methods
(C1 and C2). (A) First step of ’classical’ gating strategy - gating on the cell population using FCS
vs. SSC plot. (B) Second step of ’classical’ gating strategy – gating on viable cells using a plot
with viability marker (in this case 7-AAD). (C) Position of the viable cells on the FSC vs. SSC
plot after the ’classical’ gating. (D) First step of optimised gating strategy – gating on negative
population using a plot with viability marker (in this case 7-AAD). (E) Second step of optimised
gating strategy – gating on positive population using a plot with nucleated cell marker Syto13.
(F) Position of alive nucleated cells (black) on the FSC vs. SSC plot after the optimised gating. Blue
events represent debris, erythrocytes and dead cells. FSC = forward scatter; SSC = side scatter;
7-AAD = 7-aminoactinomycin D.
68 Viability assessment of mononuclear cells and pancreatic islets
cells includes all cells (lymphocytes, granulocytes and other nucleated cells) regardless of
their light scatter properties which is in stark contrast to the rather artificial border created by
the ’classical’ technique (Figure 3.2A, B, and C).
3.3.2 Quantification of viability and cryopreservation efficacy
Accurate detection of viable cells in the sample does not necessarily lead to correct reporting
of the outcome of cryopreservation. In cryobiology publications, it is often not specified
which denominator was used to report the % viability/survival, although there are multiple
possibilities:
1. % of total number of recorded events (often with unspecified FSC threshold)
2. % of all cells with position typical for the particular cell type on FSC/SSC plot
3. % of all cells positive for a marker characteristically expressed by all the analysed cells
(e.g. CD45+ for mononuclear cells)
As explained in Section 3.2, is it advantageous to report absolute numbers of cells which
in fact eliminates the need for choosing the ’correct’ denominator. However, where the
absolute count was not available in this project, following approximation relating to the
number of all singlet events was used to calculate viability as % of alive nucleated (AN)
cells (Syto13+, 7-AAD- with the assumption that the amount of debris in different samples
negatively correlates with the success of cryopreservation):




To obtain absolute cell counts in flow cytometry, counting beads can be added to the
stained cell sample and calculations performed as described in the Methods section 2.5.1.
The cell count should ideally be performed just before cryopreservation (by removing a
small volume from the cryovial before freezing) and at the end of the thawing procedure
(Figure 3.3A). If the counted cells are stained with the above mentioned viability and nuclear
dyes, the efficacy of the cryopreservation (CEtotal) can then be calculated using the absolute
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Fig. 3.3 Method of quantification of absolute number of cells and cell subsets surviving cryopreser-
vation. In a form of Venn diagram, the strategy is visually demonstrated. (A) Small known volume
of cell suspension is transferred from the cryovial before freezing into the BD TrucountTM tube and
using no-wash protocol to avoid cell losses, stained with Syto13 and 7-AAD. Same procedure is
then repeated post-thaw and absolute number of alive nucleated cells is compared with the pre-freeze
count. (B) Prior to freezing, small known volume of cell suspension is transferred into a counting tube
(same as (A)) and into an additional staining tube where the subset analysis is done using cell subset
specific markers along with Syto13 and 7-AAD. Using the absolute number of alive nucleated cells
and % of the cell subset as a proportion of alive nucleated cells, absolute number of the cell subset
can be calculated. When identical analysis is performed post-thaw, cryopreservation efficacy for the
specific cell subset can be calculated. In the outlined example, majority of the cells in the subset S
survived the cryopreservation, while the number of the remaining alive nucleated cells was decreased.
AbsAN = absolute number of alive nucleated cells; AN = alive nucleated cells; CB = counting beads;
S = cell subset.
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3.3.3 Survival of cell subsets
For an accurate quantification of cells using counting beads, washing steps must be eliminated
from the staining protocol to prevent the unavoidable cell loss during centrifugation and
pipetting. However, identification of cell subsets, especially of rare populations, require
carefully optimised staining protocols, which almost invariably include washing steps. Their
purpose is to remove any background signal from the unbound antibodies or stains in order
to decrease the chance of detecting false positive events.
While washing DNA-binding dyes (such as viability dyes or Syto13) is not necessary,
many conjugated antibodies or dyes cause a significant noise signal. In these cases, one
strategy is to split the original sample into two (or more) tubes. First tube would contain
the counting beads and no-wash staining with Syto13 and 7-ADD (or similar) would be
performed. In the other tube(s), staining with other antibodies/dyes is performed along with
the Syto13 and 7-AAD. Since the alive nucleated (AN, Syto13+ 7-AAD-) cells can be gated
in all the fluorescent panels and their absolute number is known from the counting tube,
the absolute numbers of cell subsets from the other tubes (Abs(subset)) can be related to this
absolute number (Abs(AN)) in the following way:




Analogically to the equation 3.2, to calculate the efficacy of cryopreservation for a particular






The suggested protocol is depicted in Figure 3.3B for further clarification.
3.4 Cryosurvival assessment for pancreatic islets
3.4.1 Current viability assessment method evaluation
Imaging viability across the pancreatic islet
Because islet quality evaluation method must be reasonably quick and accessible to the
clinical islet isolation laboratories, they mostly rely on simple dual fluorescent viability
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Fig. 3.4 Current imaging method for pancreatic islet viability assessment. FDA shown in green,
PI in red and Hoechst 33342 in blue.(A) Pancreatic islet stained with FDA and PI imaged by a
wide-field fluorescent microscope on top of a coverslip. (B) Pancreatic islet stained with FDA and
PI imaged by a wide-field fluorescent microscope flattened in between two coverslips. (C) 3D-
reconstruction of the flattened pancreatic islet in between two coverslips imaged on a confocal
microscope (FDA/PI/H33342 staining). (D) Z-stack of the flattened pancreatic islet in between two
coverslips imaged on a confocal microscope (FDA/PI/H33342 staining). (E) Z-stack of a pancreatic
islet on top of a coverslip (unflattened) imaged on a confocal microscope (FDA/PI/H33342 staining).
FDA = fluorescein diacetate; PI = propidium iodide; H33342 = Hoechst 33342.
staining and imaging on wide-field microscope (see Methods 2.6.2). Because wide-field
microscopy uses non-directed light, the visible cells are located mostly at the outer layer of
the stained pancreatic islets (Figure 3.4A).
This original method was initially adapted by gently placing a coverslip on top of the
glass slide which led to flattening of the 3D islet into a thinner disc. This theoretically allows
the majority of the cells to be detected in the plane of focus of the wide-field microscope,
although the information about the original localisation of each cell within islet is lost
(Figure 3.4B). Confocal microscopy demonstrated that using this method, islets are flattened
to a thickness of approximately 20 µm, equivalent to 2 – 3 layers of cells (Figure 3.4C and
D).
Because current viability assessment method described above completely ignores the
information about the viability of the cells localised in the centre of the pancreatic islets,
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Fig. 3.5 Diffusion of nuclear dye into pancreatic islets at room temperature. (A) Staining profile
of pancreatic islets incubated with Hoechst 33342 nuclear dye for 15 min, 6 h or 12 h (n = 3 – 5).
(B) Linear relationship between time and square of distance shown for four different fluorescent
intensities from the plot in (A). RFU = relative fluorescence intensity.
confocal microscopy was employed to image the viability of the whole islet in 3D. This
would be especially crucial in order to confirm that viability of cryopreserved islets is retained
in both on the periphery and in the core. Nevertheless, it was impossible to image the central
cells in pancreatic islets using the confocal microscope (Figure 3.4E). Two mutually non-
exclusive possible reasons were identified: insufficient staining time to allow for staining
of the central cells and imaging limitations of the confocal microscopy due to characteristic
properties of live islets.
Diffusion of dye molecules into pancreatic islets
Because isolated pancreatic islets are devoid of (flow in) vasculature, all molecules are
transported by diffusion. The diffusion pattern of dye molecules was therefore studied to
confirm whether all cells within the pancreatic islets were stained.
Depending on the nature of the molecule of interest, these either diffuse only through the
extracellular spaces (non-penetrating molecules), or pass freely through cell membranes. In
the case of Hoechst 33342, passage through cell membrane is possible but the diffusion by
this channel will be slowed down by the ’uptake’ of dye molecules by binding to the nuclear
DNA. Hoechst 33342 nuclear dye was chosen over the original viability staining molecules
due to the fact that it stains all cells regardless of their viability (PI would only stain small
fraction of cells) and its resistance to photobleaching (FDA starts losing its intensity within
seconds of excitation). The diffusion rate of Hoechst 33342 is not identical to other molecules
but since all the dyes of interest are small molecules travelling in an aqueous solution, the
assumption was made that the data generated is a good approximation for other dyes.
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The depth of diffusion of the dye was determined using a novel method described in
Methods section 2.6.4. Initial experiments included the original staining procedure – staining
at room temperature for 15 min. Additional, longer staining times were used to characterise
the diffusion rate at these conditions. As shown in Figure 3.5A , after 15 min of incubation
with Hoechst 33342, only 3 – 4 outer layers of cells were stained while any cells beyond the
distance of 40 µm into the islet core lacked any staining. Increasing the incubation time led to
higher intensity of staining in the central regions of the islets but even after 12 h of staining
at room temperature, homogenous staining of the islets was not achieved. Because clinical
and research laboratories stain pancreatic islets for very short time (typically <15 min), this
finding confirms that the current clinically-used methods assess viability of the cells on the
periphery of the islet, while ignoring the cells in the centre.
3.4.2 Increasing diffusion rate of molecules into pancreatic islets
The diffusion of molecules of one substance in another substance down its concentration
gradient is described by Fick’s law. If we assume a spherical pancreatic islet with a constant
surface boundary and initial concentration of the surface equal 0, Fick’s law can be modified





where D is diffusivity (diffusion coefficient) of a substance specific to a mixture with another
substance; t is time and x is distance. It follows that square distance of the penetration
increases linearly with the time allowed for penetration. As shown in Figure 3.5B, the data
from the diffusion experiment in Section 3.4.1 experiment follows this relationship and it can
be assumed simple molecular diffusion is the main process responsible for the movement of
molecules in this system.
The nature of clinical islet transplantation requires rapid assessment of pancreatic islet
quality. One of the reasons why the current viability scores do not correlate with function of
pancreatic islets or even clinical outcomes may be because it only takes into account fraction
of the cells on the periphery of the islet. However, it appears that the diffusion of molecules
at the above staining conditions is relatively slow and would require increasing the incubation
time to length which would not be practical.
Diffusivity is dependent on temperature, pressure and because it is described for every
pair of specific compounds, on the presence of other compounds in the system [172]. In
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Fig. 3.6 Diffusion of nuclear dye into pancreatic islets with DMSO as a penetration enhancer. Staining
profiles of pancreatic islets incubated Hoechst 33342 and 0 %, 1 % or 10 % DMSO for (A) 15 min,
(B) 1 h, (C) 3 h, (D) 6 h (n = 5 – 17). (E) Bright field and Hoechst 33342 fluorescence images of
islets incubated with 0 % DMSO for 3 h. (F) Bright field and Hoechst 33342 fluorescence images of
islets incubated with 10 % DMSO for 3 h. BF = bright field; H33342 = Hoechst 33342.
the below sections, the influence of these parameters on increasing the rate of diffusion was
studied.
Effect of DMSO as a penetration enhancer
The diffusion rate of one compound can be influenced by the concentration gradients of
another compound present in the mixture. One of the compounds known for its higher
diffusivity is DMSO. While current data demostrates that a dye molecule in aqueous solution
can take many hours to equilibrate, Benson et al. showed that 1.5 mol/kg DMSO can
equilibrate with an islet of 150 µm diameter in about 600 s at room temperature [72]. DMSO is
also known to be a chemical penetration enhancer, meaning that it can accelerate diffusion of
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other molecules across membranes, likely due to its interactions with membrane lipids [173].
A following hypothesis was tested: addition of DMSO during the staining with Hoechst
33342 will increase the rate of diffusion of the dye.
Two concentrations of DMSO (1 % and 10 %) were tested in addition to the control.
While a clear effect of 1 % DMSO on the diffusion rate was not observed (Figure 3.6A, B,
C and D), 10 % DMSO enhanced the diffusion rate significantly, as shown in Figure 3.6B).
Nevertheless, at 3 h incubation, DMSO toxicity was apparent both in the staining profiles
(decrease of staining intensity close to the outer edge) and in the images (necrosis-related
karyolysis at the periphery of the islets can be observed as diffused nuclear staining).
In conclusion, DMSO at 10 % concentration increases the diffusion rate of the nuclear
dye but leads to toxicity which makes this method unsuitable for use in viability assessment
staining.
Effect of hydrostatic pressure
Diffusivities are also known to increase with pressure. Since the islets are immersed in
solution during staining, the impact of increasing hydrostatic pressure on diffusion was
investigated next. Hydrostatic pressure (Ph) is a function of height of fluid column (h),
density of liquid (r) and acceleration of gravity (g):
Ph = h ⇥ r ⇥ g. (3.6)
Increasing the density of liquid would be counterproductive since the denser the liquid,
the slower the diffusion (Graham’s law of effusion). Changing the height of fluid column is
possible but the effect will be limited by the size of the container. The most practical way
to increase hydrostatic pressure in this system was therefore to increase the gravitational
force (g) which was achieved by centrifugation at different speeds.
Islets were incubated with the Hoechst 33342 nuclear dye for 15 min at room temperature
with (35 ⇥ g or 105 ⇥ g) or without (0 ⇥ g) centrifugation. The result suggests that there
is marginal improvement in the depth of the diffusion (Figure 3.7A). The only observable
effect was concentration of the dye molecules on the surface of the islet (Figure 3.7B and C).
While it is possible that an effect could be observed at longer incubation times, there is
a concern that prolonged centrifugation could have an impact on the viability of the islets.
Additionally, Hoechst 33342 dye (and most other dyes) may cause toxic effect to cells at
high concentrations and this method appears to cause a local increase in the concentration of
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Fig. 3.7 Effect of hydrostatic pressure on diffusion of nuclear dye into pancreatic islets. (A) Staining
profiles of pancreatic islets incubated Hoechst 33342 for 15 min at 0 ⇥ g, 35 ⇥ g or 105 ⇥ g (n = 6).
(B) Hoechst 33342 fluorescence image of islets stained with Hoechst 33342 at 0 ⇥ g for 15 min.
(C) Hoechst 33342 fluorescence image of islets stained with Hoechst 33342 at 35 ⇥ g for 15 min.
H33342 = Hoechst 33342.
the dye on the surface of the islets. It was therefore concluded that this method is not suitable
for accelerating diffusion in pancreatic islets.
Effect of temperature
Diffusivities of compounds are closely dependent on the temperature in the system. Higher
temperatures increase the kinetic energy of molecules, making them move at higher speed.
Along with incubation at room temperature, in this experiment islets were stained at 37 °C.
The result from this experiment confirms the previous finding that at room temperature,
even staining of pancreatic islets cannot be achieved even after 24 h (Figure 3.8A). At 37 °C,
however, pancreatic islets were homogeneously stained after only 6 h. Staining for 24 h
further increased the intensity of the staining throughout the islet (Figure 3.8B).
In a second experiment, shorter incubation times at 37 °C were investigated. However,
after 1 or 3 h of staining, there was still very low staining in the central part of the islets. Six
hours of incubation achieved staining in the whole volume of the islets, although the intensity
was not the same across the whole section as in the previous experiment (Figure 3.8C).
To confirm that the islets stained with Hoechst 33342 for 6 h at 37 °C remained viable
during the assay, FDA/PI staining was performed. Although there is a small drop in viability,
which can likely be attributed to the Hoechst 33342 toxicity (Figure 3.8D), it is not expected
that this drop in viability would have a large effect on the outcome of the above diffusion
experiments.
Since pancreatic islets can be cultured for 6 h at 37 °C without decrease in viability,
incubation with dyes at non-toxic concentrations at this temperature is a possible solution to
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Fig. 3.8 Effect of temperature on diffusion of nuclear dye into pancreatic islets. (A) Staining profiles
of pancreatic islets incubated Hoechst 33342 for 15 min, 6 h or 24 h at room temperature (n = 6 – 7).
(B) Staining profiles of pancreatic islets incubated Hoechst 33342 for 15 min, 6 h or 24 h at 37 °C
(n = 5 – 7). (C) Staining profiles of pancreatic islets incubated Hoechst 33342 for 15 min, 1 h, 3 h
or 6 h at 37 °C (n = 7 – 15). (D) Viability of pancreatic islets incubated for 6 h at 37 °C in culture
medium (Control) or Hoechst 33342 staining solution (Hoechst). On the right, an example image
of pancreatic islet incubated with Hoechst 33342 stained for viability at the end of the incubation.
FDA = fluorescein diacetate; H33342 = Hoechst 33342; PI = propidium iodide.
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the diffusion problem. It will therefore be used for investigation of the imaging methods for
islet viability assessment.
3.4.3 Improvement of islet viability imaging method
With the knowledge of the appropriate incubation time, imaging of islet viability was repeated
using confocal microscopy. However, increasing the incubation time with viability dyes
to 6 h did not bring a significant improvement to the quality of imaging of the islet core
(Figure 3.9A). Even after 24 h of staining, it was not possible to detect the viability near the
centre using confocal microscope (Figure 3.9B). The only fluorescent signal detectable near
the centre of the cluster comes from PI, likely because red dyes, with their longer wavelengths
which are not absorbed by cellular components, allow deeper penetration of light [175].
The next method investigated for imaging the viability of pancreatic islet in 3D was
two-photon microscopy. This imaging was done in collaboration with Kevin O’Holleran and
Martin Oliver Lenz from the Cambridge Advanced Imaging Centre. After 24 h staining, it
was possible to image deeper cell layers than with confocal microscopy, but the staining in
the centre of the islet still remained undetectable (Figure 3.9C).
Light sheet microscopy was investigated as another alternative imaging method in col-
laboration with Till Moreth and Francesco Pampaloni from Goethe University in Frankfurt.
While the Hoechst and FDA staining still had very low resolution in the central part of
the islet, it is possible to clearly image the presence of dead cells using PI (Figure 3.9D).
Additionally, light sheet microscopy offers a possibility of multi-angle imaging which can
further increase the resolution of the final 3D-reconstruction of the islet (Figure 3.9E). As
shown in this Figure, it is possible for an islet to have a difference in viability of the periphery
and the core.
To conclude, it was not possible to image the core of pancreatic islets using confocal or
two-photon microscopy, likely because of the limited imaging depth. Pancreatic islets are
densely packed clusters of cells, filled with insulin granules which highly scatter light [176].
These optical properties make islets particularly difficult to image, especially in the case
of fresh tissue imaging (such as viability imaging) where procedures such as fixation and
clearing are not available. Nevertheless, multi-angle light sheet microscopy seems to be able
to provide a reliable image of the whole cell cluster viability, especially the presence of dead
cells stained by propidium iodide. This method is not high-throughput and would not be
suitable for clinical assessment of viability (due to time and equipment limitations) but it
can be a useful tool for confirmation of viability in research settings (such as in efficacy of
cryopreservation protocols).
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Fig. 3.9 Imaging of pancreatic islet core using confocal, two-photon and light sheet microscopy.
(A) Pancreatic islet stained with FDA (green), PI (red) and Hoechst 33342 (blue) for 6 h at 37 °C
imaged as a Z-stack on a confocal microscope. (B) Pancreatic islet stained with FDA (green), PI
(red) and Hoechst 33342 (blue) for 24 h at 37 °C imaged as a Z-stack on a confocal microscope.
Long incubation time caused bleaching of FDA so the settings of the microscope was changed to
detect the weak signal, resulting in high background signal. (C) Pancreatic islet stained with FDA
(green) and Hoechst 33342 (white) for 6 h at 37 °C imaged as a Z-stack on a two-photon microscope.
PI was not imaged using this method since the two-photon microscope was not equipped with the
appropriate emission filter for PI wavelength. (D) Pancreatic islet stained with FDA (green), PI
(red) and Hoechst 33342 (white) for 6 h at 37 °C imaged as a Z-stack on a light sheet microscope.
(E) 3D-reconstruction from multi-angle imaging (4 angles, 90° apart) of pancreatic islet stained with
FDA (green), PI (red) and Hoechst 33342 (white) on a light sheet microscope. The PI-stained core
is likely to be so called hypoxic core: a result of impaired oxygen diffusion to the centre of large
islets [174]. FDA = fluorescein diacetate; H33342 = Hoechst 33342; PI = propidium iodide.
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3.5 Discussion
3.5.1 Mononuclear cell viability assessment
In Section 3.3, the adaptations to flow cytometric analysis for cryopreserved samples were
outlined with regards to the cryobiology-specific needs of viability assessment method
(Section 3.2).
The use of dual staining consisting of Syto13 and membrane-permeability dye has
previously been suggested and validated for cryopreserved samples by Reardon et al. [88].
This chapter builds on this idea, by adding the steps of absolute count determination and
comparison to pre-freeze samples. Moreover, the method was adapted to be able to determine
post-thaw survival of cell subsets in mixed cell populations.
The method of assessment of absolute cell count of cell subsets has long been used
for specific purposes - such as haematopoietic progenitor enumeration for transplantation
where the kits of the enumeration of CD34+ cells are commercially available. However,
these single-platform enumeration protocols (where counting beads are added directly to
the stained cell sample) can only be performed in cases where the markers do not require
washing steps. The method developed in this project, on the contrary, can be adapted for a
variety of cell types and staining agents.
Many approaches for quantification of viability exist in the cryobiology field, many of
which have significant shortfalls. Development of a standardised method and its adoption
by the field would be very beneficial and would enable results from different laborato-
ries/publications to be directly compared. The method suggested in this Chapter (reporting
absolute number of cells both before and after freezing using flow cytometric analysis) could
possibly be used for this purpose if validated and adopted by the cryobiology community.
3.5.2 Pancreatic islet viability assessment
Limitations of current staining and imaging
In Section 3.4, it was demonstrated that the current viability staining and imaging protocol
ignores the viability of cells in the core of pancreatic islets. It is therefore not surprising
that viability often does not correlate with function [92]. Figure 3.9E shows an example
of an islet in which the viability in the periphery and the core is very different. This islet
would, by current methods, be identified as a fully viable islet. Regarding the fact that central
necrosis is a common phenomenon in large islets [174], this would suggest that viability of
islet batches could be commonly overestimated.
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The optical properties of live islets are particularly challenging since the detection of
fluorescent signals from the core of even average-sized (100 µm) islets is very difficult or
impossible using many available technologies. This may be related to the light-scattering in-
sulin granules contained in b -cells [176]. The light sheet technology was the most successful
in imaging the core of pancreatic islets, likely because it utilises multi-angle imaging.
The suggested staining and imaging method is suitable for research laboratories, but it is
unfortunately not ideal for clinical use due to time limitations and equipment requirements.
Other limitation of this work is the fact that identified diffusion properties are specific for
Hoechst 33342 in aqueous solution. If exact diffusion rates of dyes and molecules are needed,
the experiments would need to be repeated and include additional incubation times and
replicates. Nevertheless, diffusion of other small molecules in aqueous solutions should,
in theory, be quite similar and could be applied in design of new freezing protocols using
non-penetrating cryoprotectants.
For future applications of these findings in staining or design of cryopreservation proto-
cols, the variation in shape and size of islets should be taken into consideration: the ideal
incubation time for each of them will vary. While it may be possible to sort islets by their
size in laboratory experiments, it would be complicated in the clinical settings and therefore
the optimal incubation time will be the one which works best for average sized islets, leaving
small islets overexposed to the reagent and large islets not fully penetrated. Moreover,
multicomponent diffusion may need to be taken into account in cryopreservation, especially
when combining different cryoprotectants which may have different diffusion kinetics.
Issues to be addressed in islet viability image analysis
Achieving unbiased and precise image analysis of islets stained for viability constitutes
another challenge. The current analysis comprises of manually classifying them into few
groups. To enable objective quantification of viability of each individual islet and to inter-
and intra-observer variation, the image analysis must be streamlined and automated.
Over the course of this project, thousands of images of islets stained with FDA and PI were
taken on a wide-field microscope and analysed using a simple pixel intensity thresholding in
ImageJ. Although the staining and microscope settings were identical within each experiment,
significant variability in the fluorescent intensity between individual islets was identified.
Taking into account the fact that the images were taken on a wide-field microscope, the likely
reasons for this are the incomplete staining of all islets and variable size of the islets (small
islets typically had higher fluorescent intensities than large ones because they would not
flatten out easily under the pressure of a coverslip).
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A second issue identified was related to the fact that PI only stains cell nuclei whereas
FDA stains the cytoplasm. Viabilities calculated using the positive areas therefore always
overestimate the viability since the average size of a FDA-stained cell is larger than an
average PI-stained nucleus. This fact is not necessarily an issue when comparing viabilities
of different cryopreservation conditions but it could be another reason for the poor correlation
between viability and functional assays.
Creation of a script in a suitable programming language (i.e. Python) which can be
applied to quantify viability of islets of different sizes and fluorescent intensities and can be
shared between labs and islet isolation centres would be the key step for standardising the
analysis. To address the above issues, a suitable thresholding method must be identified and
correction must be applied to address the cell size discrepancy between live and dead cells.
While writing the macro code itself was not in the scope of this thesis, suggestions of the
individual steps needed to achieve an unbiased, automated process are summarised below.
A simple thresholding protocol would include an analysis of the pixel intensity histogram
for each colour channel, fitting a function onto the histogram and using the function parame-
ters (such as centre (C), error (d ), etc.), determining the position of the threshold (e.g. C-2d ).
Area of the picture with the pixel intensity above this threshold would then be measured.
The type of function (e.g. Gaussian, bimodal etc.) and the parameter which will be applied
as a threshold will need to be carefully considered since the histogram shapes can vary
significantly depending on the amount of staining in each colour channel relative to the
background and spillover from the other channels.
For this reason, applying a conventional thresholding may not be sufficient even if the
parameters of the imaging are kept the same within and between experiments. There is an
option to employ adaptive thresholding (and/or machine learning) approach which would
enable applying dynamic thresholds to different areas of one image, depending on the
intensity of the surrounding pixels. This would also solve another problem which stems from
the fact that using conventional viability staining method, the intensity of staining will not be
the same throughout the islet volume.
The issue of the discrepancy between the FDA and PI area measurements could theoreti-
cally be solved by measuring the size distribution of individual FDA-stained and PI-stained
cells and applying an appropriate correction to adjust for differences in positive areas of live
and dead cells.
However, practically this approach would have several caveats. While the PI-stained
nuclei are spaced out and can be easily counted to calculate an average size of PI-stained
nucleus, with FDA-stained cytoplasm the borders of the cells are not always obvious and
calculating area of these cells with currently existing tools will be complicated. Imaging on
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the wide-field microscope also means that several layers of cells can be seen in one image
which makes this analysis almost impossible. Using confocal could make the image analysis
easier but confocal microscope is not a standard piece of equipment in islet isolation centres.
Nevertheless, applying this correction is not crucial for the accuracy of the measurement as
long as it is acknowledged that the viability measured by this method is an overestimation of
the actual viability.
3.6 Conclusion
Cryobiological assessment of sample viability after freezing and thawing presents special
challenges compared to classical viability assessment in other fields. Although looking at
cellular function provides more useful view of the cryopreserved sample quality, viability
assessment has an important function in rapid screening of cryopreservation conditions and
development of unbiased and precise methods is crucial.
A method of cryopreservation efficacy assessment for single cells which answers the
specific needs of cryobiology was proposed in this Chapter and demonstrated on the example
of mononuclear cells. In this method, two variables are recorded: the viability of the sample
and the absolute cell count, which in combination provide the absolute number of viable cells.
These variables should be recorded before freezing and after thawing for an accurate and
robust evaluation of the efficiency of cryopreservation. This method is unbiased, reproducible
and adaptable to specific characteristics of different cell populations.
The quality of the current viability assessment of pancreatic islets was investigated and it
was demonstrated that the current staining protocol does not allow sufficient time for the dye
diffusion throughout the cell cluster, resulting in the assessment of peripheral islet cells only.
Approaches to accelerate diffusion were tested (including the use of DMSO as a penetration
enhancer, increase in hydrostatic pressure and temperature). It was found that it can take up
to 6 h at 37 °C to achieve full staining by a nuclear dye. Furthermore, the imaging depth of
confocal microscopy did not allow imaging of the islet core and therefore more powerful
imaging methods were investigated. Multi-angle light sheet microscopy was identified as a




trehalose and permeabilising polymers
4.1 Introduction and aims
Studies of DMSO-free cryopreservation methods for clinically-relevant cell types are limited.
The only investigation of efficacy of trehalose without any penetrating cryoprotectants in
single mononuclear cells showed decreased viability but increased clonogenic capacity
compared to DMSO-cryopreserved cells [130]. Successful protocols which are free from
DMSO or other penetrating cryoprotectants for cell clusters such as pancreatic islets or
embryos have not been reported.
Realising the complexity of cell cluster cryopreservation, I opted to first use mononuclear
cells to test the efficacy of trehalose and permeabilising polymers in cryopreservation. As
single cells, mononuclear cells provide a simpler model for cryopreservation: it is not
necessary to account for diffusion of cryoprotectants into and out of cell cluster or heat
transfer. Cryopreservation of mononuclear cells (especially the progenitor fraction) is also
used in treatment of patients and development of DMSO-free cryopreservation protocol
would be potentially translatable to clinical practice. Their use was therefore preferred to the
use of cell lines, whenever possible.
While haematopoietic progenitors already have use in clinical transplantation, therapies
utilising T cells or B cells (such as regulatory T cells) are under development and their
successful cryopreservation will be necessary. I therefore used the mixed population of
mononuclear cells isolated from human spleen or bone marrow and analysed the survival of
CD34+ haematopoietic progenitors, CD3+ T cells and CD19+ B cells.
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The first aim of this chapter was to determine the initial efficacy of trehalose alone
and trehalose with PP-50 polymer using parameters chosen based on evidence in literature
(200 mM trehalose and 100 µg/mL PP-50 concentrations). These initial results are described
in Section 4.2.
The second aim was to investigate protocol parameters which were not specific to
trehalose or polymers, to ensure that the work is done with the most efficient DMSO and
trehalose protocols available. These parameters include cell density during cryopreservation,
addition of fetal calf serum and variables involved in thawing protocol. Results are described
in Section 4.3.
Using the optimised general protocol, I investigated the optimal times, temperatures and
pH for incubation with trehalose and polymers in Section 4.4 and their optimal concentrations
which balance efficacy and toxicity in Section 4.5. The development of a novel method of
intracellular detection of trehalose by Raman spectroscopy is summarised in Section 4.6.
The initial experiment using this method were then used to generate insights into the polymer-
mediated trehalose uptake and safety of the new method.
4.2 Initial efficacy of trehalose and PP-50
In order to demonstrate the ability of the new cryopreservation method utilising trehalose and
PP-50 polymer to preserve viable and functional mononuclear cells, singe cell suspensions
generated from human spleen and bone marrow were cryopreserved in trehalose alone or
trehalose with PP-50 and compared to DMSO controls. The overall post-thaw viability
and percentages of cell subsets were determined by flow cytometry analysis. In addition to
viability assessment, functionality of the CD34+ cell subset was determined using in vitro
colony forming unit assays.
4.2.1 Efficacy for cryopreservation of splenic mononuclear cells
Splenic mononuclear cells from seven donors (Appendix A) were cryopreserved in three
cryoprotectant combinations, all supplemented by FCS: DMSO, trehalose alone (T), trehalose
with PP-50 (TP). The composition of cryoprotectant combinations used is shown in Table 4.1.
Samples were cryopreserved at the cell density of 107 cells/mL and without any pre-freeze
incubation time. Additionally, cells from one donor (D16) were cryopreserved with no
cryoprotectant as a control. After thawing, the samples were stained with the Panel B1 and
B2 antibodies (Appendix B) and analysed by flow cytometry to determine viability and
phenotype.
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Table 4.1 Composition of cryoprotectant solutions
Code Cryoprotectant solution composition
DMSO 10 % DMSO + 10 % FCS + DMEM
T 200 mM trehalose in DMEM + 10 % FCS
TP 200 mM trehalose in DMEM + 100 µg/mL PP-50 + 10 % FCS
Notes: Codes used in this chapter and exact composition of each cryopreservation solution. DMSO =
dimethyl sulphoxide, T = trehalose, TP = trehalose + PP-50.
The percentage of doublets detected during flow cytometry analysis did not differ sig-
nificantly between the three cryoprotectant conditions (data not shown), which suggests
that there is no significant difference in adherence of cells cryopreserved in T, TP and
DMSO. The percentages of alive nucleated cells and alive nucleated non-apoptotic cells were
significantly lower after cryopreservation in T and TP compared to DMSO. Nevertheless,
trehalose-cryopreserved samples had improved survival if compared to cells frozen without
any cryoprotectant (Figures 4.1A and B). There is, therefore, a potential for the T and TP to
be used for cryopreservation of human splenocytes.
There was no significant difference between the conditions in the frequency of CD34+
haematopoietic progenitors in the population of alive nucleated cells (Figure 4.1D). There
were three donors (D8, D12 and D14) with much higher percentage of CD34+ cells in all
conditions (on average 0.312 ± 0.075 % of alive nucleated cells) and four donors with low
percentage of CD34+ cells (on average 0.060 ± 0.012 %). There we no significant differences
in the donor demographics, suggesting that the differences cannot be explained by age, sex
or type of the donors (DBD vs. DCD).
The percentages of CD19+ B cells were similar in DMSO, T and TP cryoprotectants
(Figure 4.1E). However, significant difference was found between the frequency of CD3+ T
cells after cryopreservation with DMSO and T or TP (Figure 4.1F). Lower survival in the
trehalose, which generally did not provide as high protection as DMSO, would suggest that
T cells may be more prone to damage caused by the freezing and thawing process compared
to B cells. This may be a consequence of higher sensitivity of T cells to osmotic stress or
dehydration but this hypothesis has yet to be tested.
Overall, no difference was found in cryoprotectant efficacy of trehalose alone and tre-
halose with PP-50. One potential reason for the failure of PP-50 to improve the cryopreser-
vation outcome with trehalose is that the experimental design did not control for the pH of
the freezing medium before addition to the cells. Permeabilising biopolymers are known to
change their conformation in different pH and they were shown to improve trehalose loading
only below the pH of 7.05 [141]. The medium used (DMEM) has a neutral pH of 7.4, which
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Fig. 4.1 Initial efficacy of DMSO, trehalose and PP-50 for cryopreservation of human mononuclear
cells from spleen. (A) Percentage of alive nucleated cells (7-AAD- Syto13+) out of all singlet events.
(B) Percentage of alive nucleated non-apoptotic cells (7-AAD- Syto13+ annexin V-) out of all singlet
events. (C) Percentage of apoptotic cells (7-AAD- Syto13+ annexin V+) out of alive nucleated cells.
(D) Percentage of CD34+ progenitor cells out of alive nucleated cells. (E) Percentage of CD19+ B
cells out of alive nucleated cells. (F) Percentage of CD3+ T cells out of alive nucleated cells. Mean of
7 experiments is shown by the line, individual values are presented as full circles. Differences between
cryopreservation conditions were tested by one-way repeated measures ANOVA followed by Tukey’s
HSD test. Significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01; ⇤⇤⇤ p  0.001;
⇤⇤⇤⇤ p  0.0001. no CPA = no cryoprotectant; T = trehalose, TP = trehalose + PP-50.
may be too high for efficient trehalose loading. Further experiments will be required to test
this hypothesis, including the impact of low pH on cells.
4.2.2 Efficacy for cryopreservation of bone marrow mononuclear cells
Mononuclear cells from bone marrow of four deceased human organ donors (Appendix A)
were cryopreserved using DMSO, T and TP cryoprotectant solutions (for composition, see
Table 4.1). After thawing, cells were stained with Panel B1 and B2 antibodies (Appendix B)
and analysed by flow cytometry.
The frequency of doublets did not significantly differ in the three cryopreservation
conditions (data not shown). The percentage of alive nucleated cells and alive nucleated
non-apoptotic cells was considerably lower in T and TP (Figure 4.2A and B). However,
conversely to cryopreserved splenocytes, the level of apoptosis was significantly higher in
TP cryopreserved bone marrow mononuclear cells (Figure 4.2C).
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Fig. 4.2 Initial efficacy of DMSO, trehalose and PP-50 for cryopreservation of human mononuclear
cells from bone marrow. (A) Percentage of alive nucleated cells (7-AAD- Syto13+) out of all singlet
events. (B) Percentage of alive nucleated non-apoptotic cells (7-AAD- Syto13+ annexin V-) out of all
singlet events. (C) Percentage of apoptotic cells (7-AAD- Syto13+ annexin V+) out of alive nucleated
cells. (D) Percentage of CD34+ progenitor cells out of alive nucleated cells. (E) Percentage of CD19+
B cells out of alive nucleated cells. (F) Percentage of CD3+ T cells out of alive nucleated cells. Mean
of 7 experiments is shown by the line, individual values are presented as full circles. Differences
between cryopreservation conditions were tested by one-way repeated measures ANOVA followed by
Tukey’s HSD test. Significant differences are marked by an asterisk. T = trehalose, TP = trehalose +
PP-50.
Significant difference was also found between the frequencies of CD34+ progenitors in
DMSO and TP, even though the variation between the donors was high with percentages of
CD34+ cells ranging from 0.52 % to 1.51 % for DMSO-cryopreserved cells (Figure 4.2D).
As with cryopreserved splenocytes, there was a trend towards better survival of bone
marrow CD3+ T cells in DMSO, although the difference was not statistically significant
(Figure 4.2F). Conversely, CD19+ B cells survived significantly better in T and TP than
in DMSO (Figure 4.2E). This was consistent with the hypothesis that B cells have lower
sensitivity to the stress accompanying freezing than T cells.
There was no difference in efficacy of cryopreservation of bone marrow mononuclear
cells in trehalose alone and trehalose supplemented with PP-50 (Figures 4.2A and B). This
was also the case with splenocytes and suggests that mononuclear cells from these two
sources behave similarly during the freezing and thawing procedure.
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Fig. 4.3 Comparison of three cryopreservation conditions in 14-day haematopoietic CFU assay.
(A) Total number of colonies grown at day 14 of culture per 100 CD34+ cells seeded. (B) Ratios
of different colony types as a percentage of total colony number. (C) Average number of cells
grown per 100 CD34+ cells seeded determined by analysis in BD TrucountTM tubes. (D) Ratio of
erythroid (CD235a+) and myeloid (CD33+) cells from all colonies determined by flow cytometry.
(E) Average colony size, equivalent to average number of cells (determined by analysis in BD
TrucountTM tubes) per colony. (F) Ratio of macrophages (CD14+) and granulocytes (CD15+) from all
colonies determined by flow cytometry. In figures A, C and E, the mean of two experiments is shown
by a line, individual values are presented as full circles. Statistical analysis was not performed due to
a low sample size. T = trehalose, TP = trehalose + PP-50.
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4.2.3 Colony forming ability of cryopreserved CD34+ cells
In addition to maintenance of viability, successfully cryopreserved CD34+ cells (haematopoi-
etic progenitors) need to retain their function to be clinically useful. In vitro haematopoietic
colony forming unit assays were performed to demonstrate that haematopoietic progenitors
cryopreserved in trehalose or trehalose with PP-50 maintain their ability to proliferate and
differentiate into different haematopoietic lineages.
Samples cryopreserved in DMSO, T and TP from two deceased human organ donors
were thawed, the population of CD34+ cells was selected by FACS and CFU assays were
performed. Between 700 and 1000 CD34+ cells were sorted and seeded for each condition.
Number of colonies after 14 days of culture were then related to number of cells seeded for
each condition. Cell sorting and CFU preparation was performed with the help of Emily
Calderbank from the Stem Cell Institute, University of Cambridge. Flow cytometry of the
cells post-culture was performed to determine the percentages of erythroid cells (from the red
and mixed colonies) and myeloid cells (from the white and mixed colonies), and as subsets
of myeloid cells, granulocytes and macrophages. Analysis in BD TrucountTM tubes was
performed to determine absolute numbers of cells grown during the assay.
The ability to form colonies of haematopoietic cells was decreased in T and TP conditions,
compared to the DMSO control (Figure 4.3A). However, the distribution of colony types
was similar for all three conditions, with approximately 60 % of colonies of the BFU-E type,
33 % CFU-GM and 6 % CFU-GEMM (Figure 4.3B). Analysis of surface markers by flow
cytometry confirmed that the ratio of erythroid and myeloid cells did not differ between
these three conditions (Figure 4.3D) but there was a significant difference in percentages
of macrophages and granulocytes between the conditions (Figure 4.3F). The proliferation
potential of each seeded CD34+ progenitor was also higher in DMSO (Figure 4.3C) but the
average colony size was greater for T, although there was a considerable variability between
the experiments (Figure 4.3E).
The data suggested that progenitors cryopreserved in each of these three cryopreservation
solutions were capable of forming all haematopoietic lineages studied in this experiment
(erythroid and myeloid cells, granulocytes and macrophages). However, the clonogenic
efficiency of cells cryopreserved in trehalose or trehalose with PP-50 was decreased. This
suggests cells cryopreserved in T or TP cryoprotectant solutions were more prone to suffer
sublethal damage during cryopreservation. The possible mechanism could include decreased
expression or loss of growth factor receptors resulting in unresponsiveness to growth factors
driving the proliferation and differentiation of progenitors in CFU assay, as suggested for
cryopreserved cells by Sasnoor et al. [177].
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4.3 General parameters of cryopreservation protocol
Before further investigating the parameters specific to trehalose cryoprotectant, such as its
concentration and variables involved with the pre-cryopreservation incubation period, general
parameters of the trehalose cryopreservation protocol were optimised. These included cell
density, addition of fetal calf serum and multiple thawing protocol parameters.
When optimising these general parameters for trehalose, an appropriate DMSO control
was included in all experiments.
4.3.1 Cell density
For the purposes of clinical transplantation, it would be advantageous to cryopreserve cells
in higher densities (over 107 cells/mL). However, in research practice, cells are often cryop-
reserved in the concentration range of 106 to 107 cells/mL, mostly for practical purposes. I
therefore investigated whether cell density has an impact on cell survival after cryopreserva-
tion with DMSO or alternative solutions containing trehalose and PP-50. The influence of
difference cell densities has been previously studied for a narrow range of densities (108 vs.
2 x 108 [178], 9 x 107 vs. 3 x 108 [64] or 2-5 x 107 vs. 2 x 108 cells/mL [179] etc.), most of
which did not detect any difference between the cell densities. In this project, the effect of
cryopreservation of cells over a wider range of cell densities, from 106 to 109 cells/mL, was
compared.
Table 4.2 Numbers of deceased human donor samples used for the cell density study
106 cell/mL 107 cell/mL 108 cell/mL 109 cell/mL
DMSO n = 3 (D6, D8, D9) n = 3 (D6, D8, D15) n = 4 (D8, D9, D10, D15) n = 2 (D8, D10)
T n = 3 (D6, D8, D9) n = 3 (D6, D8, D15) n = 4 (D8, D9, D10, D15) n = 1 (D10)
TP n = 3 (D6, D8, D9) n = 3 (D6, D8, D15) n = 4 (D8, D9, D10, D15) n = 2 (D8, D10)
Notes: For each condition characterised by the cryoprotectant used and the cell density, samples from
n different donors were cryopreserved. In the brackets, the specific donor codes are indicated
(demographics data can be found in Appendix A).
Samples were cryopreserved in three different cryoprotectants (DMSO, 200 mM trehalose
(T), 200 mM trehalose + 50 µg/mL PP-50 (TP) at four different cell densities (106, 107, 108 or
109 cells/mL). In total, splenocytes from five deceased human organ donors were dedicated
for this set of experiments. However, due to the limitation of the low total cell yield per
spleen, it was not possible to cryopreserve samples in all cell densities from every donor
(Table 4.2). After thawing (following the un-optimised thawing protocol, Section 4.3.3),
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Fig. 4.4 Effects of different cell densities on the outcome of cryopreservation with DMSO, trehalose
and trehalose + PP-50. (A) Percentage of alive nucleated cells (eFluor780- Syto13+) out of all
singlet events. (B) Percentage of apoptotic cells (eFluor780- Syto13+ annexin V+) out of alive
nucleated cells. (C) Percentage of CD34+ cells of alive nucleated cells. (D) Post-thaw cell yield
expressed as a percentage of cell count after thawing out of pre-freeze cell count. All bars represent
mean ± SD, differences between cell densities of each cryoprotectant were tested by two-way mixed
model ANOVA followed by Tukey’s HSD test, no significant differences were found. T = trehalose,
TP = trehalose + PP-50
the absolute cell count was determined using the haemocytometer and viability and surface
markers were analysed by flow cytometry (using panels A1 and A2 described in Appendix B).
For the control DMSO condition, higher cell densities resulted in better cell survival
(Figure 4.4A) and lower apoptosis (Figure 4.4B). For T and TP, the impact of cell density
on cell survival was less clear, although a cell density of 108 cells/mL appeared to be most
effective for both conditions (Figures 4.4A and B). There was no difference in survival
of CD34+ progenitors in different cell concentrations for any of the three cryoprotectants
(Figure 4.4C).
Lowest absolute cell losses (determined by post-thaw haemocytometer count) were
detected for the 107 cell/mL concentration in all three cryoprotectants (Figure 4.4D). Possible
reasons for the decrease in absolute cell count after thawing include freezing-related cell
losses and losses during the two washing steps in the thawing procedure. For concentrations
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of 108 cells/mL or higher, cell clumping represents a major cause of cell losses; large clumps
were visible at 108 cells/mL cell density for T and TP and in 109 cells/mL cell density for all
the conditions. The reason for decreased yield at the 106 cells/mL concentration is less clear.
One hypothesis is that in lower cell densities, the volume of extracellular fluid is larger which
has an impact on dynamics of the freezing process. The extracellular space has a different
composition and generally freezes much earlier than the cytoplasm [36]. The cells at low
concentrations do not effectively limit ice crystal growth in the extracellular space (during
both freezing and thawing), leading to increased damage to the cells. Theoretically, toxicity
of the cryoprotectant could also play a role as more molecules of DMSO or trehalose can act
on fewer cells but this would be less likely with a non-toxic cryoprotectant such as trehalose.
In conclusion, the highest tested cell density resulted in the best cell survival in DMSO.
However, in the 109 cells/mL concentration, the cells tended to clump which caused signifi-
cant cell losses. The ideal cell concentration for DMSO would therefore be between 108 and
109 cells/mL. For trehalose (conditions T and TP), the cell clumping started to occur at the
108 cells/mL density. Therefore, for these conditions, the ideal cell density would be lower
than for DMSO, likely between 107 and 108 cells/mL. Unless the clumping can be prevented
by additives (such as DNase, anticoagulants such as acid-citrate- dextrose and heparin or
hydroxyethyl starch [180]), cryopreservation in higher densities than those stated seems to
be impractical.
4.3.2 Addition of fetal calf serum
Addition of fetal calf serum (FCS) into the cryopreservation medium was previously shown
to have a beneficial effect on cell recovery of bone marrow cells from mouse and human [52,
181]. Addition of serum is thought to protect the cells both during the freezing process
and subsequent post-thaw processing when the marrow cells are fragile [181]. The effect
of supplementation of cryopreservation media with FCS on cell yield and recovery of
mononuclear cells from human spleen was evaluated in this Section.
Samples of splenic mononuclear cells from three deceased human donors were cryop-
reserved at 107 cells/mL using DMSO or 200 mM trehalose supplemented with different
amounts of FCS (0 %, 10 %, 50 % or 100 %). After thawing, cells were stained for flow
cytometry using antibody panels A1 and A2 (Appendix B) and absolute cell count was
determined using Trucount beads.
Addition of FCS to DMSO cryopreservation medium did not affect the post-thaw per-
centages of cryopreserved CD34+, CD19+ or CD3+ subsets in the samples (Figure 4.5A and
B). However, slightly lower percentage of alive nucleated cells could be found after thawing
in sample without FCS and with 10 % or more FCS added (not statistically significant,
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Fig. 4.5 Effects of addition of fetal calf serum to DMSO-cryopreserved splenocytes. (A) Post-thaw
percentage of CD34+ cells of alive nucleated cells. (B) Post-thaw percentages of CD3+ and CD19+
cells of alive nucleated cells. (C) Post-thaw percentage of alive nucleated non-apoptotic cells (7-AAD-
Syto13+ annexin V-) out of all singlet events. (D) Post-thaw absolute number of alive nucleated cells
(7-AAD- Syto 13+) normalised to the absolute number of alive nucleated cells in 0 % FCS for each
donor. Mean of three experiments is shown as a line, individual values are presented as full circles.
Differences between conditions were tested by one-way repeated measures ANOVA followed by
Tukey’s HSD test, no significant differences were found.
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Fig. 4.6 Effects of addition of fetal calf serum to trehalose-cryopreserved splenocytes. (A) Post-thaw
percentage of CD34+ cells of alive nucleated cells. (B) Post-thaw percentages of CD3+ and CD19+
cells of alive nucleated cells. (C) Post-thaw percentage of alive nucleated non-apoptotic cells (7-AAD-
Syto13+ annexin V-) out of all singlet events. (D) Post-thaw absolute number of alive nucleated cells
(7-AAD- Syto 13+) normalised to the absolute number of alive nucleated cells in 0 % FCS for each
donor. Mean of three experiments is shown as a line, individual values are presented as full circles. In
(D), individual values of two experiments are displayed (data is missing for one donor due to technical
error). Differences between conditions were tested by one-way repeated measures ANOVA followed
by Tukey’s HSD test, no significant differences were found.
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Figure 4.5C). There was also a trend in the absolute number of alive nucleated cells: all
samples with added FCS (regardless of concentration) had higher numbers of cells than
samples without FCS (Figure 4.5D).
In trehalose-cryopreserved samples, the overall viability was much lower, as expected.
Percentage of surviving CD34+ cells did not significantly differ between the different FCS
concentrations but there was a trend towards higher proportion of surviving CD34+ cells
in samples will less FCS added (Figure 4.6A). The same trend was observed for CD19+
cells while the opposite was true for CD3+ cells (Figure 4.6B). Regarding total number of
alive nucleated non-apoptotic cells, large variability was observed and no clear trend was
distinguishable (Figure 4.6C). However, the absolute number of surviving cells in 200 mM
trehalose in 100 % FCS was more than double the other conditions (Figure 4.6D).
The addition of FCS to the DMSO-based medium showed small but significant difference
in the percentage of surviving cells and a trend towards higher absolute numbers. This
is in agreement with previous studies although different assays were used there (mainly
cell yield and CFU assays) [52, 181]. Since FCS is known to exhibit certain amount of
cryoprotective effect, its addition has had a large effect on the success of cryopreservation
with trehalose (as seen in Figure 4.6D). It would be reasonable to postulate that this effect
may be somehow diminished if the cryopreservation efficacy of this condition is increased
(possibly to a level similar to the DMSO-cryopreserved samples seen in Figure 4.5D). The
trend towards better survival of CD34+ and CD19+ in harsher conditions has been observed
across all the experiments with splenocytes.
To conclude, although the addition of FCS had a limited effect in successful cryopreser-
vation conditions, in subsequent experiments, all cryopreservation media were supplemented
with FCS based on the evidence from these experiments and previous publications. Since
the positive effect of FCS addition was not found to be concentration-dependent in the
DMSO-cryopreserved samples, 10 % FCS was used in all subsequent cryopreservation ex-
periments. There is some evidence that using homologous serum instead of fetal calf serum
is advantageous [181] and the substitution of FCS for a GMP-compatible alternative would
be necessary before clinical translation. However, due to the unavailability of homologous
serum and cost of GMP-compatible alternatives, FCS was used for subsequent experiments.
4.3.3 Optimisation of thawing protocol
Thawing protocols introduce many variables into the cryopreservation procedure which may
impact outcomes. These variables include: thawing rate, thawing time, composition of the
thawing medium, temperature and pH of the thawing medium, technique of addition of
the thawing medium, the final dilution of the cryoprotectant, method of cell manipulation
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(centrifugation speed, pipetting), and number of washes. I therefore investigated the effects
of some of these variables on post-thaw viability and apoptosis of human splenocytes. The
parameters examined were:
• thawing time (until the last ice crystal visible or 10 minutes)
• temperature of the thawing medium (room temperature or 37 °C)
• technique of cryoprotectant addition (quickly or drop-wise)
• number of washes (one or two).
Rapid thawing in 37 °C water bath is recommended in most protocols. Removing the
sample from the water bath as soon as the ice has thawed is also thought to prevent the
damage caused by DMSO in higher temperatures [106]. It is recommended that thawing
medium should then be added slowly to reduce the osmotic shock to the cells [69]. The
number of washing steps varies in different laboratories; some prefer no washing steps in
order to eliminate any cell losses, while others wash the cells twice to thoroughly remove
the cryoprotectant. The standard protocol used in many laboratories involves rapid thawing
in 37 °C water bath until the last crystal is visible, drop-wise addition of thawing medium
at room temperature (DMEM + 50 % FCS) up to ten times the original volume (for 1 mL
of sample it is diluted to 10 mL) and two washing steps for removal of the cryoprotectant
(Figure 4.7A).
Samples from three donors were cryopreserved in DMSO and different three donors
in TP (Appendix A). All samples were cryopreserved at density of 107 cells/mL with no
incubation time. This study was designed with two arms: one for DMSO-cryopreserved
samples and one for trehalose cryopreserved samples. It was assumed that the optimal
thawing protocol for trehalose and trehalose with PP-50 will be similar and therefore the
samples were cryopreserved using trehalose and PP-50. Moreover, because of low cell yields
from the thawed TP samples, only four different thawing protocols were investigated for
each thawed sample, compared to eight different protocols from the DMSO samples. The
design of this study is outlined in Figure 4.7.
After thawing the samples, cells were counted using haemocytometer, stained with Panel
C antibodies (Appendix B) and analysed by flow cytometry. Comparisons of combinations
of thawing protocols which were used to inform decisions about the final optimised protocol
are shown for each arm of this study. Separate optimal protocols were then derived for
DMSO-cryopreserved samples and trehalose-cryopreserved samples.
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Fig. 4.7 Study design of the thawing protocol refinement for DMSO and TP (trehalose + PP-50)
samples. (A) Current un-optimised protocol for thawing mononuclear cells from spleen, bone marrow
and peripheral blood. (B) Study design for DMSO samples. First sample was thawed until the last
crystal was left, second one for 10 min. Each sample was then split into 8 tubes for 8 different
protocols as outlined. Blue circles mark derivation from the currently used protocol. (C) Study design
for TP samples. First sample was thawed until the last ice crystal was left, split into four tubes and
used for decision about the medium temperature and medium addition. Based on this decision, the
medium temperature was fixed to 37 °C and medium addition technique to drop-wise in the following
experiments. Two samples were thawed, one until the last crystal left and one for 10 min, each was
split into two tubes and thawed following the outlined protocols. RT = room temperature; LC = last
crystal; Q = quickly; DW = drop-wise
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Fig. 4.8 Effect of thawing protocol changes on cryopreservation with DMSO. (A) Schematic of the
decision points in the thawing protocol, the optimal option for each variable is shown in blue circle.
(B) Percentage of alive nucleated cells (7-AAD- Syto13+) of all singlet events for selected protocol
combinations which served as a basis for the decision. (C) Percentage of apoptotic cells (7-AAD-
Syto13+ annexin V+) of alive nucleated cells for selected protocol combinations which served as a
basis for the decision. Means of three experiments (circles) are shown by the horizontal lines. No
significant differences were found after testing with two-way ANOVA with Tukey’s HSD test. RT =
room temperature.
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Fig. 4.9 Final comparison of thawing protocols for DMSO-cryopreserved samples. (A) Cell yield after
first and second wash showed as a percentage of the original cell count before freezing. This data was
derived from the results in cell density study in the Section 4.3.1. (B) Percentage of alive nucleated
cells (7-AAD- Syto13+) of all singlet events for the least optimal protocol (10 min, room temperature,
quick addition, 1 wash), currently used protocol (last crystal, room temperature, drop-wise addition, 2
washes) and the optimal protocol (last crystal, 37 °C, drop-wise addition, 2 washes). (C) Percentage
of apoptotic cells (7-AAD- Syto13+ annexin V+) of alive nucleated cells for the least optimal protocol,
currently used protocol and the optimal protocol. Bars in (A) represent mean ± SD, difference was
tested by paired t-test. Means of three experiments in (B) and (C) (circles) are shown by the horizontal
lines differences between the protocols in (B) and (C) were tested by one-way repeated measures
ANOVA followed by Tukey’s HSD test. Significance (p  0.05) is marked by an asterisk.
Thawing procedure for DMSO-cryopreserved samples
To inform decisions about the four variables in the thawing protocol described earlier, I
compared percentages of alive nucleated cells and percentage of apoptotic cells from the 16
thawing protocols (mean data from three experiments). Only selected protocols are shown
in Figure 4.8 for clarity but the result was derived from comparison of all protocols tested.
The variability between samples was high and no significant differences were found after
analysis by two-way ANOVA with Bonferroni post-hoc test. Nonetheless, trends detected
by the comparison of all the protocols are noted and described, as even small improvement
caused by changing an individual variable can potentially contribute to greater efficacy of the
final optimised protocol.
Of the two thawing durations tested, thawing at 37 °C until the last crystal is visible
showed a trend towards better mean viability for all the conditions tested, compared to
thawing for 10 min (Figure 4.8B). There was no difference in the level of apoptosis. Thawing
medium temperature of 37 °C appeared to be superior, with lower percentage of apoptotic
cells for all conditions and higher viability, especially for samples with the quick addition of
the thawing medium (Figure 4.8C). Human splenocytes appeared to be adversely affected by
quick addition as it made them sensitive to every change in the protocol. In contrast, when
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using drop-wise addition of medium, the viability and apoptosis remained generally stable in
all 8 protocols (Figure 4.8D).
Washing the cells twice (rather than once) resulted in overall higher quality of the thawed
cells (Figure 4.8E) but it also led to decreased absolute cell count, although the difference
was not statistically significant. As a part of the cell density study (Section 4.3.1), a cell count
both after first and second wash was performed to determine the average cell loss caused by
the washing. The decrease in cell yield between the first and second wash was on average
18.8 ± 9.1 % (Figure 4.9A). The decrease in viability of the cells that have been only washed
once is likely caused by toxic effects of the remaining DMSO in the system. In the optimised
protocol, I therefore opted to wash the cells once but with increased volume of the thawing
medium to achieve higher dilution of DMSO.
The recommended optimal protocol, which was used in all subsequent experiments,
consisted of thawing until the last crystal is visible, drop-wise dilution of the cryopreserved
sample to 20⇥ of the original sample volume by thawing medium (DMEM + 50 % FCS)
warmed up to 37 °C, followed by one centrifugation and washing step (Figure 4.8A). The
protocol is similar to that routinely used in many laboratories, with the exception of medium
temperature, and does not result in significant changes in viability and apoptosis. Compared to
the least optimal protocol (thawing for 10 min, quick addition of medium at room temperature,
1 wash), the most successful protocol resulted in a statistically significant increase in viability
(13.2 %) and 10.5 % decrease in apoptosis (Figures 4.9B and C).
Thawing procedure for trehalose-cryopreserved samples
For TP samples, it was not possible to split each sample into eight tubes to test all 16 protocols
simultaneously due to low post-thaw cell count of individual cryopreserved samples. Instead,
using each sample, I was able to compare four different protocols (Figure 4.7C). In the first
set of experiments, all four protocols included thawing until the last crystal left and two
washes. The decision about medium temperature and technique of medium addition was
based on this first set of experiments.
There was no significant difference between the two techniques of thawing medium
addition but similarly to the DMSO samples in previous section, the quick addition of
the medium appeared to make the cells more susceptible to changes in thawing procedure
(Figure 4.10D). This suggests that this effect is not dependent on the type of cryoprotectant
and is likely the result of the osmotic shock that cells undergo during quick removal of
the cryoprotectant. I therefore opted for drop-wise addition of the thawing medium in
the optimised protocol. No obvious trend was apparent when comparing the two medium
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Fig. 4.10 Effect of thawing protocol changes on cryopreservation with trehalose + PP-50.
(A) Schematic of the decision points in the thawing protocol, the optimal option for each vari-
able is shown in blue circle. (B) Percentage of alive nucleated cells (7-AAD- Syto13+) of all singlet
events for selected protocol combinations which served as a basis for the decision. (C) Percentage of
apoptotic cells (7-AAD- Syto13+ annexin V+) of alive nucleated cells for selected protocol combi-
nations which served as a basis for the decision. Means of three experiments (circles) are shown by
the horizontal lines. No significant differences were found after testing with two-way ANOVA with
Tukey’s HSD test. RT = room temperature.
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Fig. 4.11 Final comparison of thawing protocols for TP-cryopreserved samples. (A) Cell yields
after first and second wash showed as a percentage of the original cell count before freezing. This
data was derived from the results in cell density study in the Section 4.3.1. (B) Percentage of alive
nucleated cells (7-AAD- Syto13+) out of all singlet events for the least optimal protocol (last crystal,
37 °C, drop-wise addition, 1 wash), currently used protocol (last crystal, room temperature, drop-wise
addition, 2 washes) and the optimal protocol (10 minutes, 37 °C, drop-wise addition, 2 washes).
(C) Percentage of apoptotic cells (7-AAD- Syto13+ annexin V+) out of alive nucleated cells for
the least optimal protocol, currently used protocol and the optimal protocol. Bars in (A) represent
mean ± SD, difference was tested by paired t-test. Means of three experiments in (B) and (C) (full
circles) are shown by the horizontal lines; differences between the protocols in (B) and (C) were tested
by repeated measures ANOVA followed by Tukey’s HSD test. No significant differences were found.
temperatures (Figure 4.10C). Therefore, 37 °C thawing medium was used in the optimised
protocol, similar to the DMSO thawing protocol.
After confirming the 37 °C thawing medium and drop-wise addition steps, two additional
samples were thawed from each donor, one until the last crystal was left and one for 10 min.
Two protocols were performed with each sample, varying in number of washes (Figure 4.7C).
The thawing time appeared to have the biggest influence the outcomes of the thawing
procedure in the case of trehalose-cryopreserved splenocytes. Unlike DMSO samples,
trehalose-cryopreserved human splenocytes showed higher viability if the thawing time in
the 37 °C water bath was prolonged to 10 min, although this was not statistically significant
(Figure 4.10B). It is possible that the short period of culture before the cryoprotectant removal
allows more time for equilibration of cells with the now unfrozen extracellular solution,
which ameliorates the subsequent osmotic shock caused by the dilution of the cryoprotectant.
Since trehalose (unlike DMSO) does not exert toxic effects on cells at this concentration, the
post-thaw culture period could be extended to maximise beneficial effect.
The choice of the optimal number of washes follows the same reasoning as for the
DMSO-cryopreserved samples. Cell losses caused by an extra wash appeared to be greater
than the small increase in cell viability. Analysis of data from the cell density experiments
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(Section 4.3.1) indicates that two washes result in an additional 11.8 ± 7.5 % and 19.8 ± 8.5 %
cell loss in for T and TP cryopreservation solutions respectively (Figure 4.11A).
In conclusion, the final optimised protocol for TP differs from the ideal thawing protocol
for DMSO-cryopreserved cells only in the thawing time (Figure 4.10A). No changes in the
apoptosis level could be observed between the least optimal, currently used and the optimal
protocol derived by this set of experiments (Figure 4.11C). However, the recovery of the
cells markedly increased in the optimised protocol. The thawing protocol resulted in up to
16.9 % improvement in the viability of the TP cryopreserved splenocytes (Figure 4.11B).
While the previously used standard protocol was close to optimal for DMSO-cryopreserved
samples (Figures 4.9B and C), it resulted in inferior cryopreservation outcomes for trehalose-
cryopreserved samples.
4.4 Incubation parameters for trehalose and PP-50
4.4.1 Incubation time at 37 °C
Trehalose does not freely permeate through the cellular membrane with the exception of
small amount of passive diffusion. Increasing the incubation time with trehalose before
freezing could therefore enable sufficient time for trehalose to diffuse into the intracellular
space and thus increase its protective effect. Another approach is to facilitate loading of
trehalose using different approaches which were summarised in the Introduction section
1.9.3. In this thesis, the approach explored was by using permeabilising polymers (PP-50 and
PP-75) which were shown to increase trehalose loading into ovine erythrocytes as a function
of incubation time [141, 182].
Human splenocytes were cryopreserved using three cryoprotectant conditions: DMSO
(0 h or 1 h incubation), T and TP conditions (0 h, 1 h, 2 h or 3 h incubation). Flow cytometry
of the fresh samples was performed (Antibody panels A1 and A2) and all samples were
cryopreserved at 107 cells/mL. After addition of the cryoprotectant, samples were either
transferred immediately to the -80 °C freezer in a freezing container (0 h) or incubated in
water bath set to 37 °C for the specified time and then frozen. After thawing, using the
optimised cryopreservation procedure (Section 4.3.3), samples were analysed using Antibody
panels B1 and B2 (Appendix B) and absolute count determined by counting beads.
The results confirm that incubation with DMSO has a detrimental effect on cells: it
decreased viability, cell yield after cryopreservation and increased apoptosis (Figures 4.12A,
B and C). Because this result confirmed the expected toxic effect, incubation with DMSO
was not pursued in the following replicates of the experiment (hence n = 1 for DMSO 1h).
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Fig. 4.12 Optimisation of length of incubation at 37 °C before splenocyte cryopreservation (A) Per-
centage of alive nucleated cells (7-AAD- Syto13+) out of all singlet events. (B) Percentage of apoptotic
cells (7-AAD- Syto13+ annexin V+) out of alive nucleated cells. (C) Post-thaw absolute cell count
determined by flow cytometry analysis with BD TrucountTM tubes. All bars represent mean ± SD
(n = 3, except for n = 1 for DMSO 1 h). Differences between different incubation times were tested
by two-way ANOVA followed by Tukey’s HSD test for T and TP sets of conditions. No significant
differences were found. T = trehalose, TP = trehalose + PP-50.
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A trend of decrease of viability and absolute cell count with increasing incubation time
was observed with trehalose alone (although much slower compared to DMSO)(Figure 4.12A
and C) and the apoptosis level did not change over the studied period (Figure 4.12B).
Increased incubation time did not result in a statistically significant improvement in
viability. In both T and TP conditions, trehalose would enter the intracellular space of
cells very slowly by passive diffusion. This should theoretically lead to improvement of
cryoprotection. The reason of the decrease of post-thaw cell yield and viability observed
in these experiments could hypothetically be due to the non-ideal culture conditions during
incubation. In other words, any beneficial cryoprotective effect of longer incubation with
trehalose would be masked by the rate of cell death during the incubation. The rates of cell
death in culture was therefore investigated in Section 4.4.2.
In conclusion, the pre-freezing incubation period at 37 °C with cryoprotectant is not
beneficial for DMSO or trehalose alone but for trehalose supplemented with PP-50 polymer,
one-hour incubation results in slight improvement in post-thaw cell yield and cell survival.
Adjusting the culture conditions during incubation could further increase the potential of
including an incubation period before cryopreservation.
4.4.2 Incubation temperature
In the previous section it was shown that pre-freeze incubation does not improve cryopreser-
vation with trehalose. Since some of the cell death may occur during the incubation period
due to non-ideal culture conditions (rather than during the cryopreservation), a series of
experiments were conducted to optimise the temperature during the pre-cryopreservation
incubation period.
Culture with 200 mM trehalose at different temperatures
In the first set of experiments, the rate of cell death in culture at 4 °C, 20 °C and 37 °C
in 200 mM trehalose was investigated over the course of 3 h (as described in the Methods
section 2.5.3). Absolute numbers of alive nucleated cells were measured at five time points
for each temperature (0, 30, 60, 120 and 180 min).
This confirmed that incubation at 37 °C with 200 mM trehalose causes detrimental effects
to the splenocytes, decreasing the absolute cell count to 79.4 ± 5.7 % of the original cell
number after three hours of incubation (Figure 4.13A and B, p = 0.024). No significant
difference was found between incubation at 4 °C and 20 °C, likely because of the high
variability of the 4 °C group but there was a trend of higher cell counts in the 4 °C group at
most time points (Figure 4.13A).
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Fig. 4.13 Optimisation of incubation temperature before splenocyte cryopreservation. (A) Absolute
count of alive nucleated cells (7-AAD- Syto13+) normalised to 0 min time point after culture with
200 mM trehalose at 3 different temperatures. (B) Absolute count of alive nucleated cells (7-AAD-
Syto13+) after 180 min of culture in 200 mM trehalose normalised to 0 min time point for 3 different
temperatures. (C) Percentage of alive nucleated cells (7-AAD- Syto13+) out of all singlet events
after cryopreservation of cells incubated for 1 h at 3 different temperatures. (D) Post-thaw absolute
counts of alive nucleated cells (7-AAD- Syto13+) after cryopreservation of cells incubated for 1 h at
3 different temperatures, normalised to DMSO control for each replicate. Full circles in (A) represent
mean ± SD (n = 3), (B) shows the results of each individual replicate with mean shown as a horizontal
line, difference was tested by one-way repeated measures ANOVA followed by Tukey’s HSD test.
Bars in (C) and (D) represent mean ± SD (n = 3), difference was tested by two-way ANOVA followed
by followed by Tukey’s HSD test, significance is marked by an asterisk: ⇤ p  0.05.
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Cryopreservation with T and TP incubated at different temperatures
Next, the splenocytes were incubated with trehalose (T) or trehalose + PP-50 (TP) for 1 h at
4 °C, 20 °C or 37 °C, or frozen without any incubation. Cells were then cryopreserved and
assessed for post-thaw absolute cell count and viability using Trucount tubes and Antibody
panels B1 and B2 (Appendix B).
After 1 h incubation, no significant differences were found in the post-thaw percentage of
alive nucleated cells for the three different temperatures (Figure 4.13C). Nevertheless, there
was a significant temperature-related decrease in the absolute cell count in T. Again, the
4 °C group exhibited high variability. Similar trend, although without statistical significance,
was observed in the TP group (Figure 4.13D). Overall, none of the conditions resulted in an
increase in viability compared to no incubation control.
There are few previous reports of splenocyte culture (mouse or human) and previous
studies have almost always included mitogens (such as phytohemagglutinin, concanavalin A,
lipopolysacharide) or other factors (2-mercaptoethanol) in the culture medium to stimulate
growth and activation of cells. Culture conditions of mononuclear cells from peripheral blood
or bone marrow were also not systematically studied. Moreover, these results are not directly
comparable with previous report as the culture medium was supplemented with trehalose
during the incubation, which may exhibit an additional beneficial or toxic effect.
Effect of culture with trehalose
A series of experiments was next conducted to examine the survival of cells in culture with or
without 200 mM trehalose at room temperature. Absolute cell counts were measured at 2 h,
24 h and 48 h using Trucount beads combined with Syto13 and 7-AAD staining of the cells.
While viability of cells in culture medium alone decreased significantly over time,
addition of trehalose caused more rapid rate of cell death. However, this effect was negligible
for a 2 h incubation time (Figure 4.14A). Change in light scatter characteristics of the cells
could be observed, especially in the granulocyte population (Figure 4.14B) even at short
incubation times.
Splenocytes cultured with culture medium only (without trehalose) show relatively high
rate of cell death over a 48 h period. Majority of cells in spleen are differentiated cells
unable to divide without specific stimuli. Moreover, there is significant stress involved during
processing of the spleen into single cell suspension, accompanied by release of intracellular
contents by necrotic cells which can trigger apoptosis or clumping of other surviving cells.
For all these reasons, splenocytes generally do not tolerate long-term culture. Nevertheless,
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Fig. 4.14 Culture of splenocytes with culture medium or 200 mM trehalose. (A) Absolute count of
alive nucleated cells (7-AAD- Syto13+) at 0 h, 2 h, 24 h and 48 h of culture in culture medium (CM) or
200 mM trehalose (T). Full circles represent mean ± SD, n = 3, differences between conditions were
tested by two-way repeated measures ANOVA followed by Tukey’s HSD test, significance is marked
by an asterisks: ⇤ p  0.05; ⇤⇤ p  0.01. (B) Flow cytometry plots (FSC vs. SSC) of splenocytes
cultured in culture medium only (0 mM) or 200 mM trehalose for 2 h, 24 h or 48 h. Alive nucleated
cells (7-AAD- Syto13+) are shown in blue and all other singlet events, including counting beads,
debris, dead cells and erythrocytes are shown in black.
short incubation times should be possible without significant cell losses or manifestation of
toxic effects of cryoprotectants.
With short incubation times at 20 °C, the cell death seems to be independent of tre-
halose (Figure 4.14A), although there appeared to be an effect specific for granulocytes
(Figure 4.14B). It was also apparent from the culture experiments in Figure 4.13 that most of
the temperature-related damage is caused during the incubation period and that this incuba-
tion does not result in increased cryoprotection for any of the temperatures tested. In two
publications using permeabilising polymers, incubation time was reported to have beneficial
effect on the cryosurvival of cells [182, 142]. However, cells used in these studies (SAOS-2
cells and erythrocytes) survive well in culture compared to mononuclear cells.
There was no difference between 4 °C and 20 °C in the TP group and extensive cell
death was also observed during culture at 37 °C. The toxic effect of DMSO is reportedly
temperature-dependent [106], which may also be the case with trehalose. Use of low
temperatures during incubation would therefore minimise toxicity but it must be highlighted
that the ultimate goal was to optimise the incubation conditions for the function of the polymer.
At low temperatures, diffusion rates of molecules are decreased (or halted) and the membrane
becomes less fluid which will hypothetically decrease transport of trehalose through the
membrane. Subsequent experiments were therefore conducted at room temperature and short
incubation times to minimise trehalose toxicity and ensure rapid movement of molecules
across the membrane.
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To conclude, incubation of splenocytes with trehalose at 37 °C increased the rate of cell
death and is therefore not recommended for pre-cryopreservation incubation. No significant
difference was found between incubation at 4 °C and 20 °C which both worked better
than 37 °C. However, none of the incubation temperatures provided an improvement which
would justify for the inclusion of incubation time. Short incubations at 4 °C or 20 °C may
be possible but there is no evidence that this incubation is beneficial for cryosurvival of
splenocytes.
4.4.3 Incubation pH
PP-50 and PP-75 polymers are pH-sensitive and have been shown to only provide efficient
intracellular loading of trehalose at pH 7.05 or lower [125]. This could underlie the lack of
efficacy of the polymer to improve cryosurvival was not observed when polymer was used in
previous experiments. If splenocytes can survive a short period of incubation at pH 7.05, and
if this results in increased uptake of trehalose, this may lead to improved cryopreservation.
To determine the effect of pH on the survival of splenocytes during the incubation period,
freshly isolated human splenocytes were resuspended in culture medium with or without
100 µg/mL PP-50 with pH 7.05 or 7.4 and incubated at room temperature for 48 h. At 2 h,
24 h and 48 h, the absolute count and viability were determined using Trucount beads and
Syto13 + 7-AAD staining.
The result shows a decrease in the amount of alive cells when the pH of the medium is
7.05 compared to 7.4 but this is only observable at longer incubation times (24 h or 48 h).
Decrease can also be observed in the conditions where PP-50 has been added compared to
the medium without PP-50. Overall, the best survival was shown for splenocytes incubated
without PP-50 at pH 7.4. Short incubations (2 h) at either pH do not seem to affect the
survival in culture (Figure 4.15A).
Next, human splenocytes were resuspended in 200 mM trehalose with (TP) or without
(T) 100 µg/mL PP-50 with pH 7.05 or 7.4 and either frozen immediately using a freezing
container or incubated for 1 h at room temperature and subsequently frozen. After thawing,
absolute cell count and viability were determined using Trucount beads and B1 + B2 Antibody
panels (Appendix B).
No differences were detected between the cells cryopreserved in the media of different
pH. Both the percentage of alive nucleated cells and their absolute number were similar for
pH 7.05 and 7.4, both with and without pre-freeze incubation with the polymer (Figures 4.15B,
C and D and E).
Lowering the pH to 7.05 has been shown to have a beneficial effect on trehalose loading
in erythrocytes [125]. Erythrocytes have been shown to have stable properties over the pH
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Fig. 4.15 Optimisation of incubation pH before splenocyte cryopreservation. (A) Absolute number of
alive nucleated cells (7-AAD- Syto13+) for splenocytes incubated for 2 h, 24 h or 48 h at pH 7.05 or
7.4; with or without PP-50 (n = 1). No statistical analysis could be performed due to a low number
of replicates. (B) Post-thaw percentage of alive nucleated cells (7-AAD- Syto13+) out of all singlet
events for splenocytes without incubation. (C) Post-thaw percentage of alive nucleated cells (7-AAD-
Syto13+) out of all singlet events for splenocytes with 1 h incubation. (D) Post-thaw absolute number
of alive nucleated cells (7-AAD- Syto13+) for splenocytes without incubation. (E) Post-thaw absolute
number of alive nucleated cells (7-AAD- Syto13+) for splenocytes with 1 h incubation. In (B)-(E),
splenocytes were cryopreserved in 200 mM trehalose with (TP) or without (T) PP-50; pH adjusted to
7.05 or 7.4 and vials either frozen immediately or after 1 h of incubation; n = 3, in (B) – (D), statistical
analysis performed using repeated measures two-way ANOVA followed by Sidak’s correction, no
significant differences were found.
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range of 6.3 - 7.9 [183] and are therefore suitable for incubation at pH 7.05. Splenocytes
which already have a high cell death rate in culture, appear to be more sensitive to this change
of pH based on these experiments.
In summary, the data indicate that incubation of splenocytes at low pH leads to increased
cell death pre-cryopreservation (time-dependent) with no beneficial effect on post-thaw
survival when cryopreserved with trehalose and PP-50 polymer.
4.5 Concentration of components
4.5.1 Concentration of trehalose
The optimisation steps described earlier (cell density, addition of FCS, incubation time,
temperature and pH or thawing technique) did not result in a significant improvement in the
efficacy of the trehalose cryopreservation protocol. Another obvious variable which signifi-
cantly contributes to the success of cryopreservation is concentration of the cryoprotectants.
Trehalose was used at a concentration of 200 mM in the previous experiments, based on
previously published studies. The optimal concentration of trehalose has, however, not been
determined for mononuclear cells, including splenocytes. This was explored in the next
series of experiments.
Cryopreservation with a range of trehalose concentrations
Splenocytes were incubated with 0 – 800 mM trehalose for 1 or 24 h at room temperature,
before being frozen using a freezing container. Before cryopreservation and upon thawing,
absolute number and percentage of alive nucleated cells were determined using Trucount
beads and staining with Syto13 and 7-AAD.
The pre-cryopreservation absolute counts suggest that after a 1 h incubation, the number
of viable cells in the sample is the same in all concentrations tested. However, longer
incubations led to a decrease in the number of viable cells in samples in a concentration-
dependent manner (Figure 4.16A).
After thawing, trehalose concentrations lower than 200 mM did not seem to provide effi-
cient cryoprotection. After a 1 h incubation, the percentage of alive nucleated cell increased
with concentration in all three replicates, with the highest proportion found consistently in
samples incubated in 800 mM trehalose for 1 h. For 24 h incubation, 200 mM trehalose was
the most effective but this longer incubation did not provide any added benefit compared
to the 1 h incubation time (Figure 4.16B). The absolute counts after thawing were highly
variable in the three donors but the general trend was that the most successful concentrations
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Fig. 4.16 Optimisation of trehalose concentration and incubation time. (A) Pre-freeze absolute
number of alive nucleated cells (7-AAD- Syto13+) incubated in 0 – 800 mM trehalose for 1 or
24 h. Full circles connected by a line represent data from a single replicate/donor. (B) Post-thaw
percentage of alive nucleated cells (7-AAD- Syto13+) out of all singlet events for samples incubated
in 0 – 800 mM trehalose for 1 or 24 h. Full circles connected by a line represent data from a single
replicate/donor. (C) Post-thaw absolute number of alive nucleated cells (7-AAD- Syto13+) incubated
in 0 – 800 mM trehalose for 1 or 24 h. Individual replicates coming from different human donors
shown in separate graphs. (D) Absolute numbers of alive nucleated cells (7-AAD- Syto13+) in toxicity
assay performed on fresh splenocytes incubated with 0 – 800 mM trehalose. (E) Post-thaw percentage
of alive nucleated cells (7-AAD- Syto13+) out of all singlet events for samples incubated in 200 mM
or 400 mM trehalose for 0, 1, 2 or 3 h. (F) Post-thaw percentage of apoptotic cells (7-AAD- Syto13+
annexin V+) out of alive nucleated cells for samples incubated in 200 mM or 400 mM trehalose for 0,
1, 2 or 3 h. Bars in (E)-(F) represent mean ± SD. In (A) and (B), n = 3, two-way repeated measures
ANOVA followed by Tukey’s HSD test was performed. In (D), two-way repeated measures ANOVA
followed by Dunnet’s correction was used to compare the conditions to the control (0 mM trehalose),
significance is marked by an asterisks: ⇤ p  0.05; ⇤⇤ p  0.01. For (E) and (F), n = 2, no statistical
analysis was performed.
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were between 300 – 400 mM for 1 h incubation and 100 – 300 mM for 24 h incubation
(Figure 4.16C).
When examining the high percentage of alive nucleated cells in Figure 4.16B, it must
be taken into consideration that this is a percentage of all singlet events. Theoretically, cells
may undergo a very different fate in the case of 800 mM to that of cells in 100 mM trehalose.
For example, cells which were already dead may have been so fragile after this considerable
osmotic stress that they may have disintegrated and been washed away during the preparation
for flow cytometry. This would in turn decrease the total number of events, giving a false
perception of high viability.
It follows, therefore, that comparing the post-thaw absolute numbers is a more appropriate
measure of efficacy of cryopreservation. Due to high variability between donors/preparations,
it was not possible to pool the samples together and perform statistical analysis but it is
still clear that in all three donors, 800 mM trehalose was not the optimal concentration
(Figure 4.16C).
Successful cryopreservation protocols aim to strike a balance between the efficacy of a
cryoprotectant with the cryoprotectant toxicity. Both typically increase with the concentration
of the cryoprotectant. This set of experiments confirmed that the efficacy of trehalose
for cryopreservation increases with concentration at the 1h incubation time, while this
effect is reversed when longer incubation is used at higher concentrations. To confirm the
concentration limit beyond which trehalose can be considered toxic, a set of experiments
was designed to examine the effect of trehalose during culture over 48 h.
Trehalose toxicity
Freshly isolated splenocytes from three human donors were seeded into a 96-well plate
with 0 – 800 mM trehalose and toxicity assay was performed as described in Methods
Section 2.5.2. Measurements were taken at the beginning of the assay and at 2 h, 24 h and
48 h.
No toxic effect was detected at 2 h time point for concentration of 200 mM or lower
but some level of toxicity was observed at 24 h and 48 h for all trehalose concentrations
compared to the control. 400 mM and 800 mM concentrations exhibited the toxic effect at
the 2 h time point, although this was highly variable in the three donors (Figure 4.16D).
While the reason for this toxicity of trehalose for splenocytes is unknown, it is possible
that this toxicity is not due to specific trehalose properties but rather a non-specific effect of
high concentration resulting in osmotic stress followed by cell shrinkage. However, the data
suggests that it may be possible to use even these concentrations for short incubation times.
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Incubation time with 400 mM trehalose
The incubation time experiments from Section 4.4.1 were therefore repeated, using only
200 mM and 400 mM trehalose concentrations and testing incubation times 0 to 3 h at room
temperature.
There was no significant difference between 200 mM and 400 mM trehalose, both in
terms of absolute number of alive nucleated cells and level of apoptosis in the post-thaw
samples (Figures 4.16E and F). All absolute numbers were, however, still considerably lower
than for cells cryopreserved with DMSO. Consistently with previous experiments, an increase
in incubation time did not improve the outcome of cryopreservation (Figure 4.16F). The best
overall result was achieved by 400 mM trehalose without any incubation but this result was
not significantly different from the other conditions.
While evidence from the literature typically suggests the use of 200 mM concentration
with regards to toxicity [54, 128], evidence from the above experiments suggests that it is
possible to successfully use higher concentration if the incubation time is limited. This may
be due to different susceptibility of other cell types (hepatocytes and TF-1 hematopoietic cell
line in the mentioned publications).
In conclusion, cryopreservation with 400 mM trehalose without incubation was identified
as the most successful condition. If longer incubation are needed, the concentration must
be reduced in order to avoid the concentration-dependent toxicity of trehalose. However,
by changing trehalose concentrations, efficacy of cryopreservation cannot be significantly
increased.
4.5.2 Concentration of polymers
Earlier experiments did not demonstrate any benefit of PP-50 permeabilising polymer over
trehalose alone in improving post-thaw viability. The PP-50 concentration used for all
experiments was 100 µg/mL based on previous reports [141]. I next explored whether
different concentration of the polymer may be more effective in this human splenocyte
model. Toxicity and efficacy of PP-50 for splenocytes was thus determined using range of
concentrations of the polymer, together with a polymer variant, PP-75. This variant contains
higher ratio of phenylalanine grafted onto the polymer backbone (PLP).
Toxicity of PP-50 for splenocytes
Freshly isolated splenocytes from three human donors were seeded into a 96-well plate with
0 – 1600 µg/mL of PP-50 or PP-75 and toxicity assay was performed as described in Methods
4.5 Concentration of components 117
Fig. 4.17 Optimisation of PP-50 and PP-75 polymer concentration. (A) Absolute numbers of alive
nucleated cells (7-AAD- Syto13+) in toxicity assay performed on fresh splenocytes incubated with
0 – 1600 µg/mL PP-50. Bars represent mean ± SD, differences were compared to Control by repeated
measures two-way ANOVA followed by Dunnett’s correction. (B) Post-thaw absolute number of
alive nucleated cells (7-AAD- Syto13+) incubated in 400 mM trehalose with 0 – 1000 µg/mL PP-50
or PP-75 for 1 h at room temperature. Bars represent mean ± SD, full circles represent the individual
replicates, data was normalised to Control (no polymer), differences were tested by repeated measures
one-way ANOVA followed by Tukey’s post-hoc test, significant differences are marked by asterisks:
⇤ p  0.05; ⇤⇤ p  0.01.
Section 2.5.2. Measurements were taken at the beginning of the assay and at 2 h, 24 h and
48 h.
There was a concentration-dependent decrease in absolute number of surviving cells for
all incubation times. For short-term 2 h incubation, PP-50 concentrations up to 400 µg/mL
caused only a small decrease in viability. At longer incubation times (24 h and 48 h),
only concentrations of 200 µg/mL and lower did not lead to a significant drop in viability.
Concentrations over 400 µg/mL of PP-50 showed high toxicity at all incubation times tested
(Figure 4.17A). Results of the toxicity test with PP-75 were similar and are not shown.
In previous publications, PP-50 has been shown to be toxic for SAOS-2 cells in concentra-
tions over 200 µg/mL after 2 and 24 h [142]. This is in agreement with the above experiments
performed on splenocytes. This implies that use of concentrations over 200 µg/mL will
result in decreased viability of the cells even before cryopreservation, if incubation period
is included in the protocol. Previous publications on different cell types disagree on the
ideal polymer concentration to be used for efficient uptake of trehalose and cryopreservation.
Therefore, cryopreservation efficacy after addition of wide range of polymer concentrations
to human splenocytes was next examined.
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Concentration of PP-50 and PP-75 for cryopreservation
Initial concentration of PP-50 was chosen based on previous publication as 100 µg/mL [182].
Short incubation was used in order to limit the cell death occurring during the culture
of splenocytes. Human splenocytes from three donors were incubated for 1 h at room
temperature with 0, 10, 100 or 1000 µg/mL of PP-50 and cryopreserved using the freezing
container. After thawing, absolute numbers of alive nucleated cells were determined using
Trucount beads combined with Syto13 and 7-AAD staining.
For both PP-50 and PP-75, the absolute numbers of cells after thawing decreased with
increasing concentration of the polymers. Post-thaw absolute numbers of splenocytes in-
cubated at the highest concentration (1000 µg/mL) of PP-50 and PP-75 were very small
(26.76 ± 12.79, (p = 0.0396) and 19.25 ± 16.79 % (ns) of the control, respectively). The
lowest concentration (10 µg/mL) of the polymers was comparable to the control without any
polymer, although there was some variation in the individual replicates (Figure 4.17B).
The concentrations were chosen to cover a wide range and included toxic concentration
of 1000 µg/mL. Sharp et al. [142] have previously shown that PP-50 increased recovery
of SAOS-2 cells after cryopreservation only for concentration of 25 µg/mL but not higher.
Similar but very small effect was observed in some of the splenocyte donors. Overall, this
effect was not consistent and not strong enough to justify for the use of the polymers in
cryopreservation of splenocytes.
To conclude, PP-50 concentrations of (200 µg/mL) and lower did not decrease viability of
splenocytes during the toxicity assay. However, improvement of trehalose cryopreservation
has not been observed for non-toxic concentrations of 10 and 100 µg/mL, regardless of the
variant of the polymer (PP-50 or PP-75).
4.6 Function and safety of permeabilising polymers
4.6.1 Trehalose uptake measurements by Raman spectroscopy
To study the function of permeabilising polymers, their efficacy in delivering trehalose to the
intracellular space must be tested. Methods for measurement of intracellular concentration
of trehalose exist but they require lysis and often cannot distinguish between different
saccharides. This project needed a method which would enable measurement of intracellular
trehalose concentration not only for single cells but also multicellular aggregates, such
as pancreatic islets. Raman spectroscopy was identified as a potential method and pilot
experiments were performed on cancer cell lines since splenocytes would present additional
challenges related to their availability and need for immobilisation on a substrate.
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Fig. 4.18 Raman spectroscopy for trehalose uptake measurement and total protein assay. (A) Valida-
tion of Raman spectroscopy for measurement of trehalose: Raman spectra of 50 – 800 mM trehalose
solutions in H2O; arrow shows the trehalose-specific peak of the Raman spectrum. (B) The linear re-
lationship between trehalose concentration and the Raman intensity at the 844 cm-1 peak. (C) Raman
intensities at the trehalose-specific peak 844 cm-1 for SAOS-2 cells incubated with culture medium
(control), 200 mM trehalose or 200 mM trehalose + 100 µg/mL PP-50 for 6 h. Boxplots show median
and 1st and 3rd quartiles, 200 points across 10 cells for each condition were measured. (D) Raman
spectra of SAOS-2 cells incubated with culture medium (control), 200 mM trehalose or 200 mM
trehalose + 100 µg/mL PP-50 for 6 h. Trehalose-specific peaks highlighted by vertical dotted lines.
(E) Total intracellular protein concentration in splenocytes incubated with 0, 10, 100 or 1000 µg/mL
PP-50 for 4 h at room temperature. Bars represent mean ± SD, all values normalised to control, n = 2,
no statistical tests were performed.
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All Raman spectroscopy experiments were performed and analysed by Jakub Surmacki
from the Cavendish Laboratory, University of Cambridge. First, the Raman measurements
of trehalose were validated using 50 – 800 mM trehalose solutions and specific peaks were
identified (Figure 4.18A). Identification of 844 cm-1 peak in cells was then validated using
MDA-MB-231 cell line (data not shown).
SAOS-2 cells were prepared and measurements performed as described in detail in
Methods Section 2.7.4. This experiment consisted of three groups of cells, incubated either
in culture medium, 200 mM trehalose or 200 mM trehalose + 100 µg/mL PP-50 for 6 h in
duplicates.
Raman intensities from the intracellular space of cells incubated with 200 mM trehalose
show that there is only a small number of measurements where the trehalose concentration
was detected above the level of the control cells. While some very high Raman intensities
were measured in the 200 mM trehalose + PP-50 group, it is clear from the collected data
that the background signal in this group has decreased when compared to the control and the
200 mM trehalose group (Figure 4.18B).
It was also apparent from the average spectra of the three conditions where the peaks in
200 mM trehalose + PP-50 appear blunted and lower than in the the other two conditions,
that this is a trend across the whole spectrum, not only at the 844 cm-1 peak (Figure 4.18C).
Raman spectroscopy is a powerful technique which is being developed for the purposes
of many fields to measure concentrations of substances, increasingly also in living cells.
Nevertheless, applying this technology for measurement of intracellular trehalose is very
novel, being used only once in a study of spin-dried cells [184]. The challenge of this
technique is to exclude the signal from the extracellular space since the ability of the
instrument to exclude signal from the non-imaged layers (above and below the intracellular
space) is limited. Extensive washing procedure was therefore employed in these experiments
to reduce any strong trehalose signal from the extracellular space. Despite this challenge,
these experiments demonstrate that it is possible to use this technique for a measurement
of intracellular trehalose and it could be a useful non-destructive method for intracellular
trehalose measurements in cryobiology and other fields.
Comparison of the 200 mM trehalose and 200 mM trehalose + PP-50 group was not
possible due to the decrease in background signal in the latter group. Because this decrease
was observed across the whole Raman spectrum, it could suggest a drop in concentration
of different cellular components (proteins, lipids, small molecules), caused perhaps by a
significant damage to the cellular membrane. While penetrating biopolymers such as PP-50
were developed to make plasma membrane more liquid for delivery of substances into the
cells, it is not clear whether this also allows intracellular molecules to leak out of the cells.
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This leakage has not been previously examined in literature, but nonetheless could have
implication for safety of these molecules in clinical use. On the other hand, this observation
could be an artefact of the cell preparation if, for example, PP-50 made the cells more
susceptible to membrane damage during the fixation process.
4.6.2 Safety of permeabilising biopolymers
To further explore the possibility of molecules leaking out of cells, total intracellular protein
was measured after incubation of splenocytes with range of concentrations (10, 100 and
1000 µg/mL) of PP-50 and PP-75. Cells were incubated with the polymer at room temperature
for 4 h before washing and performing BCA total protein assay.
A trend in concentration-dependent decrease in total intracellular protein was observed
for both PP-50 and PP-75. However, for 10 and 100 µg/mL concentrations, this decrease was
insignificant compared to the control incubated without any polymers (Figure 4.18D).
While these results are preliminary, they would suggest that some level of molecule
leaking from cells may be present during the use of permeabilising polymers PP-50 and PP-
75. This effect is likely to be more pronounced at higher concentrations of the polymer and
presumably also at longer incubation times. Moreover, the leaking will likely be dependent
on the size of molecules. It was shown for a similar polymer (PLP-NDA) in erythrocytes to
selectively allow entry of dextran molecules up to 70 kDa but not larger [185].
There are several potential safety risks associated with leaking of molecules outside of
cells. First of all, these cells could potentially lose components critical to their function.
Secondly, if these cells were used in vivo, there would be a risk of releasing factors (short
nucleic acid strands, metabolites and small molecules) which can act as damage-associated
molecular patterns and could result in inflammation or apoptosis of surrounding cells. Safety
of these permeabilising polymers should therefore be thoroughly tested before they are used
as part of therapies.
4.7 Discussion
4.7.1 Trehalose as an alternative to DMSO
The cryopreservation efficacy of DMSO is currently sufficient to provide viable CD34+ cell
numbers needed for clinical transplantation. As it was demonstrated in Section 4.3, the
current DMSO protocol could only be improved marginally by optimisation of thawing
protocol, cell density or addition of FCS. Nevertheless, the need to improve this protocol
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remains because of the demonstrated cellular and systemic toxicity of DMSO. One of the
approaches to do this is the use of an alternative non-toxic cryoprotectant.
The experiments in this Chapter explored this approach by completely substituting DMSO
for disaccharide trehalose. Trehalose has been previously tested on mononuclear cells or
their subsets in combination with DMSO [131, 132, 186] or on its own [130]. While the
observations from these publications confirm that trehalose on its own does not match to
DMSO in its cryopreservation efficacy, none of the publications attempted a comprehensive
and systematic optimisation of trehalose cryopreservation like the one performed in this
project.
Numerous parameters were optimised in the current experiments, including thawing
protocol, incubation time, temperature, pH and concentration. The parameter which had the
biggest influence on the success of trehalose cryopreservation are trehalose concentration
(average increase by 101.2 % from 200 mM to 400 mM). Nevertheless, the post-thaw absolute
numbers of cells cryopreserved in trehalose (400 mM trehalose, 0 h incubation, optimised
thawing, 107 cells/mL, 10 % FCS) were on average still only 18.5 % of the number of cells
which survived freezing by DMSO. While the possibility of trehalose efficacy as a sole
cryoprotectant can still not be ruled out, the results from this project do not support its use
for cryopreservation of mononuclear cells, partially because of the difficulty with incubation
of these cells.
Other approaches of minimising DMSO toxicity will therefore need to be explored.
These could include combining DMSO with another cryoprotectant while decreasing DMSO
concentration or development of efficient thawing and washing protocols which will minimise
the cell losses and toxicity of DMSO.
4.7.2 PP-50 as a method of intracellular trehalose delivery
One of the approaches which could still improve trehalose performance in cryopreservation
of cells is intracellular trehalose delivery. While a variety of approaches for this exists, the
one explored in this project was the use of membrane permeabilising biopolymers PP-50 and
PP-75.
These polymers have previously been shown to improve cryopreservation of red blood
cells [141]. However, the data collected here does not confirm this efficacy in mononuclear
cells. There are some suggestions that in nucleated cells, which are capable of endocytosis,
the localisation of these polymers is not on the membrane [146]. The attached polymers
appear to be endocytosed and based in small vesicles close to the cell nucleus which could
potentially prohibit the intended function of being the gateway of trehalose on the cell surface.
If the same rate of endocytosis was maintained whether or not the polymer is present, it is not
4.7 Discussion 123
clear how the polymer would encourage the increased uptake of trehalose. It is, however, also
possible that the polymer encourages endocytosis and extracellular trehalose is transported
to the cell interior in the central part of these vesicles. The details of this have not been
previously investigated.
Another class of PLP backbone-based polymers has been developed and its journey
along the endocytosis pathway further investigated. Along the endosome journey towards a
more acidified lysosome, polymers change their conformation and help to release the intra-
vesicular contents into the cytoplasm [185]. This would presumably release the trehalose to
the cytoplasm. Nevertheless, Mercado et al. [146] have observed localisation of trehalose
only in these intracellular vesicles.
While most nucleated cells possess the ability to endocytose, some may do this more often
than others and if endocytosis is indeed involved in the function of these polymers, it may be
difficult to work with mixed cell populations such as mononuclear cells where the extent to
which each cell type can endocytose differ. Moreover, endocytosis is temperature-dependent
and is almost halted at temperatures below 10 °C [187]. Lynch et al. [141] have shown
that the maximum effect of polymers was achieved at incubation temperature of 37 °C and
long incubation times of nine hours. However, experiments with splenocytes described in
Section 4.4 have shown that incubation at 37 °C and for prolonged periods of time results in
reduced viability.
4.7.3 Safety of the new protocol
While the function of permeabilising polymers should be further studied and optimised for
different nucleated cell types, assessing safety of these compounds is of utmost importance if
they are to be used as part of clinical therapies.
First, correct concentrations of the components must be established. While the toxic
concentrations of trehalose and the polymers were tested in this project by measuring viability
of cells, there may be more subtle effects which could only be detected by more sensitive
assays (RNA sequencing or functional assays such as CFUs for HSCs, immune cell activation
assays) or in long term studies. Long term survival and function of any cryopreserved cell
must be always evaluated before translation into a therapy.
Second, the possibility of washing off the polymer must be explored. Although it was
suggested in the early publications about the polymers that these can be easily removed from
the cells by changing the pH [141], it is not clear how this relates to the polymer molecules
which have been endocytosed. It must also be taken into account that some cell types may
not well tolerate pH changes.
124 Splenocyte cryopreservation with trehalose and permeabilising polymers
Finally, other potential risks must be ruled out. One of these is leakage of molecules
from the cells to the extracellular space. Chen et al. [185] have shown that after incubation
of erythrocytes with PLP-NDA, they were able to create so called ’erythrocyte ghosts’.
These are erythrocyte-like structures consisting of erythrocyte membrane which released
intracellular contents and are now filled with extracellular medium. PLP-NDA shares the
same PLP backbone with PP-50 and PP-75 but is grafted with hydrophobic decylamine
instead of simple hydrophobic amino acids. While their efficacy in membrane destabilisation
can differ, the functional principal remains the same and both could therefore pose the same
safety risks. Leakage of molecules important for the cell survival and function and release of
inflammatory molecules should be thoroughly examined before the work with these polymers
proceeds.
4.8 Conclusion
Current protocols for cryopreservation of mononuclear cells utilise DMSO as a cryoprotec-
tant. DMSO, however, is toxic to cells and patients and therefore trehalose was selected
as a possible alternative cryoprotectant. By systematic screening of protocol variations,
including incubation parameters, composition of cryopreservation medium and concentration
of components, this project has shown that trehalose as a sole cryoprotectant does not provide
protection for cryopreservation of human mononuclear cells from spleen comparable to the
current protocol using DMSO.
Addition of permeabilising polymers PP-50 and PP-75 was tested to allow for intracel-
lular trehalose delivery, which should improve cryoprotection with trehalose. Experiments
featuring a variety of concentrations, incubation times and conditions showed that these
polymers do not provide this protective effect in splenocytes. Moreover, a concentration- and
time-dependent toxic effect of the polymers were identified, as well as a potential side-effect
of the permeabilising polymers resulting in intracellular molecule leakage. The use of poly-
mers in cryopreservation of primary mononuclear cells can therefore not be justified based
on these experiments.
Chapter 5
Developing a novel islet cryopreservation
protocol
5.1 Introduction and aims
Efforts to cryopreserve pancreatic islets started in the 1980s and peaked in 1990s, led by the
groups of Dr. Raymond V. Rajotte, Dr. Jonathan R. T. Lakey and others. These resulted in
development of a protocol utilising DMSO which is now considered the gold standard in the
field [73]. This protocol was however never properly introduced into clinical practice due
to suboptimal post-thaw survival of islets and the use of FCS [26]. In 1997, Beattie et al.
reported that addition of trehalose to the DMSO cryopreservation protocol resulted in suc-
cessful cryopreservation [83]. Since 1990s, the research in islet cryopreservation has not
experienced any notable progress and these promising results using trehalose addition were
not validated in further studies. The full potential of cryopreservation of islets with trehalose
has, therefore, not been explored.
The objective of this chapter was to validate the current standard (DMSO) method of
pancreatic islet cryopreservation [73] by systematic screening of variables and to explore the
potential of cryopreservation with trehalose alone or its addition to the standard DMSO-based
protocol. Where possible, the results were replicated using human islets but this could not be
achieved for all the experiments due to limited availability of human pancreatic islets.
The first aim was to determine the safety of cryoprotectants used in this chapter: DMSO
and trehalose. Results of these experiments are presented in Section 5.2 and used to inform
optimal incubation times with the cryoprotectants in subsequent sections of this Chapter.
The second aim was to optimise the parameters for a DMSO-only protocol. This was
undertaken because these optimisations were either not clearly defined in literature or their
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modification could potentially simplify and/or improve the final protocol. These included the
methods of DMSO addition, DMSO removal and comparison of controlled vs. uncontrolled
freezing of pancreatic islets. Results of these experiments are presented in Section 5.3 and
the findings were used to inform all following experiments of this and following chapters.
The potential of trehalose to fully substitute for DMSO was then investigated in Sec-
tion 5.4. Next, trehalose was explored as an additive to the optimised DMSO protocol in
Section 5.5. Among the variables, incubation time and concentrations of the cryopreservation
solution components were explored to ensure high survival of cells and minimal cellular
stress and toxicity. In Section 5.6, the capacity of antioxidants salidroside and MitoQ to
further improve the post-thaw survival of pancreatic islets was examined.
Finally, in vitro and in vivo viability and function of the islets cryopreserved using the
newly developed successful protocols was tested by a range of assays to demonstrate the
potential of this method for clinical use in Section 5.7.
5.2 Toxicity of cryoprotectants for pancreatic islets
Cryopreservation of cell clusters requires prolonged incubation with cryoprotectants before
freezing to allow their diffusion throughout the cluster. The cryoprotectants are also nec-
essarily present after thawing, before they diffuse out from the cells and are substituted by
non-toxic media. It is well-known that DMSO is toxic to other cell types at the concentrations
used for cryopreservation and cryopreservation protocols aim to minimise the cells’ exposure
time to DMSO. However, the toxicity of 2 M DMSO (used in published pancreatic islet cry-
opreservation protocols) has not been comprehensively studied. Quantifying the toxicity of
DMSO to pancreatic islets is essential for the design of cryopreservation protocols. Moreover,
safety of trehalose must also be demonstrated to confirm that any damage to cryopreserved
islets is not caused by trehalose during the pre-incubation. The survival of mouse and human
pancreatic islets in a presence of a range of concentrations of trehalose (0 – 800 mM) and
2 M DMSO was therefore tested, using the protocols described in Section 2.6.5.
5.2.1 Toxicity of DMSO
No decrease in viability was observed in the control islets incubated with standard culture
medium for both mouse and human islets. While 2 h incubation with DMSO in human
islets caused a non-significant decrease in viability from 95.4 ± 5.0 % to 88.7 ± 5.5 %
(Figure 5.1B), the same incubation caused statistically significant drop in viability of mouse
pancreatic islets to 78.5 ± 12.9 % (Figure 5.1A). Similarly, at 24 h, the viability of mouse
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Fig. 5.1 Toxicity of DMSO and trehalose for human and mouse pancreatic islets after 2, 24 and 48 h
incubation. (A) Viability of mouse pancreatic islets after incubation with 2 M DMSO and 200 mM
trehalose (mean ± SD of one experiment shown, viability of each experimental condition calculated as
an average viability of 5 – 12 islets). (B) Viability of human pancreatic islets after incubation with 2 M
DMSO and 200 mM trehalose (mean ± SD of two experiments shown, viability of each experimental
condition calculated as an average of 3 – 13 islets). (C) Viability of mouse pancreatic islets after
incubation with different concentrations of trehalose (0 – 800 mM; mean ± SD of one experiment
shown, viability of each experimental condition calculated as an average of 1 – 12 islets). Differences
between each group and control group (Control or 0 mM trehalose) were tested by two-way ANOVA
followed by Dunnett’s test. Significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01;
⇤⇤⇤ p  0.001; ⇤⇤⇤⇤ p  0.0001. Treh = trehalose.
islets was already below 2 % but in human islets, the survival was 83.3 % and 10.19 % in the
first and second repeat of the experiment, respectively. After 48 h, 24.8 % and 5.2 % viable
cells could still be find in the human islets incubated with 2 M DMSO in the two repeats of
the experiment (Figure 5.1B).
As expected, DMSO exhibited acute toxic effects at 2 M concentration: a decrease in
viability could be observed after 2 h in both mouse and human islets. In human islets, there
was significant variability between the two experiments performed, suggesting that different
batches of islets could react differently to this treatment (possibly due to different level of
damage caused to the islets during their isolation or transport or donor-specific features).
Further repeats of these experiments are required to determine the extent of toxicity of DMSO
for human islets. Pancreatic islet cryopreservation protocols require 45 min incubation with
DMSO (although the protocol starts at lower concentration and is increased over time) and
while this will likely result in some damage to the islets, sufficient islet mass will still be
viable before cryopreservation. Human and mouse islets, although similar in size, differ in
their cell composition, architecture or gene expression [188, 189]. As an example, human
islets are known to contain higher proportion of a-cells [188]. Since sensitivity to toxic
effect of DMSO of different cell types differs, it would not be surprising if this is the case for
the different cell types within pancreatic islets. This could be determined by studying the
survival of the a- and b -cell subsets but was not within the scope of this study.
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5.2.2 Toxicity of trehalose
For mouse islets, there was no change in viability after incubation with 200 mM trehalose
but toxic effects were noted at concentration of 400 mM. The islets maintained high viability
after short incubation at 400 mM but dropped to 3.4 ± 5.8 % viability after 24 h (Figure 5.1C).
In 800 mM trehalose, a significant decrease in viability (to 26.2 ± 15.6 %) could already be
observed after 2 h of incubation and no viable islets were detected at 24 h and 48 h. Due
to the scarcity of human islets, a single concentration of trehalose was tested (200 mM).
There was a slow, non-significant decrease in viability during incubation with trehalose, from
95.4 ± 5.0 % at 0 h, to 88.0 ± 2.1 % at 48 h (Figure 5.1B).
The experiments suggest that toxic effects of trehalose manifest at concentrations over
200 mM and at longer incubation times (24 h). Concentrations up to 200 mM showed no toxic
effect over the course of 48 h. Toxicity of trehalose likely results from the impermeability
of cell membrane to trehalose. High concentrations in the extracellular space cause strong
concentration gradient, efflux of water from cells and result in shrinkage of cells in this
hypertonic solution. The only available study on islet cryopreservation with trehalose
(combined with DMSO) used 300 mM trehalose and 2 M DMSO, incubated for 45 min
before freezing. Although the toxicity of trehalose was not specifically tested in this study,
successful cryopreservation was achieved using this solution, suggesting that there was little
or no toxicity to the islets before cryopreservation [83].
In summary, the experiments confirmed that DMSO is acutely toxic to mouse and
human pancreatic islets, but short incubations (< 2 h) may be possible to enable uptake of
cryoprotectant by the islets. Pancreatic islets can be safely incubated with up to 200 mM
trehalose for 48 h and possibly with higher concentrations (300 or 400 mM) if the incubation
time is shortened accordingly.
5.3 Optimisation of DMSO protocol parameters
5.3.1 Addition of DMSO
In cryopreservation of single cells, prolonged incubation with penetrating cryoprotectants is
not needed before freezing. However, the size and architecture of pancreatic islets requires
prolonged incubation to allow diffusion of solutes into the centre of the cell cluster. It is
reasonable to assume that without penetration of the cryoprotectant into the islet core, the
central cells would remain unprotected by the cryoprotectant. On the other hand, prolonged
incubation may result in increased cellular toxicity (as described in Section 1.6.2). A protocol
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Fig. 5.2 Design of the DMSO addition protocol study. Time 0 represents the starting point of
the DMSO addition to islets suspended in culture medium (100 µL for Protocol A but all medium
removed for Protocols B and C). Each colourful circle represents an addition of DMSO (in 2 M or 3 M
concentration) and numbers above the circles represent minute from time 0 at which the addition was
performed. The three protocol require different time and the shorter protocols were therefore started at
later time points to aim for the same freezing time. (A) Schematic of Protocol A: Three-step addition
of DMSO over 30 min with 15 min equilibration before freezing. (B) Schematic of Protocol B: Single-
step addition of DMSO with 15 min equilibration before freezing. (C) Schematic of Protocol C:
Single-step addition of DMSO without equilibration. (D) Model of changes of concentrations of
DMSO over time using the three different DMSO addition protocols. For the first 30 min, samples are
kept at room temperature and they are moved onto ice for the final 15 min equilibration.
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including step-wise addition followed by equilibration protocol has been suggested by
Rajotte [190] and is used widely in the field.
Three different DMSO addition protocols were compared, which differed in the number
of DMSO addition steps and the length of equilibration (Figure 5.2). The final concentration
of DMSO in all three protocols was 2 M and the samples followed the same freezing and
thawing procedure. Protocol A included step-wise addition of DMSO over 30 min, followed
by 15 min of equilibration on ice (the Rajotte’s protocol [190]). In Protocol B, DMSO
was added in single step and sample is equilibrated on ice for 15 min prior to freezing. In
Protocol C, DMSO was again added in a single step but no equilibration period followed
before freezing. It was hypothesised that that whole islets require a period of equilibration as
a consequence of their 3D architecture rather than the individual islet cell properties. The
three DMSO addition protocols were therefore tested using both whole pancreatic islets and
dissociated islet cells.
Whole islet cryopreservation
In mouse islets, Protocol A resulted in post-thaw viability of 56.5 ± 17.1 %, Protocol B
in viability of 51.7 ± 22.6 % and Protocol C 54.9 ± 12.3 % (Figure 5.3A). After three
days in culture, average viability dropped in all three protocols by approximately 28 %. No
significant differences between protocols were detected.
In human islets, immediate post-thaw viability was 69.6 ± 9.2 %, 68.8 ± 10.0 % and
50.8 ± 6.9 % for protocols A, B and C, respectively (Figure 5.3B). After three days in culture,
the viabilities in all three protocols were approximately the same in all three conditions. The
data were not statistically analysed due to the low number of repeats because of limited
availability of human islets.
There are a number of mathematical models to describe the diffusion of DMSO into
tissues, but experimental evidence is limited. Benson et al. observed that 1.5 mol/kg DMSO
can equilibrate with an islet of 150 µm diameter in about 600 s at room temperature [72].
Longer incubation times can nonetheless be necessary due to the use of different, gradually
increasing DMSO concentrations in the protocol. Based on this model, Protocol B may be
expected to be as effective as Protocol A, as both provide sufficient time for equilibration
with DMSO. However, addition of 2 M DMSO in a single step causes rapid osmotic change
which could be detrimental to some cells.
In the absence of previous studies comparing different DMSO addition protocols, the
optimal DMSO addition protocol for further studies was selected as Protocol A based on the
data generated from these experiments. The results from mouse islet cryopreservation were
inconclusive: All three protocols showed similar post-thaw survival both immediately and
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Fig. 5.3 Comparison of DMSO addition protocols for mouse and human pancreatic islets. Post-thaw
viability of mouse (A) and human (B) pancreatic islets immediately after thawing and 3 days after
thawing. Each triangle represents the average viability from one experimental sample; horizontal
line represents the mean (n = 2 – 3, viability of each experimental condition calculated as an average
viability of 5 – 14 mouse islets or 8 – 18 human islets). (C) Post-thaw viability of mouse dissociated
pancreatic islet cells immediately post-thaw. Each triangle represents a single sample’s viability,
horizontal line represents the mean, different repeats of the experiment are shown in different colours
(n = 3). Statistical comparison of groups in (C) was performed using one-way repeated measures
ANOVA followed by Tukey’s HSD test. No statistical differences were found.
24 h post-thaw. In human islets, Protocols A and B were equivalent. Protocol C (single-step
addition without equilibration) was slightly inferior to the other two tested protocols where
equilibration step was included.
Dissociated islet cryopreservation
In dissociated mouse islet cryopreservation, longer incubations with DMSO before freezing
resulted in trend towards decreased viability of cells: 35.5 ± 9.3 % in Protocol A and
43.4 ± 17.4 % in Protocol B compared to 48.2 ± 16.3 % after no incubation (not statistically
significant, Figure 5.3C).
While pre-incubation with the cryoprotectant appeared to enhance cryopreservation
of whole islets, longer equilibration period with DMSO appeared to result in decrease in
viability of dissociated (single) islet cells. This is likely because each single islet cell has
direct exposure to DMSO in the solution and requires a shorter time to equilibrate with the
cryoprotectant than whole islets. The prolonged incubation, therefore, results in overexposure
to DMSO and toxic effects.
In conclusion, equilibration with DMSO is beneficial in cryopreservation of whole human
pancreatic islets and does not decrease viability in mouse islet cryopreservation. However,
it has detrimental effect if islets are dissociated into single cells and cryopreserved. All
subsequent experiments with whole pancreatic islets were therefore performed using the
step-wise addition with equilibration protocol (Protocol A) as described by Rajotte [190].
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Subsequent experiments with dissociated islet cells were performed using single step addition
of 2 M DMSO followed by immediate freezing (Protocol C).
5.3.2 Freezing rate
Mazur’s two-factor hypothesis [35] suggests that injury to cells during freezing occurs either
due to dehydration (if cooling is too slow) or intracellular ice formation (if cooling is too
rapid). Optimal freezing rate for a specific cell type balances these two processes in order to
minimise freezing damage. In pancreatic islets, the optimal slow freezing rate was found to
be  0.25 or  0.3 °C/min [74, 191]. While islets can also tolerate rapid cooling rates of over
 70 °C/min [191], slow-freezing was used in all experiments.
Two different methods of achieving specific cooling rates were compared: using a pro-
grammable freezer and a conventional freezing container (Mr. FrostyTM). While freezing
containers cannot achieve cooling rates as slow as  0.3 °C/min, their use may be advanta-
geous due to the fact that programmable freezers are costly and not widely available across
research and clinical laboratories. The following two freezing protocols for mouse and
human islets were therefore tested: Firstly, a controlled-rate freezer was used to achieve the
freezing rate of  0.3 °C/min (Controlled freezing), and secondly, a Mr. FrostyTM freezing
container placed at  80 °C freezer was used to simulate higher freezing rate (approximately
 1 °C/min) in an uncontrolled manner (Uncontrolled freezing). The latter protocol is
identical to that used for freezing mononuclear cells in Chapter 4.
Mouse pancreatic islets
There were significant differences in the viability of cryopreserved mouse pancreatic islets
depending on the freezing rate used (p < 0.01 on Day 0, p < 0.0001 on Day 3, p = 0.001
on Day 6, Figure 5.4A). The viability of islets frozen by the Controlled method did not
decrease below 70 % on Days 0, 3 and 6 while the Uncontrolled samples were 30.6 ± 7.8 %
viable immediately after thawing and less than 17 % viable on following days. Although
the variability in size of islets was large, islets frozen using controlled-rate freezer were on
average larger than those from freezing container (Figure 5.4B).
Human pancreatic islets
In human islets, the viability of islets from both protocols was identical on all the days
measurement was taken (Figure 5.4C). There was a trend of larger islets surviving when the
Controlled protocol was used, however these differences were not statistically significant
(Figure 5.4D).
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Fig. 5.4 Comparison of controlled and uncontrolled freezing for mouse and human pancreatic islets
from Day 0 to Day 6 after thawing. (A) Viability of mouse pancreatic islets frozen by controlled-rate
freezer (Controlled) vs. freezing container (Uncontrolled). (B) Size of thawed mouse pancreatic
islets. (C) Viability of human pancreatic islets frozen by controlled-rate freezer (Controlled) vs.
freezing container (Uncontrolled). (D) Size of thawed human pancreatic islets. Average ± SD
viability/size of each experimental sample is shown, calculated from viability of n = 6 – 10 mouse
islets or n = 4 – 21 human islets. Statistical comparison was done using two-way ANOVA followed
by Sidak’s correction, significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01;
⇤⇤⇤ p  0.001, ⇤⇤⇤⇤ p  0.0001.
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This data suggests that slow cooling rate of  0.3 °C/min achieved by a controlled-rate
freezer is superior to uncontrolled freezing at the rate of  1 °C/min in both mouse and human
islets. This is in agreement with a previous study conducted by Rajotte et al. who tested the
same freezing rates and observed that islets frozen at rate of  0.3 °C/min we able to reverse
diabetes in a rat model while islets frozen at  1 °C/min were not [74].
In the experiments presented here, the difference between the two methods has been less
pronounced in human islets than in mouse islets. Rajotte et al. compared cryopreservation of
rat and canine pancreatic islets and, noting different outcomes, suggested that differences in
tissue of small (mouse, hamster, rat) and large (dog, human) species may call for different
parameters of cryopreservation, including freezing rate [192]. It is therefore possible that
human islets can tolerate wider range of cooling rates than mouse islets.
To conclude, my results suggest that the use of programmable freezers to achieve slow
cooling rates for islet cryopreservation is necessary to preserve their viability and size, both
of which contribute to the functional pancreatic islet mass available for transplantation. All
subsequent experiments were therefore conducted using a programmable freezer at the rate
of  0.3 °C/min.
5.3.3 DMSO removal protocol
Post-thaw removal of DMSO is a necessary step of the cryopreservation protocol ensuring
that the high toxic concentrations are removed and cells are brought back into a physiological
medium. This must be done in a manner that reduces the osmotic shock caused by the rapid
change in solution osmolarity. The cryoprotectants are therefore ideally diluted post-thaw in
a step-wise fashion to allow the cells to adjust to the new concentration of solutes without
risking damage. In single cell cryopreservation, drop-wise addition of thawing medium is
often recommended to prevent the osmotic shock [193, 194].
In islet cryopreservation, several approaches are used to ensure optimal transfer of islets
from the cryoprotectant medium into the culture medium. The most widely used protocol
utilises 0.75 M sucrose which is exchanged for the 2 M DMSO immediately after thawing.
This dilutes the DMSO down to concentrations which have low toxicity while preventing
osmotic shock to the islet cells. Sucrose is then diluted in several steps before the islets
are brought back to normal culture medium. This approach has been suggested by Rajotte
and Mazur and remains the standard method in islet cryopreservation [193]. An alternative
approach suggested by Lakey et al. recommends slow dilution of DMSO with culture
medium without addition of sucrose [87].
Three different DMSO removal protocols were tested in parallel to identify the optimal
method to thaw both mouse and human islets (schematic representation in Figure 5.5). The
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Fig. 5.5 Design of the islet cryoprotectant removal protocol study. Time 0 represents the time when the
last small ice crystal is observed after rapid thawing in a water bath. Numbers above colourful circles
represent time in minutes from this time point. Each circle represents an addition of culture medium
(CM) or 0.75 M sucrose to the thawed islets. (A) Schematic of QUICK thawing protocol: 10⇥
dilution of DMSO in a single step. (B) Schematic of the SLOW thawing protocol: step-wise dilution
of DMSO using CM over 24 min until 10⇥ dilution is reached. (C) Schematic of the SUCROSE
thawing protocol - at time 0, DMSO is exchanged for 0.75 M sucrose and incubated on ice for 30 min,
followed by step-wise dilution of sucrose. (D) Model of changes of concentrations in DMSO and
sucrose over time using the three different cryoprotectant removal protocols. Dotted and dashed lines
show the decreasing concentration of DMSO (left y axis) while the solid line shows the concentration
of sucrose in SUCROSE protocol (right y axis).
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first protocol, referred to as ’QUICK’, contains a single-step 10⇥ dilution of the cryopreser-
vation medium with islets. The second protocol, ’SLOW’, is the step-wise dilution with
culture medium described by Lakey et al. [87]. The third protocol, ’SUCROSE’, is the
protocol designed by Rajotte et al. [193] which involves the exchange of DMSO for sucrose.
In addition, the QUICK and SLOW protocols were tested in cryopreservation of dissociated
mouse pancreatic islet cells to examine whether the use of step-wise protocols benefits both
single cells and cell clusters.
Mouse pancreatic islets
In cryopreservation of mouse islets, the highest viability immediately after thawing and
3 days post-thaw was achieved using the SLOW protocol (74.4 ± 9.2 %; Figure 5.6A).
The SLOW protocol also better preserved their morphology, including size and fibrous islet
capsule surrounding the cells (observed as a thin dark line around the islets; Figure 5.6B).
The QUICK protocol resulted in a decreased post-thaw viability (54.4 ± 25.2 %) which
remained low even after three days of culture. The morphology of islets was also changed;
the cell clusters were no longer surrounded by the fibrous islet capsule with the exception
of few very small islet-like clusters which are surrounded by it. Islets thawed using the
SUCROSE protocol had decreased viability immediately post-thaw (46.6 ± 16.9 %), which
recovered marginally after three days of culture. Moreover, they lost a large portion of their
volume and high proportions of small fragments were observed (Figures 5.6A and B).
Human pancreatic islets
The experiments were repeated using human islets. A fourth protocol was added in the
human islet thawing, to address the increased amount of debris observed in the SUCROSE
protocol. The modification involved pouring the cell suspension instead of pipetting and
handpicking the islets instead of centrifuging to minimise any mechanical stress (MODIFIED
SUCROSE protocol).
The viability of islets thawed by the QUICK method was again decreased (52.0 ± 0.2 %)
and did not recover over time (Figure 5.6C). The viability in the rest of the conditions was
similar to the QUICK protocol immediately after thawing but seemed to recover in culture
over time. There was no observable difference in viability between the SLOW, SUCROSE
and MODIFIED SUCROSE protocol. When comparing the SUCROSE and MODIFIED
SUCROSE protocols, more fragments were found in the SUCROSE protocol (Figure 5.6D).
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Fig. 5.6 Comparison of thawing protocols for mouse and human pancreatic islets. (A) Post-thaw
viability of mouse pancreatic islets thawed using three different protocols immediately after thawing
and 3 days after thawing (n = 2). Each triangle represents the average viability of one experimental
sample calculated from 6 – 14 islets; horizontal line represents the mean. (B) Bright field images of
mouse pancreatic islets thawed using three different protocols. Top row shows all islets recovered
after thawing, bottom row show the same islets under magnification. (C) Post-thaw viability of human
pancreatic islets thawed using four different protocols immediately after thawing and 3 days after
thawing (n = 2). Each triangle represents the average viability of one experimental sample calculated
from 5 – 17 islets; horizontal line represents the mean. (D) Bright field images of human pancreatic
islets thawed using sucrose protocol and its modification. All recovered islets shown. (E) Post-thaw
viability of dissociated mouse pancreatic islets (n = 3). (F) Post-thaw absolute cell count of dissociated
islet cells (left) and fold-change relative to the absolute cell count in QUICK protocol (right; n = 3).
Each triangle represents viability of one sample, matching samples from one experiment are shown in
the same colour. Statistical comparison was done using paired t-test, statistically significant p-values
are specified in each graph.
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Dissociated islet cells
For dissociated islet cells, the SLOW protocol resulted in significantly higher viability than
the QUICK protocol (36.2 ± 11.9 % versus 14.5 ± 3.6 %; t-test, p = 0.0453, Figure 5.6E).
The absolute cell yield after cryopreservation was also higher (2.3 ± 0.2 times) using the
SLOW thawing protocol (Figure 5.6F).
Based on these findings, optimal DMSO removal protocols were selected for mouse and
human islets to be used in all following cryopreservation experiments. In mouse islets, the
SLOW protocol was superior to the other protocols both in viability and morphology. In
human islets, the SLOW and SUCROSE protocols appeared to preserve viability equally
well. In studies which compared these two protocols, SLOW protocol was equally good [74]
or better [87] than SUCROSE protocol. The current results are therefore in agreement with
these studies. The protocols, however, have not been previously compared using human islets
and it appears as there are some inter-species differences. Slow dilution of DMSO was also
beneficial in dissociated islet cell thawing, suggesting that single cells and cell clusters are
equally sensitive to osmotic stress.
Lakey et al. [87] suggested that the decreased cryosurvival after addition of 0.75 M
sucrose during thawing may be caused either by osmotic stress from the sucrose or centrifu-
gation step which could lead to fragmentation of islets. The tested MODIFIED SUCROSE
protocol indeed resulted in decreased amount of debris in the post-thaw suspension. However,
this may have been caused by omitting the small islet fragments during manual handpicking
rather than the debris not being present after thawing. These modifications are used in all
future experiments to avoid possible negative effects of dead cell presence in post-thaw
culture of islets.
In summary, based on the current data and the evidence from the literature, the SLOW
protocol was used for subsequent experiments with whole and dissociated mouse islets.
Since the SUCROSE protocol is the standard in the field of human islet cryopreservation, it
was used in all following human islet cryopreservation experiments with the modifications
we introduced to decrease the mechanical stress to the islets (i. e. MODIFIED SUCROSE
protocol).
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5.4 Trehalose as a sole cryoprotectant for islets
5.4.1 Trehalose concentration
With the DMSO protocol optimised, efficacy of trehalose for cryopreservation of pancreatic
islets was tested. In the first instance, trehalose was used on its own to investigate its potential
as a sole cryoprotectant for pancreatic islets.
In the first set of experiments, mouse pancreatic islets were cryopreserved in different
concentrations of trehalose (without any incubation) in the controlled-rate freezer and thawed
using the SLOW thawing protocol. Viability of islets was evaluated using FDA/PI staining
immediately post-thaw.
The post-thaw viability of all islets cryopreserved using trehalose alone was very low
compared to the DMSO control (0.06 – 8.79 % viability for trehalose, Figure 5.7A). While
there was a considerable variability between the three replicates, 200 mM trehalose performed
the best in all three repeats of the experiment but nonetheless provided minimal protection.
Viability was not measured again at a later time point (24 h post-thaw), as all the remaining
islets in the trehalose groups died and disintegrated during this period. Trehalose alone,
without any incubation, therefore is not an effective cryoprotectant for islets.
5.4.2 Trehalose incubation time
Because islets are cell clusters, diffusion of cryoprotectant to all the cells naturally takes time.
Diffusion of small molecules was investigated in Section 3.4 of Chapter 3. The findings
proposed that it takes 6 h at 37 °C for a dye to equilibrate in all cells of the islet. Trehalose,
being also a small molecule travelling in an aqueous solution, may be expected to require
a similar time to diffuse throughout the cluster. As shown in Section 5.2.2 of this Chapter,
prolonged incubation of mouse islets with 200 mM trehalose did not have a negative effect
on their viability. It was hypothesised, therefore, that incubation time before cryopreservation
could increase the viability of trehalose-cryopreserved islets.
Mouse islets
The hypothesis was first tested using mouse pancreatic islets which were incubated with
200 mM trehalose for 15 min to 48 h and then cryopreserved using the programmable freezer.
After thawing using the SLOW protocol, viability was measured immediately. Control
DMSO islets were cryopreserved along with the trehalose samples.
Again, viability of islets in all samples where trehalose was the only cryoprotectant was
extremely low and did not in these two experiments exceed 2.95 % in any of the conditions
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Fig. 5.7 Cryopreservation with trehalose only: concentrations and incubation times. (A) Post-thaw via-
bility of mouse pancreatic islets cryopreserved with DMSO or different trehalose concentrations (100 -
400 mM). Viabilities of the individual replicates (M19, M32 and M34) of trehalose-cryopreserved
islets are shown in the zoomed graph on the right. Bars represent mean ± SD, n = 3. (B) Post-thaw
viability of mouse pancreatic islets cryopreserved with DMSO (no extra incubation) or 200 mM
trehalose (15 min, 3 h, 6 h, 24 h or 48 h incubation prior to freezing). Viabilities of the trehalose-
cryopreserved islets are shown in the zoomed graph on the right. Bars represent mean ± SD, n = 1-2.
(C) Post-thaw viability of human pancreatic islets cryopreserved with DMSO (no extra incubation),
no cryoprotectant or 200 mM trehalose (2 h or 24 h incubation prior to freezing). Viabilities of the
individual replicates (Donor A or Donor B replicates 1 and 2) of trehalose-cryopreserved islets are
shown in the zoomed graph on the right. Bars represent mean ± SD, n = 3. Triangles represent
average viabilities from each replicate calculated from 4 – 17 mouse islets or 2 – 14 human islets,
triangles of same colour represent results from the same experiment, horizontal lines represent mean.
Differences in (C) were compared using mixed effects one-way ANOVA followed by Tukey’s HSD
post-hoc test. Statistically significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01.
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(Figure 5.7B). Highest viability in both experiments was measured for the incubation time of
24 h.
Because the number of replicates was low, no statistical comparisons were made but
there seemed to be a trend of viability increasing with incubation time, peaking at 24 h of
incubation.
Human islets
The experiments were repeated using human islets, but the number of trehalose conditions
was reduced due to the shortage of tissue to 2 h and 24 h only. DMSO and no cryoprotectant
(no CPA) controls were included. Islets from two donors were used and the experiment was
repeated twice for the second donor. Thawing was performed using MODIFIED SUCROSE
protocol and viability measured immediately post-thaw.
Although not statistically significant, there is a clear trend to higher survival of pan-
creatic islets at 24 h incubation time, compared to 2 h incubation (22.2 ± 9.3 % vs.
3.4 ± 3.2 %, p = 0.2444; Figure 5.7C). Both of these were still significantly lower than
DMSO-cryopreserved islets (64.6 ± 16.9 %, p = 0.0159 and p = 0.0032, respectively).
The 2 h incubation of human islets with trehalose provided similar result to cryop-
reservation without any cryoprotectant, confirming that trehalose cannot be used as a sole
cryoprotectant without sufficient incubation. Data from mouse islets suggest the same,
although repeating the experiment would provide more conclusive result. However, even
without additional repeats it is clear that even long incubation times do not increase the
efficacy of trehalose to provide results comparable to the standard DMSO protocol.
The viability of human islets cryopreserved with trehalose only and incubated for 24 h
was higher than the one measured for mouse pancreatic islets. One potential explanation
may be that the human islets generally have worse quality after isolation and before the
cryopreservation than mouse islets. The edges of human islets are not smooth and the fibrous
capsule may be damaged, giving easier access of trehalose to all the cells. Human islets may
additionally be more resistant to cryoinjury.
Cryopreservation with trehalose on its own could not be compared to any results from the
literature because similar experiments have never been published. It is possible that trehalose
performance in these experiments could be improved by its intracellular loading. Preliminary
experiments on the addition of PP-50 and PP-75 polymers were performed and the results are
shown in Appendix C. Briefly, the addition of the polymers did not show any improvement
over using trehalose without intracellular loading at 2 h and 24 h, regardless of the polymer
type. This is in agreement with data obtained from cryopreservation of splenocytes with
trehalose and the polymers in Chapter 4.
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To conclude, a range of trehalose concentrations and incubation times were tested for
mouse and human pancreatic islets but none of the conditions provided protection comparable
to the current DMSO standard. The presented data, therefore, confirm that trehalose alone
cannot be used instead of DMSO for cryopreservation of pancreatic islets.
5.5 Addition of trehalose to DMSO protocol
Because trehalose is not an effective cryoprotectant on its own, the next approach tested in
this project was its addition to the standard DMSO protocol. While trehalose combined with
DMSO was tested in pancreatic islets previously by Beattie et al. [83], this approach has
never been tested systematically or subsequently reported.
5.5.1 Effect of pre-incubation with trehalose
The evidence from diffusion experiments in Chapter 3 and even from Section 5.4 suggests
that incubation time of 6 – 24 h may be needed for trehalose to fully permeate the whole
volume of pancreatic islets. However, because of toxicity, such long incubation times with
DMSO would not be possible. A new protocol was therefore designed which includes an
incubation time with trehalose only, subsequently supplemented with DMSO as per the
standard protocol.
Incubation time
Mouse islets were pre-incubated with 200 mM trehalose for 1 – 48 h at 37 °C. 45 min before
the end of this incubation time, the DMSO was added using the previously described protocol
(see DMSO A protocol in Section 5.3.1), while keeping the trehalose concentration constant
at 200 mM (the added DMSO solutions contain 200 mM trehalose). All samples were then
cryopreserved in the programmable freezer, thawed and assessed for viability immediately
post-thaw and 24 h post-thaw.
Immediately after thawing, the viability of DMSO + trehalose (DT) samples was not
significantly different from DMSO-cryopreserved samples, regardless of the incubation time
(Figure 5.8). At 24 h after thawing, samples incubated with trehalose for 1 h or 3 h again
did not show significantly different survival. However, there was a significant improvement
of viability of the sample pre-incubated with trehalose for 6 h (DT 6h) compared to DMSO
(p = 0.0402). Longer incubation times (24 h and 48 h) did not perform better than the 6 h
incubation at 24h after thawing and there was a significant decrease in viability for the 48 h
incubation when compared to 6 h.
5.5 Addition of trehalose to DMSO protocol 143
Fig. 5.8 Supplementation of the DMSO protocol with trehalose. Post-thaw viability of mouse
pancreatic islets pre-incubated with 200 mM trehalose for 1 – 48 h and cryopreserved in 2 M DMSO
+ 200 mM trehalose along with fresh, 2 M DMSO only and 200 mM trehalose only controls. Viability
measured immediately post-thaw (light blue bars) and 24 h post-thaw (dark blue bars) shown. Bars
represent mean ± SD, n = 3 (each measurement calculated from 5 – 35 islets), repeated measures
two-way repeated measures ANOVA followed by Tukey’s HSD post-hoc test, significant differences
are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01; ⇤⇤⇤ p  0.001, ⇤⇤⇤⇤ p  0.0001. T only =
trehalose only
These experiments suggest that trehalose can improve DMSO-based cryopreservation if
the pre-incubation period is sufficiently long. In this case, the appropriate incubation time
was 6 h. This correlates well with the findings from the diffusion experiments in Chapter 3.4
which showed that it takes 6 h for a dye to equilibrate in the whole volume of pancreatic
islets.
Survival of cell clusters
In the above experiments, immediately after thawing, each islet contained live and dead cells
in a proportion close to the average viability. The viabilities of all individual islets within a
condition had normal distribution (Figure 5.9A). Surprisingly, this was not true at 24 h after
thawing. All imaged islets either contained mostly live cells while the remaining islets were
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almost fully dead (Figure 5.9B). There was a trend of higher proportion of live islets in the
DT6h group compared to DMSO alone at 24 h.
To investigate the time course of this phenomenon, an experiment was designed where
the viability of the thawed islets was measured immediately post-thaw and then at 3 h, 6 h,
12 h and 24 h after thawing. The data suggest that predominantly dead islets can be detected
as early as 3 h post-thaw (Figure 5.9C).
The distribution of viability data 24 h after thawing was unexpected and raised additional
questions regarding survival of pancreatic islets. Viability in other cell types is always viewed
as a characteristic of each single cell but from these experiments it appears as if viability of
cells in a cluster is influenced not only by the status of the individual cells but the overall
health of the cluster or signals from the neighbouring cells. One potential mechanism may
be related to the need for a critical amount of cell-cell contact or communication between
adjacent cells. Pancreatic islet cells do not survive well when dissociated into single cells
(data not shown) and cell-cell contact or short-distance paracrine signalling could therefore
play a critical role in their survival. It is possible, therefore, that cell death within the cluster
results in a progressive loss of these trophic signals to adjacent cells. If a threshold of cell
death or injury is exceeded, the loss of trophic signals will lead to death of adjacent cells,
ultimately leading to demise of the whole islet. Conversely, islets containing mostly alive
cells may have mechanisms which enable the cluster to exclude the dead cells, leaving the
islet with predominantly live cells (Figure 5.9D).
This proposed mechanism does not necessarily need to be an active process. For example,
re-establishing cell-cell contact with live (but not dead) cells may gradually result in the
dead cells moving to the periphery and finally being excluded from the main cluster. The
underlying mechanisms, and the biological relevance of this process has not yet been explored.
Exclusion of dead cells from the cluster necessarily results in reduction of the islet size/mass.
This is very difficult to measure due to the 3D structure of islets and would require real-time
prolonged imaging of individual islets.
The distribution of data at 24 h after thawing has an important implication for their
statistical analysis. Because the distribution of the data is bimodal, standard statistical param-
eters such as central tendency or variability could be inaccurate using methods developed
for normally distributed data. Means and standard deviations shown in Figure 5.8A are,
therefore, not fully applicable but are nonetheless displayed to show the trend which can
be observed but not yet quantified. Appropriate statistical methods to analyse this data are
complex and have not yet been identified.
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Fig. 5.9 New insight into the mechanism of survival of cell clusters. (A) Post-thaw viability of
individual islets cryopreserved with DMSO only, trehalose only or combination of DMSO and
trehalose (with varying trehalose incubation time) measured immediately post-thaw. (B) Post-thaw
viability of individual islets from the experiments shown in (A) measured 24 h post-thaw. (C) Viability
of individual islets cryopreserved with DT6h and measured immediately post-thaw and 3 h, 6 h, 9 h,
12 h and 24 h post-thaw. For (A)-(C), no statistical analysis was performed. Triangles represent
individual islet viabilities, triangles of same colour represent results from the same experiment.
DT6h = DMSO + trehalose pre-incubated for 6 h; Treh = trehalose. (D) Schematic of the proposed
cell cluster fate based on the viability immediately post-thaw. Left: If majority of cells within
the cluster remained alive immediately after thawing, the islet excludes the minority of dead cells,
resulting in a smaller but fully viable islet when viability is measured at a later time point. Right: If
large amount of cells in the islet are already dead immediately after thawing, sufficient support is not
provided for the remaining live cells which results in their cell death.
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5.5.2 Concentrations of components
Combining multiple cryoprotectants has been previously suggested as a way to decrease
the concentration of the individual (often toxic) cryoprotectants. I therefore next explored
whether lowering the concentration of DMSO or trehalose in the new DT6h protocol could
provide enhanced protection by decreasing the osmotic stress or toxic effects of the high
cryoprotectant concentrations. Higher concentrations have also been explored to see if these
could provide additional protection.
Concentration of trehalose
In the first set of experiments, mouse pancreatic islets were cryopreserved using 100 - 300 mM
trehalose concentration in the same manner as the DT6h protocol (6 h incubation with the
correct trehalose concentration, followed by addition of DMSO over 45 min). DMSO
concentration in all conditions was kept at 2 M. Viability of thawed islets was assessed
immediately post-thaw and 24 h post-thaw.
The results from this experiment demonstrated that increasing the trehalose concentration
in the DT6h protocol above 200 mM led to a decrease in post-thaw viability compared to
fresh islets (p = 0.0089 for 300 mM trehalose; Figure 5.10A). On the other hand, decreasing
the trehalose concentration did not lead to worse cryoprotection (96.61 ± 2.01 % viability in
200 mM trehalose vs. 92.59 ± 7.8 % viability in 100 mM trehalose; p = 0.9976).
Because the 50 % decrease in trehalose concentration did not have detrimental effect on
islet viability, a second set of experiments was performed with the same design but lowering
the trehalose concentration from 200 mM down to 25 mM.
In this experiment, the average viabilities were approximately the same in all four
trehalose concentrations (25, 50, 100 and 200 mM; Figure 5.10B). Again, additional decrease
in trehalose concentration did not seem to negatively affect the islet viability and still
resulted in statistically significant increase in viability compared to DMSO alone (0 mM
concentration of trehalose in Figure 5.10B). Conversely, the islets cryopreserved in lower
trehalose concentration (25 mM and 50 mM) were larger in size and more similar to fresh
islets in their morphology when observed under microscope (data not shown). A lower
concentration of trehalose may, therefore, result in enhanced cryoprotection.
The decrease in viability for islets cryopreserved with 300 mM trehalose could be due to
a direct toxic effect of trehalose itself, or due to exceeding the islet tolerance for combined
osmotic pressure of DMSO and trehalose. From the available data it appears that the lowest
concentration at which trehalose exhibits its protective effect is much lower than in DMSO-
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Fig. 5.10 Trehalose concentration in the DT6h protocol. (A) Post-thaw viability of mouse islets
cryopreserved using the DT6h protocol with different trehalose concentrations (100 – 300 mM)
measured 24 h post-thaw (n = 3, each value calculated as an average viability of 4 – 24 islets).
(B) Post-thaw viability of mouse islets cryopreserved using the DT6h protocol with different trehalose
concentrations (25 - 200 mM) measured 24 h post-thaw (n = 4, each value calculated as an average
viability of 2 – 35 islets). Triangles represent average viabilities from individual replicates, triangles
of same colour represent results from the same experiment. Horizontal lines represent grand means
from the experiments. Repeated measures one-way ANOVA followed with Tukey’s HSD post-hoc
test was performed, statistically significant difference is marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01,
⇤⇤⇤ p  0.001, ⇤⇤⇤⇤ p  0.0001.
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free systems, which has been demonstrated in this project both for splenocytes (Section 4.5)
and pancreatic islets (Section 5.4.1).
Several mechanisms of cryoprotection by trehalose have been proposed in the literature
(see Section 1.9.1). It is possible, however, that in the presence of DMSO, some of these
protective mechanisms may be redundant (e.g. glass-forming properties) and therefore only
the functions which are not performed by DMSO are manifested. These could include the
potential antioxidant properties of trehalose or its role in stabilisation of proteins. This may
explain why high concentrations of trehalose are not needed in the combined DMSO-trehalose
protocol.
Concentration of DMSO
In the next series of experiments, mouse pancreatic islets were cryopreserved using DT6h
cryopreservation protocol with fixed 200 mM trehalose concentration and a range of DMSO
concentrations (1 M – 2.5 M) following protocols shown in Table 5.1. Post-thaw viability
was measured immediately and 24 h after thawing.
Table 5.1 Protocols for DT6h DMSO concentration experiments
Concentrations of DMSO at each step
Condition Step 1 Step 2 Step 3
(final concentration) 5 min at RT 25 min at RT 15 min at 4 °C
1 M DMSO 0.33 M 0.5 M 1 M
1.5 M DMSO 0.5 M 0.75 M 1.5 M
2 M DMSO 0.66 M 1 M 2 M
2.5 M DMSO 0.83 M 1.25 M 2.5 M
Notes: trehalose concentration at all steps was 200 mM; RT = room temperature
As can be seen in Figure 5.11A, 1 M DMSO concentration did not provide sufficient
protection during cryopreservation of pancreatic islets. However, lowering DMSO concentra-
tion from 2 M to 1.5 M did not result in a decrease in efficacy both immediately post-thaw
and after one day of culture. Results obtained with the highest 2.5 M DMSO concentration
showed large variability.
To check the functionality of islets cryopreserved with the decreased DMSO concentra-
tion, static glucose stimulation assay was performed on fresh, 1.5 M DMSO DT6h- and 2 M
DMSO DT6h-cryopreserved islets 24 h after thawing.
The results suggest that responsiveness to different glucose concentrations is preserved in
both cryopreserved groups but the 1.5 M DT6h-cryopreserved islets showed insulin secretion
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Fig. 5.11 DMSO concentration in the DT6h protocol. (A) Post-thaw viability of mouse islets
cryopreserved using the DT6h protocol with different DMSO concentrations (1 – 2.5 M) measured
immediately post-thaw (n = 3, each value is an average viability of 7 – 24 islets). (B) Glucose-
stimulated insulin secretion assay results measured on fresh islets and islets cryopreserved in DT6h
protocol (1.5 or 2 M DMSO) measured 24 h post-thaw. Full circles represent average viabilities/insulin
concentrations from individual replicates (n = 3), horizontal lines represent grand means from the three
experiments. Repeated measures two-way ANOVA followed with Tukey’s HSD post-hoc test was
performed, significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01; ⇤⇤⇤ p  0.001.
profile more similar to the fresh islet group (Figure 5.11B). No significant differences were
found between the three groups.
In conclusion, these experiments suggest that lowering DMSO concentration to 1.5 M
can be performed without negatively affecting viability and can potentially help to decrease
the dysregulation in glucose-stimulated insulin secretion. Decreasing DMSO concentration
during cryopreservation has been explored may times in the literature for clinically-relevant
cell types but has only been marginally explored for pancreatic islets. In the publication by
Lakey et al. [77], a reduction of DMSO concentration from 2.0 M to 1.5 M was explored
(without any trehalose addition). The differences between the experiments in this publication
and the current study include source of islets (human donors), different glucose concentration
in the stimulation assay (2.8 mM and 20 mM) and different measure of recovery (counting of
islets as opposed to FDA/PI staining). Nevertheless, the authors came to the same conclusion,
that lowering DMSO concentration to 1.5 M could have a beneficial effect.
Outstanding experiments include testing the lower concentrations of both DMSO and
trehalose, as well as exploring the functionality of the islets after cryopreservation using this
optimised DT6h protocol. Because these DT6h optimisation experiments have not yet been
finalised, the original concentrations (2 M DMSO and 200 mM trehalose) were used in all
following experiments.
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5.6 Addition of antioxidants: MitoQ and salidroside
5.6.1 Effect of antioxidants during cryopreservation
A range of cellular stresses are present during freezing and thawing. Cryopreservation
methods which combine selected compounds to comprehensively address all these harm-
ful events have the potential to be the most successful. Accumulation of ROS is one of
the significant stressors present during cryopreservation, possibly due to the presence of
DMSO [195, 196], and can lead to damage of DNA, proteins and lipids, with potentially
serious implications for the function of the cells. Many publications have shown that antioxi-
dants can improve the outcome of cryopreservation [156, 132, 197], including in pancreatic
islet cryopreservation [154].
Because pancreatic islets are highly sensitive to oxidative stress, use of antioxidants
in treatment of diabetic patients has been suggested [198]. Their use could therefore not
only provide additional support for survival of cells during cryopreservation but also deliver
protective effect to islets during in vitro culture or transplantation.
Salidroside was chosen because it has shown a great promise in red blood cell cryop-
reservation [156] and evaluation of its efficacy in pancreatic islets would provide a novel
protocol. Because ROS are primarily generated in mitochondria, a more targeted approach to
elimination of ROS may be beneficial. Therefore, another antioxidant, mitochondria-targeted
MitoQ, was chosen as the next candidate.
Salidroside
Using the two cryopreservation protocols - the standard DMSO protocol and the newly
developed DT6h protocol, the effects of salidroside and MitoQ on post-thaw viability of
islets were tested. Mouse pancreatic islets were pre-incubated for 6 h at 37 °C with culture
medium (all DMSO-based samples) or 200 mM trehalose (all DT6h-based samples) and with
or without 200 µM salidroside or 100 nM MitoQ. The optimal antioxidant concentrations
were determined in a series of preliminary toxicity and cryopreservation efficacy experiments
using whole and dissociated pancreatic islets (data not shown). The antioxidants were
present at this concentration for the whole duration of cryopreservation (6 h pre-incubation,
freezing, thawing) and during the 24 h post-thaw culture. Viability of the islets was measured
immediately post-thaw and 24 h post-thaw.
Addition of salidroside led to significant increase of the viability 24 h after thawing in
the original DMSO protocol (mean values of 64.7 ± 3.9 % with salidroside vs. 39.1 ± 4.9 %
without salidroside, p = 0.0274, Figure 5.12A and B). No clear trend was detected after addi-
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Fig. 5.12 Effect of salidroside and MitoQ antioxidants addition on post-thaw viability of pancreatic
islets. (A) Post-thaw viability of mouse islets cryopreserved using DMSO or DT6h protocol with
or without 200 µM salidroside or 100 nM MitoQ immediately and 24 h post-thaw (n = 3, average
viability in each experimental condition calculated from 5 – 35 islets). (B) Detail of selected conditions
from (A): individual islets from all three replicates are shown as full triangles, triangles of same colour
represent results from the same experiment. Horizontal lines in the same colour represent means from
the three experiments. (C) Post-thaw viability of mouse islets cryopreserved using DMSO with or
without 200 µM salidroside added at four different stages of cryopreservation, measured immediately
and 24 h post-thaw (n = 2, average viability in each experimental condition calculated from 5 – 38
islets). (D) Post-thaw viability of mouse islets cryopreserved using DT6h protocol with or without
100 nM MitoQ added at four different stages of cryopreservation, measured immediately and 24 h
post-thaw (n = 2, average viability in each experimental condition calculated from 8 – 27 islets). Bars
represent mean ± SD, for data measured immediately post-thaw in (A), repeated measures one-way
ANOVA followed with Tukey’s HSD post-hoc test was performed, statistically significant differences
are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01. DT6h = DMSO + trehalose 6 h pre-incubation;
Sal = salidroside
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tion of salidroside to the new DT6h protocol (58.3 ± 8.4 % with salidroside vs. 66.4 ± 6.8 %
without salidroside, Figure 5.12A).
MitoQ
MitoQ did not increase viability of DMSO-cryopreserved pancreatic islets (48.4 ± 15.8 %
with MitoQ vs. 39.1 ± 4.9 % without MitoQ; Figure 5.12A). However, there was a trend
of an improvement on the newly-developed DT6h protocol (82.6 ± 6.7 % with MitoQ vs.
66.4 ± 6.8 % without MitoQ), consistently in all three replicates (Figure 5.12B).
Although no significant differences were found immediately after thawing (other than
significantly lower viability of DMSO and DMSO + MitoQ compared to fresh islets), there
seems to be a benefit on the survival during the first day after thawing when salidroside was
present in the DMSO protocol and when MitoQ was present in the DT6h protocol.
Salidroside did not provide additional protection when added to the DT6h protocol, per-
haps because the protective action of trehalose and salidroside partially overlaps. Trehalose
has been previously shown to exhibit certain antioxidant effect [199, 197, 124] and since
both of these compounds would act as non-targeted antioxidants, adding both of these at the
same time may be redundant. The demonstrated beneficial effect of salidroside complements
the findings of Alotaibi et al. [156] for cryopreserved sheep erythrocytes where a signifi-
cant difference in cryosurvival was found in glycerol-cryopreserved cells but the effect was
minimal in cells cryopreserved with trehalose.
To conclude, it was demonstrated that addition of salidroside to the original DMSO
protocol and addition of MitoQ to the new DT6h protocol has the potential to further improve
cryopreservation. These two protocols were therefore evaluated for their in vitro efficacy in
the following Section 5.7.
5.6.2 Stage of antioxidant addition
To establish when during the cryopreservation protocol the antioxidants exhibit their protec-
tive effect, the antioxidants were added at different stages of cryopreservation as summarised
in Table 5.2. Viability of islets from each condition was measured immediately post-thaw
and after 24 h post-thaw culture.
Salidroside
No obvious trend in viability immediately post-thaw could be observed after adding salidro-
side at different stages of cryopreservation. After the 24 h post-thaw culture, the highest
viability was measured for the Sal A protocol (73.4 ± 1.5 %; Figure 5.12C). Late addition
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Table 5.2 Design of antioxidants addition stage experiments
Protocol name Presence of antioxidant at this step:
6 h pre-incubation Freezing Thawing Post-thaw culture
Sal/MitoQ A X X X X
Sal/MitoQ B X X X
Sal/MitoQ C X X
Sal/MitoQ D X
Notes: X marks presence of antioxidant (salidroside or MitoQ) at the particular step of the
cryopreservation protocol
of the antioxidant may result in lower viability but the differences could not be statistically
tested due to a low number of replicates (62.4 ± 2.9 % in Sal D).
MitoQ
Similar to the salidroside experiments, there were no observable differences between the
viabilities in individual conditions immediately post-thaw but a trend could be observed after
24 h culture. In the case of MitoQ, early addition of the antioxidant (MitoQ A protocol)
resulted in the lowest viability of all four tested protocols (66.6 ± 12.7 %; Figure 5.12D). The
highest viability was measured in the MitoQ D protocol, where the antioxidant was added
during the post-thaw culture only (85.3 ± 5.0 %). Number of replicates in the antioxidant
addition stage experiments was too low to perform any statistical analysis.
In the antioxidant addition stage experiments, all the post-thaw viabilities were very high
and it is therefore difficult to demonstrate a clear difference between the conditions. However,
when looking at the results at 24 h after thawing, it is apparent that may be advantageous
to add salidroside early, during the 6 h pre-incubation. Another set of experiment would
need to be designed to show whether it needs to be present for the whole duration of
cryopreservation, thawing and post-thaw culture, or whether it is sufficient to pre-incubate
with salidroside and then cryopreserve with DMSO only without the antioxidant. Potential
toxicity of salidroside has not been tested yet but if there is no toxic effect present at the
salidroside concentration used, there may be no deletrious effect of keeping the antioxidant
present. However, simplifying the protocol could be beneficial in a clinical setting.
MitoQ addition to DT6h protocol demonstrated different trend to the salidroside experi-
ment: it was sufficient to add MitoQ for the post-thaw culture to achieve the same efficacy.
This may seem as a conflicting result to the one shown if Figure 5.12A, where MitoQ was
present for the whole duration of cryopreservation and yet exhibited higher post-thaw via-
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bility than DT6h alone. It must, however, be pointed out that the number of replicates was
low in these experiments and that the viability in this last set of experiments was unusually
high in all conditions and therefore it may be difficult to demonstrate an improvement to the
DT6h viability.
Although these results are still inconclusive, this data suggests that salidroside should
be added at an early time point, ideally during the 6 h pre-incubation period, to be efficient,
while it may be sufficient to add the MitoQ for the thawing or post-thaw culture. Additional
experiments must be performed to confirm these findings.
5.7 Function of islets cryopreserved by new protocols
5.7.1 In vitro efficacy
Most previous experiments used viability as the measure of the cryopreservation outcome.
This was ideal for screening and development of new successful cryopreservation protocols
but results provided by the viability assay are too crude and must be validated using a range of
assays looking at health and function of the cryopreserved islets before proceeding to clinical
tests. Some of the newly developed cryopreservation methods were therefore compared to
fresh islets and DMSO-cryopreserved islets in the first instance in vitro using mitochondrial
DNA (mtDNA) oxidation assay, ATP/ADP ratio assay, glucose-stimulated insulin secretion
(GSIS) assay and cyclic AMP (cAMP) release assay.
For all of the assays, the islets were cryopreserved using previously described protocols.
After thawing, the islets were cultured for 24 h and then used to perform one or more different
functional assays. ATP/ADP ratio assays and mtDNA oxidation assays were performed
in collaboration with Anja Gruszczyk and cAMP release assay with Dr. Kerry Barkan.
Optimisation of the in vitro functional assays and their analysis was performed and results
can be found in Appendix D.
Mitochondrial health and metabolic status
As expected, the lowest levels of mtDNA oxidation (highest amplification number) was
measured for fresh pancreatic islets. DMSO and DT6h had comparable levels of oxidative
damage in their mtDNA, both being significantly worse than fresh islets (Figure 5.13A).
There was a trend of smaller damage of the mtDNA upon addition of the antioxidants but
the differences were not statistically significant (p = 0.9050 for DMSO vs. DMSO + Sal;
p = 0.4845 for DT6h vs. DT6h + MitoQ).
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Fig. 5.13 In vitro function of pancreatic islets cryopreserved by the optimised protocols. Cryop-
reservation conditions tested include DMSO, DMSO + 200 µM salidroside, DT6h, DT6h + 100 nM
MitoQ. All functional assays were performed at the end of 24 h post-thaw culture. (A) Mitochondrial
DNA oxidation levels of fresh and cryopreserved islets. Higher amplification numbers indicate lower
oxidation of mitochondrial DNA (n = 4). (B) ATP/ADP ratios in fresh and cryopreserved islets. Higher
ratios indicate better health of the cells (n = 3). (C) Insulin secretion of fresh and cryopreserved
islets stimulated with 3.3 mM and 16.7 mM glucose (n = 3). (D) Cyclic APM release by fresh and
cryopreserved islets after stimulation with two concentrations of GLP-1 (n = 3). In (A) and (B),
results from the same experimental sample are depicted as triangles of the same colour. Horizontal
lines in the same colour represent grand means of the three experiments. In (C) and (D), triangles
represent average values from individual replicates, horizontal lines represent grand means of the
three experiments. Repeated measures one-way or two-way ANOVA followed with Tukey’s HSD
post-hoc test was performed as appropriate, statistically significant results are marked by asterisks:
⇤ p  0.05, ⇤⇤ p  0.01. DT6h = DMSO + trehalose 6 h pre-incubation; Sal = salidroside
156 Developing a novel islet cryopreservation protocol
ATP/ADP assay showed similar results, with fresh islets having the highest ATP/ADP
ratios and DMSO-cryopreserved islets having the lowest (Figure 5.13B). Addition of salidro-
side (DMSO + Sal) or trehalose (DT6h) led to a slight, statistically non-significant increase.
This time, DT6h + MitoQ had very similar ATP/ADP ratios to fresh islets (6.4 ± 1.8 vs.
6.6 ± 1.8, p = 0.9996, respectively), and both DT6h + MitoQ and fresh islets had signifi-
cantly higher ratios than DMSO-cryopreserved islets (1.7 ± 0.5, p = 0.0208 and p = 0.0161,
respectively).
Consistently high mtDNA amplification numbers and ATP/ADP ratios of fresh islets
confirmed good health of the islets before cryopreservation. These two assays also showed the
amount of oxidative and other damage done to the mitochondria during cryopreservation and
that some of this damage may be reduced using appropriate additives during cryopreservation.
Low mtDNA oxidation levels and high ATP/ADP ratios of islets cryopreserved in DT6h
+ MitoQ are not surprising either. Both of these measures are describing the health and
function of mitochondria - the target of MitoQ. Salidroside was able to reduce some of the
harmful effects of cryopreservation on mitochondria but since its action is non-targeted, the
overall effect on cell survival may not be visible using these two assays.
Responsiveness to glucose
In the GSIS assay, the ratio of insulin concentration in high and basal glucose concentrations
(stimulation index) was 4.72 for fresh islets. The lowest stimulation index was measured for
DMSO + salidroside (1.34) but even in this condition, the islets retained some responsiveness
to changing glucose levels. The stimulation index for the remaining three conditions were
comparable (3.94 for DMSO, 3.50 for DT6h and 3.59 for DT6h + MitoQ, data not shown).
The graph in Figure 5.13C shows the actual insulin concentrations (not normalised to DNA)
measured at basal and high glucose concentrations to illustrate the variability of the results
and similarity to the stimulation profile of fresh islets.
Interpretation of the result of the GSIS assay is complex. Islets in all the cryopreservation
samples remained responsive to glucose but comparison of the individual protocols is difficult.
While high secretion of insulin is in many publications regarded as a sign of good health of
islets, it may be concerning that all the cryopreserved islets secrete higher levels of insulin
than fresh islets even at the basal level of glucose (3.3 mM). This could indicate either a
passive release of insulin from dying cells or dysregulation of insulin release pathways.
If such dysregulated islets were to be used for transplantation, it could potentially lead to
suboptimal clinical efficacy. The most optimal cryopreservation should therefore have similar
levels of insulin secretion at basal level. From this point of view, DT6h and DT6h + MitoQ
appear to have the lowest and least variable insulin production when incubated in 3.3 mM
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glucose solution and can therefore be regarded as the most successful cryopreservation
conditions.
Responsiveness to incretin hormones
Cyclic AMP release upon stimulation with incretin hormone GLP-1 produced the highest
response in fresh pancreatic islets (26.5 ± 5.66 and 27.4 ± 5.7 % of forskolin response for
10-6 M and 10-5 M GLP-1 concentrations, respectively; Figure 5.13D). There was cAMP
production in all cryopreservation conditions, suggesting that the cellular machinery remains
intact, but no obvious differences were observed between the different cryopreservation
protocols.
Not a lot of difference could be seen between stimulations with two different concen-
trations of GLP-1. One of the possible explanations may be that both of the tested GLP-1
concentrations are very high and even with the lower concentration, the cells are already
stimulated to their near-maximal level. Further experiments are, therefore, required with
lower concentrations of GLP-1.
To summarise, fresh islets provided a good control in all the four assays. DMSO led to the
highest levels of mtDNA oxidation, lowest ATP/ADP ratios, dysregulated release of insulin
and low responsiveness to different GLP-1 concentrations, and although these trends are not
statistically significant, it can be ranked as the worst of all tested cryopreservation conditions.
The decision about the best condition is more complicated. In terms of mitochondrial health,
characterised by the mtDNA oxidation and ATP/ADP ratio, DT6h + MitoQ performed the
best, likely owing to MitoQ’s ability to target ROS specifically in mitochondria. In the
stimulation assays, however, DT6h seemed to have insulin and cAMP secretion profile more
similar to the one of fresh islets than DT6h + MitoQ. Further experiments are required to
clarify these trends.
5.7.2 In vivo efficacy
As a final confirmation of the efficacy of the new cryopreservation protocols, in vivo model
of STZ-induced diabetes in NSG mice was developed and initial experiments performed
using this model. Three preliminary experiments to determine the correct dose of STZ
and transplanted pancreatic islets were performed and their results are summarised in the
Appendix E.
NSG mice were injected i.p. with 40 mg/kg STZ for five consecutive days and trans-
planted with 400 fresh, DMSO-cryopreserved or DT6h-cryopreserved mouse pancreatic
islets (from C57BL/6JAX mice) under the kidney capsule 16 days after the first STZ injection
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Fig. 5.14 In vivo function of pancreatic islets cryopreserved with DMSO and DT6h protocols. Days
of STZ injections (STZ), islet transplantations under kidney capsule (Tx) and culling of the animals
(Cull) are indicated in the graphs by vertical lines. (A) Weight losses in the three groups of STZ-treated
diabetic animals over the duration of the experiment (n = 4 – 5 animals per group). (B) Blood glucose
levels measured by portable glucose meter in the three groups of STZ-treated diabetic animals over
the duration of the experiment (n = 4 – 5 animals per group). Data points represent mean ± SD.
(C) Blood serum glucose levels in the three groups of STZ-treated diabetic animals at the beginning of
the experiment (Start), prior to transplantation (Pre-Tx) and the end of the experiment (Cull) measured
by biochemical test in CBAL laboratory (n = 4 – 5 animals per group). Bars represent mean ± SD.
Two-way mixed-effects model ANOVA followed by Tukey’s HSD post-hoc test was performed,
statistically significant differences are marked by asterisks: ⇤⇤ p  0.01, ⇤⇤⇤ p  0.001. (D) Blood
glucose levels measured by portable glucose meter in the individual mice of the FRESH group over
the duration of the experiment (n = 4). (E) Blood glucose levels measured by portable glucose meter
in the individual mice of the DMSO group over the duration of the experiment (n = 5). (F) Blood
glucose levels measured by portable glucose meter in the individual mice of the DT6h group over
the duration of the experiment (n = 4). All experimental animals shown were tested concurrently.
DT6h = DMSO + trehalose 6 h pre-incubation; Pre-Tx = before transplantation; STZ = streptozotocin;
Tx = transplantation.
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(5 mice per group). The animals were randomly allocated to the groups. Any animals
receiving lower dose of pancreatic islets (due to technical error or shortage of islets) were
excluded from the analysis at the end. Body weights and blood glucose were monitored
twice a week and blood serum was collected at the start and end of the experiment, as well
as on the day of the transplantation for biochemical measurement of glucose in the CBAL
laboratory. Animals were culled 4 weeks after transplantation.
After the initial drop in weight following the daily STZ injections, the body weights
stabilised in all animals (Figure 5.14A). After transplantation, there was a slight drop in the
weight of the DMSO group but eventually, the weights started to rise in all three groups.
Towards the end of the experiment, the weight gain stopped in the DMSO and DT6h groups.
Blood glucose was well matched in all three groups before the transplantation and reached
the portable glucometer limit of 33.3 mmol/L on the day of the transplantation in all animals
(Figure 5.14B). Transplantation of 400 fresh islets led to a rapid decrease in blood glucose
levels which led to the average blood glucose in this group being under the diabetic threshold
of 13.5 mmol/L in 9 days after transplantation. When looking at the individual animals in this
group, in 3 out of 4 the blood glucose kept decreasing until the end of the experiment and in
one animal the glucose started rising again after Day 9 post-transplantation (Figure 5.14D).
In the two cryopreserved groups (DMSO and DT6h), transplantation of 400 islets did not
lead to a decrease in blood glucose levels during 4 weeks post-transplantation (Figure 5.14B).
This was true not only on average in the two groups but also for all the individual animals,
although temporary decrease in blood glucose was seen in several animals in both groups
(Figures 5.14E and F). Towards the endpoint, many animals from the DMSO and DT6h
groups had blood glucose higher than the glucose meter limit. However, blood serum was
collected at the start of the experiment, before transplantation and before culling to enable
more precise measurement of serum glucose in CBAL biochemical laboratory.
These results showed that animals in all three groups had similar glucose levels at the
beginning of the experiment and before transplantation. At the end of the experiment,
there was significant difference between FRESH and DMSO (p = 0.0007) and FRESH and
DT6h (p = 0.0025). There was no significant difference between DMSO and DT6h group
(Figure 5.14C).
No significant weight loss was observed over the course of the experiment in any of the
mice, likely because of the reduced dose of STZ (see Appendix E) and feeding by mashed
food for the whole duration of the experiment. The small decline in body weights near
the end of the experiment in the DMSO and DT6h groups was likely caused by long-term
exposure of these mice to very high blood glucose levels (> 4 weeks of ⇠30 mmol/L glucose).
No other side effect of the prolonged period of diabetes were observed in these mice.
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Some variability was observed in the consecutive measurements of the individual mice.
Any obvious technical errors in measurements by the glucose meter were excluded but some
variability still remains. One of the reasons could be that the animals were not fasted prior to
the glucose measurements and even though the measurements were performed at the same
time of the day, it could therefore not be monitored whether the animals have eaten or not.
Nevertheless, the blood glucose level development was still obvious despite this relatively
small level of variability.
The DT6h protocol showed improvement in the in vitro tests of viability and function over
the standard DMSO protocol. However, this difference was not demonstrated by this initial
in vivo experiment. Different design of the experiment may perhaps be needed which will
test different dose of the cryopreserved islets and determine the minimal effective dose for
each of the cryopreserved islets. Sectioning and staining of paraffin-embedded transplanted
kidneys will also reveal whether any islets in the DMSO and DT6h groups under the kidney
capsule survived.
To conclude, a functional model of STZ-induced diabetes in NSG mice was generated
and used to test the ability of fresh and cryopreserved islets to reverse diabetes. While
fresh islets rapidly decreased blood glucose to non-diabetic levels after transplantation, both
DMSO- and DT6h-cryopreserved islets did not achieve this at the dose used (400 islets per
mouse) in this initial experiment. Further experiments are required to establish the minimal
dose of cryopreserved islets for reversal of diabetes in mice.
5.8 Discussion
5.8.1 Cryopreservation of islets with trehalose
In this Chapter, the ultimate aim was to develop an improved cryopreservation protocol
for mouse pancreatic islets. The current standard protocol uses DMSO, with documented
toxicity for islets, can only preserve about 50 % of the islet mass, as it was demonstrated for
both mouse and human pancreatic islets in this project.
The above experiments showed that the ability of trehalose to fully replace the cryopro-
tective effect of DMSO is limited. Even when sufficient time for diffusion of trehalose to all
cells was allowed, trehalose still performed significantly worse than DMSO. In line with the
results for splenocytes in Chapter 4, addition of permeabilising polymers PP-50 and PP-75
did not lead to improvement of post-thaw viability in preliminary experiments. It has not
been determined whether this was because of the non-functionality of the polymers or limited
cryoprotective properties of trehalose even after intracellular loading.
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Addition of trehalose to penetrating cryoprotectants has been shown to improve cryop-
reservation of several cell types, including pancreatic islets, but the addition is typically
performed in a single step without incubation. In the publication by Beattie et al. [83], fetal
islet-like cell clusters and adult human pancreatic islets were cryopreserved in a mixture of
300 mM trehalose and 2 M DMSO. Although the published protocol is not very detailed, the
trehalose was presumably added at the same time as DMSO, likely 45 min prior to freezing.
From the data produced in this project, it is clear that using such protocol, the full potential
of trehalose in islet cryopreservation would not be realised. The data available in this Chapter
systematically evaluated parameters involved in cryopreservation, allowing to maximise the
protective effect of trehalose.
Firstly, 45 min of incubation is not a sufficient time for equilibration of trehalose in the
whole volume of pancreatic islets. In this project, the ideal duration of pre-incubation with
trehalose for cryosurvival of islets was experimentally determined here to be 6 h at 37 °C.
Interestingly, the incubation time in the diffusion experiments from Chapter 3 which led to
equilibration of islets with nuclear dye was also 6 h. The assumption that the diffusion rates
measured in Chapter 3 could serve as a prediction for behaviour of other small molecules in
aqueous solutions therefore seems to be accurate.
Secondly, 300 mM trehalose used in the publication in combination with 2 M DMSO
may have been a source of increased osmotic stress, as shown in Section 5.5.2. Although the
experiments to determine ideal concentration of both cryoprotectants have not been finalised
yet, it is clear that some of this stress can be eliminated by decreasing the concentration
of one or both of them. Regarding the ideal concentration of trehalose, an interesting
observation was made: the ideal concentration of trehalose was 200 mM when used as the
sole cryoprotectant but could be decreased down to 25 mM when used in combination with
DMSO.
It is currently not clear for the newly developed protocol whether trehalose provides
protection intra- or extracellularly because intracellular trehalose uptake in pancreatic islets
was not measured as part of this project. It is expected that there is a very small amount
of passive diffusion of trehalose through the membrane but this would not increase the
intracellular trehalose concentration significantly. Beattie et al. [83] raised another very
interesting point about entry of trehalose to the intracellular space during cooling thanks
to lipid-phase transition of the membrane resulting in increased permeability. If this is
correct and lipid-phase transition indeed allows trehalose to enter cells, it certainly would
be advantageous and no other additives or interventions which could potentially complicate
translation of this method into clinical practice would be required.
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5.8.2 New insight into cell cluster survival
The present studies offer potentially important insights into the long-term survival of pan-
creatic islets. The data suggest that a critical mass of live cells within islets is needed to
support the survival of the whole cell cluster. The nature of this intra-cluster communication
has not been investigated yet but it is likely that apoptotic pathway is being activated due
to the loss of attachment to other living cells or extracellular matrix. Similar process has
been described for many adherent cell types which need attachment to extracellular matrix to
survive, otherwise they undergo a type of apoptosis which is referred to as ’anoikis’ [200].
Recently, the importance of cell-cell contact mediated by cadherins, selectines and other
adhesion molecules for survival of certain cell types is being discovered. Metastatic tumor
cells are able to avoid anoikis by activation of certain signalling pathways [201]. It may
be possible, for example, to treat islets with a therapeutic agent after thawing which would
transiently activate or block the affected pathway(s), preventing anoikis in the crucial period
after cryopreservation.
Analysis of transcriptome could reveal which receptors or pathways are involved in
survival of islets or trigger of apoptosis. Time-lapse imaging of islets after thawing could
then bring some insight into the re-formation of the surviving cells into a smaller functioning
islet.
5.8.3 Cryopreservation with antioxidants
There has been an increased interest in addition of antioxidants into cryopreservation media
for different cell types in the recent years. However, action of antioxidants in pancreatic islet
cryopreservation has not been extensively studied. Kanitkar et al. [154] used curcumin as
an additive to the standard DMSO protocol and showed that it improved post-thaw recovery
and decreased whether it was added during cryopreservation or only in the post-thaw culture.
This project evaluated the efficacy of another natural non-targeted antioxidant salidroside in
pancreatic islet cryopreservation for the first time and showed similar results - although from
the preliminary data it is apparent that early addition of salidroside provides more benefit
than adding it in post-thaw culture only.
Trehalose has also been shown to possess antioxidant properties [199, 197, 124]. Addition
of antioxidants with similar action to cryopreservation media containing trehalose could
therefore be redundant. In this Chapter, salidroside was shown to improve survival of islets in
the DMSO-based protocol but failed to improve the DT6h protocol, possibly because of this
reason. MitoQ, on the other hand, exhibits its antioxidant properties mainly in mitochondria,
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where it accumulates. Combination of several antioxidants with different actions (targeted vs.
non-targeted etc.) could be one of the approaches to minimise oxidative damage.
Similarly to antioxidants, other additives could supplement the newly developed DMSO
+ trehalose protocol. As long as they lack toxicity, they can be added during the 6 h pre-
incubation step, allowing them to diffuse to all cells of the islet. These molecules could
include nucleation inhibitors or antifreeze proteins to reduce the amount of damage during
cryopreservation, or molecules which specifically target some of the sites of damage (such as
anti-apoptotic agents).
The outstanding experiments include additional validation of the cryopreserved islet
quality and safety of the developed protocols. The assays used in this Chapter to evaluate
islet function looked at production of insulin and cAMP in islets which very specifically
indicate the function of b -cells. However, the function of the other cell types present in
islets is critical if they are to correctly regulate blood glucose levels after transplantation.
More comprehensive evaluation of hormone production could be evaluated using peptidomic
analysis. Furthermore, bulk and single-cell RNA sequencing could reveal any important
changes happening to the cells during cryopreservation. In addition, because the development
of the novel protocols was performed using mouse islets, it must also be demonstrated that
the findings can be replicated for human islets too.
5.9 Conclusion
This Chapter aimed to develop a novel method of pancreatic islet cryopreservation which
could ultimately enable cryopreserved islets to be used for clinical transplantation in the
treatment of diabetes. First, several parameters of the DMSO protocol, which is the current
standard in the islet cryopreservation research, were investigated and optimised. The devel-
opment of a new protocol was then approached using two directions: firstly, by complete
substitution of the toxic DMSO by trehalose and secondly, by improving the current DMSO
protocol using additives.
While the approach using trehalose on its own did not generate a successful protocol,
addition of trehalose to the DMSO protocol did improve cryopreservation outcomes, once the
correct incubation times were used (6 h pre-incubation with trehalose followed by step-wise
addition of DMSO in the last 45 min). The health and function of islets cryopreserved
using this successful newly developed protocol were tested and showed that combination
of trehalose and DMSO is superior to DMSO alone not only in post-thaw viability but also
other markers of islet function. Superior function in vivo was not yet demonstrated for this
164 Developing a novel islet cryopreservation protocol
new protocol in the preliminary experiments on mouse model of STZ-induced diabetes but
further experiments will be performed to evaluate this.
This newly generated and comprehensively evaluated DMSO + trehalose protocol was
then used as a stepping stone for testing additional additives in order to address the multitude
of challenges present in cryopreservation. It was shown that cryopreservation can be further
improved by addition of antioxidants, specifically MitoQ and salidroside. The possibility
of decreasing the concentration of DMSO without decrease in post-thaw recovery was also




This chapter provides a discussion of the findings, their limitations and possible future
directions, as well as their implications for the fields of islet cryobiology and clinical islets
transplantation.
In Section 6.2, the findings of this project are reviewed with reference to the aims and
objectives outlined in Chapter 1.12. The impact of the most important findings is then
explored in the context of existing literature in Section 6.3.
Limitations of this project are then outlined and discussed in Section 6.4, followed by
suggestions for future work and for translation of the novel cryopreservation protocol into
clinical practice in Section 6.5.
6.2 Research aims and major findings
The ultimate aim of this project was to develop a method for cryopreservation of pancreatic
islets which would provide sufficient viable islet mass to ultimately enable clinical trans-
plantation of cryopreserved pancreatic islets. A novel protocol was designed which uses 6 h
incubation with trehalose followed by step-wise addition of DMSO to achieve improved
cryosurvival and in vitro function compared to the standard DMSO protocol. Furthermore,
this protocol was further improved by addition of antioxidants MitoQ and salidroside to
enhance cryosurvival.
Due to the complexity of the structure of pancreatic islets, a comprehensive evaluation
of trehalose and permeabilising polymers PP-50 and PP-75 for mediating the intracellular
uptake of trehalose was first performed using human mononuclear cells as a simplified model.
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The potential of the use of these polymers in improving cryopreservation with trehalose was
not confirmed in human mononuclear cells and this approach was therefore not pursued
further in islet experiments.
A critical step for the development of an improved cryopreservation protocol was the
evaluation and improvement of current viability assessment protocols, which was performed
for both mononuclear cells and pancreatic islets. Insights into the diffusion kinetics of small
molecules determined the ideal incubation time to be 6 h at 37 °C and enabled not only
generation of an improved staining and imaging protocol for pancreatic islets but also helped
with the design of the a novel islet cryopreservation protocol.
6.3 Impact of the findings
6.3.1 Standards of viability assessment in cryobiology
In Chapter 3 of this project, I identified a need for cryobiology research to adopt common
protocols for assessment of cryosurvival and the specific requirements for such an assessment
method. Although this concept is not new, this is the first time, to my knowledge, that
a comprehensive review of existing literature and original investigations has resulted in a
proposal for a standardised method for assessment of cryosurvival. I successfully applied
this approach to develop a method for cryosurvival assessment of mononuclear cells which
meets all these cryobiology-specific needs.
By dissemination of the findings and proposal from this project, it is hoped that these
standards will be adopted by researchers in the cryobiology field, improving the ability to
compare findings of studies by different investigators, enhancing data transparency and an
unbiased approach.
6.3.2 Limitations in pancreatic islet viability assessment
It is well known that the results of pancreatic islet viability assessment do not readily
correlate with transplantation outcomes [94]. A potential factor is that viability assessment is
performed shortly after the period of ischemia during pancreas storage and a physiologically
stressful islet isolation process. However, this project identified additional important factors
which contribute to the inaccurate results obtained from viability assessment assays.
A range of imaging modalities were used in this study to assess the viability of the
core and periphery of pancreatic islets. Importantly, these studies revealed the inadequacy
of current imaging techniques in assessment of viability of the core of islets. While it is
previously acknowledged that using imaging to assess islet viability is challenging [95], the
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different methods have not previously been systematically and comprehensively assessed.
In this study, four different imaging technologies (wide-field, confocal, multi-photon and
light sheet microscopy) for assessment of pancreatic islets were compared. Importantly, I
demonstrated that the clinically-used islet viability assay based on FDA/PI dyes does not
lead to staining of the whole islet volume but rather only the peripheral cell layers, frequently
leading to incorrect estimation of islet viability.
Although other assays, especially those examining physiological function of islets, could
be regarded as more insightful, I believe that simple viability staining has an important
place in cryobiological assessment for its ability to provide rapid results during screening
of cryopreservation conditions. The data from this project generate important insights into
the underlying problems of FDA/PI staining and imaging. Addressing these shortfalls can
help develop more accurate methods not only for academic studies but also for clinical use,
which specially require rapid and reproducible methods. Furthermore, considerations for
development of an automated image analysis protocol were discussed in this thesis. Such an
approach, once fully developed and validated, could be shared with clinical laboratories for
immediate use in clinical islet assessment of fresh (and cryopreserved) islets.
6.3.3 Diffusion of small molecules into the core of pancreatic islets
Determining the minimal incubation time (6 h at 37 °C) for small molecules in aqueous
solutions to diffuse throughout pancreatic islets is a key finding of this project. This finding
has important implications not only for the design of the new islet staining methods, but also
for the development of novel cryopreservation protocols. Unlike for DMSO [72], similar
empirical studies have not previously been performed for non-penetrating cryoprotectants.
The findings of these diffusion studies have applications to not only islet cryopreser-
vation, but also for loading of other therapeutic agents into islets. In principal, a range
of therapeutics agents (antioxidants, anti-apoptotic agents or other targeted therapeutics)
may be used to decrease islet cell death rate in culture or to pre-condition the islets for
transplantation. Knowledge of the diffusion kinetics can help to design suitable incubation
times and conditions to successfully load islets with therapeutic compounds.
The method presented here for studying diffusion of H33342 into pancreatic islets was
inspired by a study done by Durand et al. [202] where gradient of staining from the periphery
to the core of tumor spheroids was used to select cells from different locations using a
fluorescent cell sorter. However, H33342 staining has not been previously used to study
diffusion kinetics. The method developed in this project can be applied for other multicellular
aggregates or even whole organs, through perfusion with a solution of H33342 for defined
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periods followed by fixation and sectioning to reveal penetration of the dye in relation to the
vasculature.
6.3.4 Trehalose potential for cryopreservation of mononuclear cells
The study presented here provided the most comprehensive optimisation of trehalose cry-
opreservation reported to date using highly accurate methods to ensure unbiased reporting
of post-thaw cell viability. DMSO cryopreserved approximately five fold more mononu-
clear cells than the optimised protocol using 400 mM trehalose. The findings of this study,
therefore, suggest that trehalose alone cannot be used to substitute the cryoprotectant DMSO.
Similar studies which used trehalose as a sole cryoprotectant without intracellular tre-
halose delivery are limited. Scheinkonig et al. [130] reported comparable viability of
mononuclear cells cryopreserved in 500 mM trehalose to DMSO, while 1 M or 250 mM
trehalose preserved significantly smaller proportion of viable cells. The colony-forming
ability of cells cryopreserved in 500 mM trehalose was improved compared to DMSO. Mar-
tinetti et al. [203] reported improved post-thaw viability of CD34+ cells using 1 M trehalose
compared to 10 % DMSO.
The difference in the findings of these studies and results reported here may stem from
the methods of viability assessment used. Both studies assessed viability using trypan blue
staining. However, as demonstrated in Chapter 3, this method of viability assessment, without
reporting of cell number, can lead to overestimation of cryosurvival. In addition, the study of
Martinetti et al. studied cryosurvival of CD34+ as opposed to mononuclear cells. Although it
has been reported and discussed in Appendix B that the freezing process is less damaging
to CD34+ cells than other mononuclear cell types, the results of Martinetti et al. are still
surprising since such success of cryopreservation with trehalose as the sole cryoprotectant
has not been reported elsewhere for CD34+ cells or any other cell type.
This study did not explore the addition of trehalose to the standard DMSO protocol
for the cryopreservation of mononuclear cells. However, this topic has been explored
elsewhere [131, 132, 204, 186]. These publications consistently reported improvement of
colony forming ability of cell cryopreserved in media supplemented with trehalose compared
to DMSO alone. In summary, trehalose may have limited potential in protocols where it is
used as the only cryoprotectant but, if used as an additive to the conventional DMSO medium,
it can potentially improve the recovery of haematopoietic cells. Efforts should therefore
be invested in optimisation of these combined protocols and for the development of more
efficient DMSO removal methods.
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6.3.5 Safety and efficacy of permeabilising polymers in primary cells
The use of permeabilising biopolymers PP-50 and PP-75 to enhance intracellular delivery of
trehalose did not improve cryopreservation of splenocytes or pancreatic islets with trehalose.
While efficacy of these polymers has previously been demonstrated for red blood cells [141],
their use in nucleated cells has so far been evaluated only in two publications which utilised
the SAOS-2 cell line [142, 146]. This project, however, is the first report on the efficacy of
these polymers for the cryopreservation of primary nucleated cells.
Sharp et al. reported an improvement in metabolic activity in trehalose-cryopreserved
SAOS-2 cells when PP-50 was added at the concentration of 25 µg/mL but not higher.
Additionally, a decrease in metabolic activity for 1000 µg/mL concentration was shown in a
toxicity test [142]. Mercado et al. provided additional insights into the cellular localisation
of PP-50 and the loaded trehalose. In this report, 25 µg/mL PP-50 was shown to increase
post-thaw survival of SAOS-2 cells. The cells were incubated at pH 7.05 with the polymer
for 2 h and 4 h, respectively, in the two studies. However, as shown in this project, incubation
of splenocytes at pH 7.05 has a detrimental effect on their viability. Long incubations, which
may be necessary for the function of these polymers, could therefore not be utilised for these
primary cells.
This project also identified additional safety concerns related to the use of these polymers.
While concentrations of polymers which do not result in a decrease of cell viability were
determined both here and in previous publications, long-term effects on cells and other safety
concerns, such as biodegradability, were not investigated. One important safety concern
highlighted in this project, which has not been considered previously, is the leakage of
intracellular molecules into the extracellular space through the membrane permeabilised by
the polymer.
Other methods of intracellular delivery have also shown greater potential in cryop-
reservation of nucleated cells. Efficient intracellular uptake accompanied by improved
protection during freezing was reported for TF-1 haematopoietic cell line, fibroblasts and
keratinocytes [54, 135] using engineered pores in the membrane, CHO-K1 cell line trans-
fected with trehalose transporter [205], oocytes by microinjections [137], umbilical cord
white blood cells using trehalose-loaded liposomes [136], adipose-derived stem cells us-
ing trehalose-encapsulated nanoparticles [206] and hepatocytes using modified trehalose
molecules [140]. These results are encouraging but the safety of these methods is yet to
be comprehensively evaluated, together with other factors relevant to their translation into
clinical practice (such as GMP compliance, scalability, cost, etc.).
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6.3.6 Novel cryopreservation protocol for pancreatic islets
The current standard in the field for pancreatic islet cryopreservation is Rajotte’s step-wise
DMSO protocol [73]. While several patients were transplanted with a combination of fresh
and cryopreserved islets in the early years of clinical islet transplantation [25], this approach
has long been abandoned, reportedly because of the GMP-incompatible presence of FCS in
the cryopreserved samples of islets [26].
The ultimate aim of this project was to develop an improved cryopreservation protocol
for pancreatic islets. Using the findings from diffusion studies, a protocol was designed
which combined cryoprotectants DMSO and trehalose in a novel manner. Since prolonged
times are required for small molecules in aqueous solutions to diffuse into the core of the
islet, in this protocol islets are loaded with non-toxic trehalose first and DMSO is added in
the last step before cryopreservation to minimise its toxic effect.
Trehalose has been previously combined with DMSO or glycerol for cryopreservation
of other cell types, in particular haematopoietic cells [131, 132, 204, 186]. Multicellular
structures such as canine trachea rings [207], skin sheets [208, 209] or murine embryos [210]
were also cryopreserved in a mixture of penetrating cryoprotectant and trehalose. In all these
publications, however, trehalose was added at the same time or later than DMSO or glycerol.
Pre-incubation with trehalose followed by addition of penetrating cryoprotectants has not
been studied for the protection of multicellular aggregates. However, long pre-incubation
with trehalose (24 h and 48 h) has been shown to improve DMSO-based cryopreservation
protocol in human embryonic stem cells [211]. Importance of prolonged incubation times
(8 h), as well as incubation temperature of 37 °C, for trehalose uptake was recognised by
Sun et al. in a study of fibroblast desiccation [212]. In these studies, the incubation time
was not needed for diffusion through multicellular structures but rather to allow for passive
diffusion of trehalose to the intracellular space.
The only previous report of cryopreservation of pancreatic islet with trehalose is by
Beattie et al. [83]. In this paper, viability of human islets cryopreserved with a combination
of 2 M DMSO and 300 mM trehalose (added simultaneously) was assessed by total DNA
and insulin measurements and compared to fresh islets. They found no differences in
these parameters, including in glucose stimulation assays. These islets survived under the
mouse kidney capsule for three months after transplantation. However, this protocol was
not compared to a DMSO protocol without addition of trehalose and therefore the exact
contribution of trehalose is not clear. Importantly, my project investigated an appropriate
pre-incubation period with trehalose, as well as generating novel insights into the ideal
concentrations of both cryoprotectants. In vitro function of the thawed islets was also
evaluated comprehensively, including both insulin secretion and cAMP secretion pathways
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and mitochondrial health and function. Together with viability assays, these assays confirmed
the beneficial effect of addition of trehalose to DMSO.
6.3.7 Potential of antioxidants in islet cryopreservation
Pancreatic islets are highly sensitive to oxidative stress due to their low expression of
antioxidant enzymes [127]. ROS accumulate in pancreatic islets during the process of organ
harvesting, islet isolation, culture and cryopreservation and there is extensive evidence that
treatment of islets with antioxidants during these procedures improves their viability and
glucose secretion [151]. Studies on the use of antioxidants in cryopreservation are limited
but beneficial effect has been shown for curcumin [154], ascorbic acid-2 glucoside [213]
and taurine [214]. Findings from this project add to this evidence of protective effect of
antioxidants in islet cryopreservation by studying salidroside and MitoQ.
Salidroside has been shown to improve cryopreservation of red blood cells [156] but its
effect has never been evaluated in pancreatic islets. Here it was shown that salidroside can
increase post-thaw viability, particularly if it is added early before cryopreservation.
The antioxidant properties of MitoQ have been studied in many systems and two clinical
trials have been performed to study its ability to treat liver dysfunction during hepatitis C [162]
and to slow progression of Parkinson’s disease [163]. Its protective effect in ischemia reper-
fusion injury has also been extensively studied in recent years [160, 161]. Here, these studies
were extended to demonstrate that MitoQ can reduce oxidative stress during cryopreservation
of pancreatic islets.
6.3.8 Cryopreservation of other multicellular aggregates
An emerging direction in regenerative and personalised medicine is the use of organoid
technology which enables ex vivo culture of human cells in 3D conditions. Organoids contain
a stem/progenitor cell population which self-organises and spontaneously differentiates in
response to the factors present in the culture medium [215]. This process can in principle
be manipulated in order to direct differentiation towards a desired cell type (e.g. pancreatic
organoids into b -cells for treatment of diabetes). This approach has great potential to
transform future treatments for patients. Similarly, tumor-derived organoids (tumoroids) can
be used for personalised screening of cancer therapies [216].
Regenerative therapies, including organoids, face practical and financial obstacles for
their clinical translation in the near future. A potential solution to this is the creation of HLA-
matched biobanks containing selected organoid lines which will provide suitably matched
cellular therapies for the majority of the population [2]. A key advantage of this approach
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is in its potential to result in almost immediate availability of the treatment, as well as the
ability to extensively validate the efficacy and safety of the cellular therapies prior to their use
in patients. Cryopreservation represents an essential step for generation of these biobanks.
Despite this pressing need, research in regenerative medicine, including organoid tech-
nology, has largely ignored the necessity of cryopreservation for translation of the therapies
into clinical practice. While some protocols for cryopreservation of organoids were pub-
lished [217–219] and specialised media are commercially available, it is not clear how
these protocols were developed or what is their efficacy in cryopreservation of the cells.
Cryopreservation of organoids encapsulated in alginate beads has been studied more exten-
sively [220, 221] but defined and optimised cryopreservation conditions are still unavailable
for most organoid types.
Although this project did not focus on organoid cryopreservation, many of its findings are
relevant to these and other multicellular aggregates. Firstly, it is clear that defining diffusion
rates of cryoprotectants and other substances into multicellular aggregates is key prerequisite
for the development of effective freezing protocols. Pancreatic islets differ from organoids
and tumoroids in their size and architecture and these parameters must therefore be defined
for each organoid type. Methods to study diffusion of small molecules in aqueous solutions
were also outlined in this project and it should be possible to use the same methods to define
optimal incubation periods for organoids.
The novel cryopreservation protocol developed in this project can also be adapted for
the organoids and tumoroids by pre-incubation of cells with non-toxic substances (tre-
halose/antioxidants) until equilibration, followed by loading of penetrating cryoprotectants
and slow-freezing. Again, the specific parameters such as concentrations, incubation times
with non-penetrating and penetrating substances or cooling rates must be optimised for each
multicellular aggregate.
Cryopreservation of whole organs represents significantly greater complexity than freez-
ing of multicellular aggregates. Nevertheless, this project’s findings about loading of non-
toxic cryoprotectants have important implications to these systems. However, additional
methods have to be developed to ensure homogenous cooling and warming throughout the
whole volume, as well as efficient methods for removal of cryoprotectants.
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6.4 Limitations
6.4.1 Assumptions for diffusion studies
In Chapter 3, diffusion of Hoechst 33342 nuclear dye into the core of pancreatic islets was
studied. It was subsequently assumed that these diffusion rates can be used to inform staining
protocols with viability dyes FDA and PI and for design of the length of pre-cryopreservation
incubation with trehalose or antioxidants. This assumption is supported by the fact that
all of these are small molecules dissolved in aqueous solution. However, behaviour of
each of the molecules within the islet may differ. Some molecules freely enter the cells
(H33342, FDA, MitoQ), while others are likely to remain mostly in the extracellular space
(trehalose, salidroside). The extent to which the concentration of these molecules in solution
will decrease by irreversible intracellular uptake, binding to cellular structures or through
metabolism may also be different to Hoechst 33342.
Attempts to replicate these diffusion studies for FDA, PI and trehalose were unsuccessful.
FDA bleaches quickly and studies similar to the one performed with Hoechst 33342 were
therefore not possible: no fluorescent signal was detectable by the end of the tissue processing.
Conversely, PI does not stain many cells within viable islets and lack of staining therefore
does not necessarily imply that the dye has not penetrated to this depth, but rather that the
cells at that location are viable. This would therefore make quantification of diffusion into
the imaged islet sections inaccurate or impossible.
Direct quantification of the diffusion kinetics of trehalose represents additional challenges.
Trehalose is difficult to image without modifications such as conjugation to a fluorescent
compound. While this is possible, attachment of fluorescent label such as FITC dramatically
changes the characteristics of the trehalose: the fluorescently-labelled trehalose would be
significantly larger than unlabelled trehalose and would differs in its ionic charge. Instability
of these fluorescent molecules also may lead to additional complexities. This approach
was therefore not pursued in this project. Imaging of label-free trehalose using Raman
spectroscopy was explored instead. Preliminary experiments with the cell line SAOS-2
showed that quantification of trehalose in cells is possible but further definitive studies are
required to explore this approach further.
6.4.2 Unavailability of islet size data
As discussed in Chapter 3, in addition to viability, the size of cellular aggregates should also
be measured and reported in cryopreservation studies. Development of a reproducible and
unbiased method to compare pre-freeze and post-thaw islet size requires additional studies.
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One approach investigate in this project involved handpicking the islets into a Petri
dish and imaging of the dish under microscope before transferring them into a cryovial
for cryopreservation and repeating the procedure after thawing. While this was technically
possible, it delayed the viability staining immediately post-thaw, which increased variability
of the results, and it increased the mechanical stress on islets due to multiple handpicking
steps. In addition, some islets are necessarily lost during cryopreservation (they may stick to
the cryovial, pipette tips etc.) and this skews the analysis because of the small sample size.
A potential solution to this limitation is by increasing the sample size and measuring
the average size of a larger number of islets in each group. Because this project used
predominantly mouse pancreatic islets, this scale-up was not possible due to the low islet
yield from each mouse. However, this approach would be recommended when the results are
replicated in larger animal models or in human.
6.4.3 Statistical analysis of the bi-modally distributed data
As it was demonstrated in Chapter 5, data obtained from viability measurements of pancreatic
islets at 24 h post-thaw consistently had a bi-modal distribution, wherein a proportion of the
islets contained nearly all alive cell and the rest of the islets were fully dead. This distribution
was unexpected and its analysis represents specific challenges. Statistical analysis for all islet
viability data at 24 h was nevertheless performed using standard methods with the assumption
that this provides suitable approximation of the true means and standard deviations.
This analysis could be improved by creating an appropriate model for the analysis of this
bi-modal distribution consisting of two b distributions (limited by the interval of viability
between 0 and 100 %) for mostly alive and mostly dead islets. Another, more simplistic way
would be to analyse this data as binary (where all mostly viable islets would be assigned
value 1 and all nearly dead islets value 0).
6.4.4 Mouse islets as an experimental model
There are significant differences in the composition and architecture of mouse and human
islets [6], as well as their quality after isolation. Because the mouse pancreas is very small,
a shorter period of enzymatic digestion is needed and efficient purification is possible,
resulting in islets with high viability and purity which are immediately available for use in
the laboratory. On the contrary, human pancreases must undergoes prolonged periods of
enzymatic digestion and isolated islets are then only partially separated from the exocrine
tissue which can release digestive enzymes into the culture. They additionally need to be
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transported from the isolation facility to the research lab, during which the islets can endure
further damage.
The experiments in this project were predominantly performed using mouse islets, and
infrequent and unpredictable availability of human islet did not enable replication of many
of the findings using human cells. This is consistent with the low number of publications
on human islet cryopreservation and is a challenge also faced by other research laboratories.
However, the clinical translation of the main findings of this project, including diffusion
kinetics studies and cryopreservation with trehalose and antioxidants, are critically dependent
on their replication using human islets. Of note, in preliminary experiments where cryopreser-
vation of mouse and human islets were compared, the results were similar in both models
Nonetheless, the efficacy of the novel protocol in cryopreservation of human pancreatic islets
should be examined in future studies.
6.4.5 Short-term cryopreservation
All islet samples in this project were thawed within a maximum of four weeks after their
cryopreservation. However, if this protocol is used as part of a therapy for diabetes, it
must be shown that this method can enable preservation of islets for longer, including up
to several years. It has been recently reported that human pancreatic islets from 43 donors
were successfully cryopreserved for a mean period of 17.6 years. They maintained their
transcriptome profiles and apoptosis levels but had decreased insulin content and decreased
ability to revert diabetes in STZ-induced diabetes mouse model in comparison to freshly
isolated islets [26].
Such studies are very important for the introduction of cryopreservation into clinical islet
transplantation. They are, however, challenging and are best performed in centres which
are specialised in human islet isolation and have facilities to maintain a biobank of islets. A
critical part of such studies is the consistent and monitored storage of the cryopreserved islets,
avoiding unnecessary temperature fluctuations in the liquid nitrogen storage and ensuring
that same methods are used for the pre-freeze and post-thaw assessment of islets which will
possibly be performed by different researchers due to the long duration of the experiment.
6.5 Future directions
6.5.1 Viability assessment
The viability assessment method for pancreatic islets proposed in this project consists of
prolonged incubation with viability dyes and multi-angle light sheet imaging. This method
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must be validated in future experiments by comparing it to results from other in vitro assays
and to the outcome of islet transplantation in mouse models.
An additional key step required for clinical translation and scale-up of the findings of
this study is the development of an automated image analysis protocol. Considerations for
this were discussed in Chapter 3. Because of the considerable variability between images
which caused by the variation in islet size and staining intensity between cells within islet and
between islets, advanced thresholding methods will have to be employed. Ideally, machine
learning algorithms would be created for this analysis which could then be trained for each
laboratory using this technique. Simpler, adaptive thresholding is also possible but the ability
to adapt this to the needs of clinical and research lab may be limited.
6.5.2 Cell cluster survival
During the development of the new cryopreservation protocol, an interesting phenomenon
was observed where the islets became committed to a binary fate during the 24 h after
thawing. A potential mechanism for this has been suggested in Chapter 5.5.1 but the exact
nature of this phenomenon should be investigated in future studies. Specifically, experiments
should be designed to investigate the specific nature of the intra-cluster communication
which, if deficient, leads to cell death. The focus should be not only to identify the adhesion
molecules responsible for the critical cell-cell contact but also pathways which are affected
when this contact ceases to exist and mechanism which may underlie the requirement for a
threshold of cell-cell contact signalling needed to maintain viability of the whole islet. This
could also generate insights into the mechanism of islet death in diabetes.
Once the cellular mechanisms have been identified, therapeutics could be designed to
target this specific pathway in order to mimic the trophic signals received by islet cells from
their neighbouring cells. This approach could provide sufficient time to overcome the initial
critical period of cellular stress after thawing and permit cells to remain attached to other
surviving cells after cryopreservation.
6.5.3 Further modifications of the cryopreservation protocol
In this project it was shown that combinations of different cryoprotectants and additives
can lead to superior viability after cryopreservation. Research in additives should therefore
continue to target the specific sources of damage during freezing and thawing.
Targeting the aspects of the freezing process which may cause damage to cells is the first
approach. In this project DMSO and trehalose have been used but other cryoprotectants are
available and have been tested, such as glycerol [79], ethylene glycol [80] or glucose [83].
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Combining cryoprotectants is also a feasible approach as it could combine the specific
protective effects of different cryoprotectants while keeping their concentration to less toxic
levels [34].
Recently, ice nucleation agents have been the focus of cryopreservation research. Without
interventions, ice nucleation in similar samples does not happen at consistent times and
temperatures. Rather, ice nucleation happens randomly upon creation of the crystallisation
nucleus. Stochastic nucleation contributes to variability between samples through variability
in size and shape of ice crystals, with potential harmful effects on cells. Ice nucleating
agents have been developed to assure homogenous and reproducible nucleation at a de-
sired temperature (without supercooling of water) and these agents show great promise in
cryopreservation [222].
Another class of molecules which could contribute to better cryopreservation are anti-
freeze proteins (AFPs). Found in variety of organisms from cold habitats, these proteins
allow thermal hysteresis (i.e. lowering the freezing point of water) and once freezing
occurs, can bind ice crystals and change their shape. The full potential of these proteins in
cryopreservation is yet to be explored but they show promise for sub-zero preservation of
tissues [223].
Targeting pathways specific to pancreatic islet survival is another attractive option. As
outlined earlier, this will require further research into the mechanisms involved in survival of
pancreatic islets. Anti-apoptotic compounds have been developed for other cell types [224,
225]. Other additives can reduce some of the damage leading to apoptosis or necrosis, such as
antioxidants. In islet cryopreservation, the tested antioxidants so far include curcumin [154],
salidroside and MitoQ (in this study) and all three showed potential to improve the health of
islets. Further validation of these antioxidants, as well as investigation of efficacy of other
protective compounds, could be investigated in future studies.
Although the potential of permeabilising polymers was shown to be limited in cryop-
reservation of splenocytes and pancreatic islets in this project, other methods of intracellular
delivery are available. Methods suitable for pancreatic islets include in particular membrane
phase transition [83] and the use of engineered trehalose molecules [140]. Development of
new permeabilising polymers or modification of the current polymers is also possible.
6.5.4 Validation of the novel cryopreservation protocol
In vivo testing and replication in human islets
The novel cryopreservation protocol developed in this project has already been validated
in vitro. The efficacy of the cryopreserved islets in reversing hyperglycaemia in diabetic mice
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is yet to be demonstrated. Preliminary in vivo experiments were performed but additional
optimisation steps are required, including nephrectomy of the transplanted kidney to ensure
the specific effect of the transplanted islets, or glucose challenge of the mice. Genomic and
transcriptomic analysis of the islets should also be performed to eliminate any undesired
effect of the novel cryopreservation procedure.
Parallel to this, the experiments must be replicated using human pancreatic islets. If
these future experiments provide supportive results, the next step would be the transition to
pre-clinical testing. In order to do this, standardised procedures must be developed which
meet the current Good Manufacturing Practice (GMP) standards and the process must be
scaled up to ensure that appropriate dose of the therapy at an affordable cost can be provided.
Only after that, the new protocol may proceed to clinical testing and become part of therapy
for diabetes.
GMP compliance
Creation of GMP-compliant protocol requires specialised facilities, trained staff and standard-
ised operating procedures to guarantee sterility and safety of the final therapeutic product.
The cells must be characterised throughout the whole process and the final product must
meet defined standards. All materials used during the isolation, culture and transport must
also be supplied by a certified source and be sterile and of standardised quality [226]. Where
possible, xenogenic products should be avoided since their use in therapies requires many
additional considerations regarding safety and quality standardisation of the animal product
used [227].
Use of human tissue in therapy must conform to additional regulations regarding the
selection of suitable donors, testing of the cells and specialised procedures to ensure safe
and standardised methods of transport, processing, preservation and storage. Much more
attention is also given to documentation of all procedures and location of samples and their
final destination to ensure compliance with Human Tissue Authority standards [226].
In this project, consideration was given to procedures and reagents and the possibility
of inclusion in a fully GMP-compliant protocol. The only reagent which will have to be
substituted or omitted is fetal calf serum due to its coming from a xenogenic source and
having largely undefined composition. Unknown components of the serum (including specific
components from unborn animals still undergoing development, rather than adults) can then
cause undesired effects on cell culture [228]. Human serum albumin is already being used
in pre-transplantation islet culture as part of the Edmonton protocol and has also been used
in cryopreservation of islets as an alternative to FCS [229]. Substitution of FCS in the final
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protocol, therefore, is not expected to represent a major challenge, although it will lead to an
increase in the cost of the final therapeutic product.
A potential safety issue specific to tissue cryopreservation is the risk of infection during
liquid nitrogen storage [62] and necessity to ensure monitored maintenance of the liquid
nitrogen storage tanks. The proposed protocol uses a liquid nitrogen-free programmable
freezer, therefore this issue is avoided for the cooling step. For long-term storage, electrical
freezers maintaining temperature of  150 °C are also available which are able to overcome
the issues related to liquid nitrogen storage.
Scaling up
Cryopreservation research is typically conducted using small volume cryovials. In this
project, all pancreatic islet samples were cryopreserved in 400 µL inside 1.8 mL cryovials.
The number of cryopreserved islets was also limited: maximal number of islets cryopreserved
in this volume in one cryovial was 250. For clinical transplantation, these methods must be
scaled up to enable cryopreservation of therapeutic dose of islets (10,000 IEQ per kilogram
body weight [21]) and also to make the final product more affordable.
Cooling and warming of large volumes necessarily entails creation of temperature gra-
dients within the sample, resulting from a slow heat transfer. Unlike in small volume
cryopreservation, the cooling of a large volume is not uniform and creation of ice upon
nucleation does not happen rapidly. Instead, the volume solidifies in a directional manner
(i.e. the cooled surface areas freeze first and the ice then propagates towards the centre of
the sample at the rate of the cooling progress) [230]. A related challenge must be overcome
during the warming of the sample. It is not possible to achieve rapid warming rates in
samples with small surface area to volume ratio. To solve this problem, solutions such as
warming devices [231] or nanoparticle warming [232] have been proposed for thawing of
large volumes.
Because this topic has not been explored in this project, it is also not clear whether the
islet density could be increased without detrimental effect on post-thaw outcome. It has
been previously shown with erythrocytes and hepatocytes that increased cell densities cause
a ’packing effect’ where the post-thaw viability decreases in high cell densities [233, 234].
For small islet densities however, bulk cryopreservation of pancreatic islets in blood freezer
bags of volume up to 250 mL has been explored [235]. It is apparent that scaling up islet
cryopreservation is possible and adaptation of the published bulk cryopreservation methods
may be possible for the protocol developed in this project.
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Clinical trials
After scale-up and development of GMP-compatible protocols, the therapy may proceed
to clinical trials. Because the new protocol introduced in this thesis uses predominantly
agents which have been well characterised and used in the clinical practice or tested in
clinical trials, its translation into clinical practice should not present challenges stemming
from adverse effect of the reagents. Specifically, DMSO is approved for use in clinical bone
marrow transplantation or as part of other therapies and its toxicity has been extensively
studied and adverse effects monitored in patients [113]. Trehalose also has a defined safety
profile and minimal side effects [118]. The proposed antioxidants have also been reported to
be safe: both MitoQ and salidroside-containing extract were successfully tested in clinical
trials [163, 159, 158].
6.6 Conclusion
Islet transplantation is currently performed in very limited numbers. Unavailability of long-
term storage for islets has impact on the organisation of transplantation, quality control of
the tissue and other issues related to multiple-donor transplantation. Although considerable
efforts have been made to develop a clinically-applicable method of islet cryopreservation,
none have progressed to clinical trials.
In this project, I first critically evaluated the viability assessment protocols for both
mononuclear cells and pancreatic islets and identified important limitations of the methods
used routinely in laboratory and clinical practice. For viability assessment of mononuclear
cells, I propose the creation of a standardised method for use in cryobiology that reports
absolute numbers of cells together with viability measurement, ideally in relation to the
pre-freeze absolute number of live cells. For pancreatic islets, I demonstrated that current
viability staining protocols are suboptimal as they only assess peripheral cells and not the
islet core. This may underlie the reported lacked of correlation between islet viability and
clinical outcomes.
I then developed a method of cryopreservation of mouse pancreatic islets which combines
cryopreservation with DMSO with pre-incubation for 6 h at 37 °C with non-toxic cryoprotec-
tant trehalose and antioxidants MitoQ and salidroside. The efficacy of the novel protocol was
validated using functional assays, demonstrating preserved function of b -cell pathways and
mitochondrial health. This method, if validated in vivo and using human islets, is potentially
suitable for clinical translation.
Investigation of cryopreservation of mononuclear cells using trehalose and permeabil-
ising biopolymers PP-50 and PP-75 revealed limited potential of trehalose alone or with
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permeabilising polymers. Polymers appear to require long incubation times which is not
compatible with limited time window for culture of unstimulated mononuclear cells.
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A.1 Demographic information of deceased human donors
Table A.1 Demographics of deceased human organ donors used in experiments
Donor code Donor type Age Gender
D1 DCD 63 F
D2 DBD 49 M
D3 DBD 47 F
D4 DBD 54 F
D5 DBD 20 F
D6 DCD 39 M
D7 DCD 21 F
D8 DCD 20 M
D9 DBD 48 F
D10 DCD 67 M
D11 DBD 52 F
D12 DCD 67 M
D13 DBD 25 M
D14 DBD 69 F
D15 DBD 24 M
D16 DCD 63 M
D17 DCD 67 F
Donor code Donor type Age Gender
D18 DBD 36 F
D19 DBD 58 F
D20 DBD 54 M
D21 DCD 46 M
D22 DBD 27 F
D23 DBD 67 F
D24 DBD 75 M
D25 DBD 51 M
D26 DBD 47 M
D27 DBD 79 F
D28 DCD 30 M
D29 DCD 44 M
D30 DBD 53 F
D31 DCD 69 M
D32 DCD 58 M
D33 DBD 69 M
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A.3 Human islet preparation characteristics




Age (years) 55 51 47
Sex (M/F) F M M
BMI (kg/m2) 27 27 29
Ethnicity white white white
HbA1c n/a n/a n/a
Cause of death intracranial intracranial intracranial -
haemorrhage thrombosis unclassified
Diabetes (Y/N) N N N
Pancreas
Source Kirkcaldy Hull Newport
Warm ischaemia time (h) 7 h 2 min 2 h 12 min 1 h 3 min
Cold ischaemia time (h) ND 14 h 9 min 11 h 24 min
Islet handling and use
Isolation centre Edinburgh Edinburgh Edinburgh
Estimated purity (%) 90 % 54 % 49 %
Estimated viability (%) 85 % n/a n/a
Total culture time (h) 70 h 45 h 70 h
Used in Chapter 2.6.1, 2.6.2 5.2, 5.3.1, 5.3.2, 5.2, 5.4
5.3.3, 5.4
This table adapted from Hart and Powers [236]. n/a = data not available

Appendix B
Flow cytometry panels and gating
strategy
Several antibody panels were used as part of this project and their development and justifi-
cation of the changes are described below together with outline of the gating strategy. The
markers of interest included viability and apoptosis stains, as well as CD3 for T cells, CD19
for B cells and CD34 for pooled haematopoietic progenitors.
All panels used for evaluation of pre-freeze or post-thaw viability of mononuclear cells
contain the combination of Syto13 and viability dye (7-AAD or eFluor780). This combination
ensured that debris can be excluded based on fluorescence, rather than less reliable light
scatter characteristics [88].
In order to better identify progenitor population, additional markers were added to the
first trial antibody panel (A1, Table B.1). Since haematopoietic progenitors are negative
for the lineage markers, I used antibodies against CD3 and CD19 conjugated to a nearly
identical fluorochromes (therefore detected at the same wavelength) and excluded these from
the analysis. In addition, anti-CD133 antibody was used to help identify the progenitor
population as is it another marker expressed by subset of progenitors [237]. The target
population was Syto13+, eFluor 780  CD45+, CD3 , CD19 , SSClow, CD34+. The gating
strategy used for the A1 panel is shown in Figure B.1A.
After performing the first experiments, the panel was optimised by substituting the
CD3 and CD19 antibodies for a more complex cocktail of lineage antibodies, containing
CD2, CD3, CD14, CD16, CD19, CD56 and CD235a, all conjugated to APC fluorochrome.
The anti-CD45 antibody was excluded from the panel since virtually all the detected alive
nucleated cells were positive for this marker. Additionally, the anti-CD133 antibody was
eliminated from the new panel because CD34+ population was easy to identify. The gating
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Fig. B.1 Gating strategies for enumeration of haematopoietic progenitor cells. (A) Gating strategy for
the A1 panel (Table B.1). In Step 1, multiplets are excluded from the analysis. Step 2 is exclusion
of dead cells using the gate on eFluor 780 positive cells, followed by selection of Syto13 positive
nucleated cells in Step 3. In Step 4, cells positive for CD45 are selected. Exclusion of T cell and B
cells from the analysis using the CD3 and CD19 markers is shown in Step 5. Finally, haematopoietic
progenitors are selected as CD34+ SSClow cells in Step 6. (B) Gating strategy for the B1 panel
(Table B.1). Steps 1 and 3 are the same as in the previous strategy. In Step 2, 7-AAD viability dye
is used for exclusion of dead cells instead of eFluor 780. Following Step 3, lineage negative cells
are selected from the population of alive nucleated cells and finally, haematopoietic progenitors are
identified as the CD34+ SSClow cell subset. FSC-W = forward scatter width, FSC-A = forward scatter
area, SSC = side scatter, 7-AAD = 7- aminoactinomycin, Lin = lineage markers.
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strategy for the resulting panel B1 (Table B.1) is shown at Figure B.1B, identifying the target
population of 7-AAD , Syto 13+, Lin , SSClow, CD34+ cells.
Simplified panel was also developed for experiments with limited amount of cells which
combined viability and apoptosis staining, CD34, CD3 and CD19 in one panel (Panel C,
Table B.1). This panel did not use the lineage cocktail but contained CD3 and CD19 which
were not only used to quantify T and B cells but also to exclude lineage committed cells
before identification of progenitors by the CD34 marker.
Last panel (Panel D, Table B.1) was used for flow cytometry of cells collected at the end
of the CFU assay and was used for identification of myeloid and erythroid cell types.
The freezing process has been previously shown to be less damaging to haematopoietic
progenitors than other cell subsets [63]. This is consistent with data from these experiments:
the frequencies of haematopoietic progenitors were typically higher in conditions which had
low overall viability of the mixed cell population (Figure B.2). To better asses the suitability
of cryoprotectant for preservation of CD34+ cells, the absolute number of CD34+ cells after
cryopreservation will be compared to that of fresh sample instead of simply comparing the
frequencies of CD34+ cells in the total population.
Fig. B.2 Comparison of cryopreservation protocols efficacy and frequencies of CD34+ cells. (A) Ab-
solute cell count of alive nucleated cells determined by flow cytometry analysis in BD TrucountTM
tubes for different cryopreservation conditions. (B) Frequency of CD34+ cells out of alive nucleated
cell subset for different cryopreservation conditions. The colour coding of all the heat maps follows
the scale on the bottom of this figure with the minimum value coded by blue and maximum value
coded by red.

































































































































































































































































Efficacy of permeabilising polymers in
islet cryopreservation
C.1 Toxicity of polymers for pancreatic islets
In Chapter 4, PP-50 was shown to lead to a decrease in viability of human splenocytes
incubated with polymer concentrations over 200 µg/mL. To select a safe concentration of
polymer for pancreatic islets, similar toxicity assays were performed.
Mouse pancreatic islets were incubated with 0 – 800 µg/mL of PP-50 and PP-75 for 2,
24 or 48 h at standard culture conditions. At the end of the incubation time, viability of all
islets was measured using FDA/PI staining. No decrease in viability was observed over 48 h
period in all concentrations tested for both polymers (Figures C.1A and B).
However, it is possible that the toxicity could only be detectable if trehalose is also
present. The experiments were therefore repeated using 100 µg/mL of PP-50 or PP-75 and
range of trehalose concentrations (0 – 800 mM). Again, no decrease in viability was observed
with the non-toxic trehalose concentrations (Figures C.1C and D). The statistically significant
viability decrease seen in 400 mM and 800 mM trehalose with polymers was mainly caused
by trehalose, as has been shown in Section 5.2.2 of Chapter 5.
Using one human islet donor, the toxicity test was repeated for selected conditions
(200 mM trehalose, 100 µg/mL of PP-50 and PP-75 or their combinations). Again, viability
was measured at 0 h, 2 h, 24 h and 48 h of incubation by FDA/PI staining. This data from
human islets confirmed the findings from the mouse model. Even long-term incubation
of islets with PP-50 or PP-75 at this concentration did not result in a decrease in viability.
They are also safe to use for short incubation times in combination with 200 mM trehalose
(Figure C.1E).
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Fig. C.1 Toxicity of PP-50 and PP-75 for mouse and human pancreatic islets. (A) Viability of mouse
pancreatic islets after incubation with different concentrations of PP-50 (0 – 800 µg/mL; mean ± SD
of one experiments shown, viability of each condition calculated using 6 – 13 islets per experiment).
(B) Viability of mouse pancreatic islets after incubation with different concentrations of PP-75 (0 –
800 µg/mL; mean ± SD of one experiments shown, viability of each condition calculated using 7 – 13
islets per experiment). (C) Viability of mouse pancreatic islets after incubation with 100 µg/mL PP-50
and different concentrations of trehalose (0 – 800 mM; mean ± SD of one experiments shown, viability
of each condition calculated using 1 – 13 islets per experiment). (D) Viability of mouse pancreatic
islets after incubation with 100 µg/mL PP-75 and different concentrations of trehalose (0 – 800 mM;
mean ± SD of one experiments shown, viability of each condition calculated using 2 – 13 islets per
experiment). (E) Viability of human pancreatic islets after incubation with 2 M DMSO, 200 mM
trehalose, 100 µg/mL PP-50 or PP-75 and their combinations; mean ± SD of one experiments shown,
viability of each condition calculated using 3 – 13 islets per experiment). All groups were compared
to control (0 µg/mL, 0 mM or Control) by two-way ANOVA followed by Dunnett test to calculate
p-values. Significant differences are marked by asterisks: ⇤ p  0.05, ⇤⇤ p  0.01; ⇤⇤⇤ p  0.001;
⇤⇤⇤⇤ p  0.0001.
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C.2 Polymer attachment to cell membrane
The attachment of the polymer to the cell membrane is necessary to facilitate loading of
extracellular molecules such as trehalose into the intracellular space. A fluorescent polymer
was therefore synthesised by conjugating AlexaFluor 647 (AF647) to PP-50 and used to
investigate its localisation in islet cells after incubation.
Whole or dissociated mouse pancreatic islets were incubated with fluorescent PP-50
for 4 – 24 h. At the end of the incubation time, the islets/single cells were stained with
Hoechst 33342 nuclear dye and PI and imaged on a confocal microscope.
In both dissociated islet cells and whole islets experiments, fluorescent PP-50 only
entered selected cells while most did not have any AF647-PP-50 staining within the cells or
on their surface. Interestingly, the cells which contained AF647-PP-50 also stained positively
for propidium iodide which normally stains only dead cells (Figures C.2A and B). The
experiment was repeated and FDA staining was added to determine viability of the loaded
cells are viable or not. In Figure C.2C, both cells which stained positively for AF647-PP-50
and PI lacked FDA staining, which is consistent with the conclusion that these cells are no
longer viable.
To fully understand the result of this experiment, it is important to consider the mechanism
of viability staining with FDA and PI. PI is a membrane impermeable dye binding nuclear
acids. It can only enter cells without an intact membrane, a marker typical for dead cells.
The mechanism of fluorescein diacetate (FDA) staining uses two characteristics of live cells:
active enzymes in the cytoplasm to cleave non-fluorescent FDA to produce fluorescent FITC
molecule, and membrane integrity of live cells which ensures that the FITC remains locked
in the cytoplasm and does not leak outside of the cells.
Two hypotheses could be postulated to explain the result observed in these experiments:
1. The polymer is only present in dead cells
• The polymer only enters dead cells OR
• The polymer kills the cells as it enters some of them.
2. The presence of polymer leads to the staining of live cells by PI
• Polymer increases fluidity of the membrane, allowing PI to enter the cells AND
• Polymer increases fluidity of the membrane so cleaved FITC leaks outside and
does not accumulate in cytoplasm in detectable levels.
Of note, PP-50 appears to be accumulating in the cytoplasm since the staining is stronger
than in the extracellular space. This observation is contrary to hypothesis 2 above and
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Fig. C.2 Attachment of fluorescent polymer to pancreatic islet cells. All images taken by a confocal
microscope. (A) Dissociated mouse pancreatic islet cells incubated with AF647-PP50 for 4 h and
subsequently stained with H33342 and PI. (B) Whole mouse pancreatic islet cells incubated with
AF647-PP50 for 4 h and subsequently stained with H33342 and PI. (C) Whole mouse pancreatic
islet cells incubated with AF647-PP50 for 24 h and subsequently stained with FDA, H33342 and PI.
AF647 = AlexaFluor 647; FDA = fluorescein diacetate; H33342 = Hoechst 33342; PI = propidium
iodide.
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suggests the polymer accumulated in dead cells. Nonetheless, FITC has very different
electrochemical characteristics from the fluorescent polymer and it is theoretically possible
for only one to leak out from the intracellular space. Nevertheless, uncontrolled leakage
of any molecules from cells caused by PP-50 is a safety concern. If the cells are indeed
dead, it is not clear whether they were already dead at the start of the experiment or died as
a consequence of the polymer entrance. This causality could be further investigated using
time-lapse imaging.
Irrespective of whether the polymer accumulates in live or dead cells, it is important
to note that it selectively enters only some, and not all, cells. The cause of this variation
is not clear (unless some cells are indeed dead from the beginning of the experiment and
selectively accumulate the polymer). Nonetheless, these results suggest that polymers would
not be suitable for safe intracellular intracellular loading of trehalose into all cells. A key
limitation of this experiment is that he characteristics of the polymer may have changed by
the conjugation to the fluorochrome.
A polymer with the same label was used to study attachment of PP-50 in SAOS-2 cells by
Mercado et al. [146]. In this publication, it was shown that PP-50 enabled labeled trehalose to
enter cells without affecting the viability of cells (measured by PI). In addition, AF647-PP-50
was detected in most cells on the presented images. Although the authors did not include
appropriate controls to show that PI staining was working, this result contradicts what was
found here for pancreatic islet cells. SAOS-2 is a cell line consisting of single cell type
and it is expected that most cells would be viable (since all non-viable cells would detach
from the surface and be washed off). However, pancreatic islets consist of many cell types
with different characteristics and dead cells would remain within the sample since they are
analysed in suspension culture. These and other differences between the cell types could
explain the discordant findings in these two studies.
C.3 Polymer efficacy in cryopreservation
To study how addition of polymer affects the cryopreservation with trehalose, experiments
were conducted using trehalose alone and in the newly developed protocol (DT6h).
First, mouse pancreatic islets were cryopreserved with 200 mM trehalose ± 100 µg/mL
PP-50/PP-75 incubated for 2 or 24 h or without incubation. Consistent with all other results,
the viabilities obtained in cryopreservation with trehalose alone were very low. The presence
of either of the polymers did not affect the post-thaw viabilities (Figure C.3A).
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Fig. C.3 Efficacy of PP-50 and PP-75 in pancreatic islet cryopreservation. (A) Viability of mouse
pancreatic islets incubated with 200 mM trehalose ± 100 µg/mL PP-50 or PP-75 for 0 h, 2 h or
24 h measured immediately post-thaw. (B) Viability of human pancreatic islets incubated with
200 mM trehalose ± 100 µg/mL PP-50 or PP-75 for 0 h, 2 h or 24 h measured immediately post-thaw
(DMSO and no cryoprotectant controls included). (C) Viability of mouse pancreatic islets incubated
with 200 mM trehalose ± 100 µg/mL PP-50 or PP-75 for 6 h, followed by DMSO addition and
cryopreservation; measured immediately post-thaw. (D) Viability of mouse pancreatic islets incubated
with 200 mM trehalose ± 100 µg/mL PP-50 or PP-75 for 6 h, followed by DMSO addition and
cryopreservation; measured 24 h post-thaw. Triangles represent viabilities from individual replicates,
horizontal lines represent mean. No statistical analysis was performed for (A) and(B), in (C) and (D),
all groups were compared to control (DT6h) by two-way ANOVA followed by Dunnett test to calculate
p-values. Significant differences (p  0.05) are marked by asterisks. no CPA = nocryoprotectant;
T = 200 mM trehalose, DT6h = DMSO + trehalose with 6 h incubation.
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The experiment was then repeated using human pancreatic islets. Although the post-thaw
viabilities were on average higher than in mouse islets, the addition of polymer again did not
lead to higher viability compared to trehalose alone (Figure C.3B).
Next, three different concentrations of PP-50 and PP-75 (10, 100 and 1000 µg/mL) were
tested in the DT6h protocol. Viability was measured immediately post-thaw and 24 h post
thaw. Immediately post-thaw, the viabilities of the two lower concentrations of both polymers
was comparable to the DT6h without any polymer. However, after 24 h post-thaw culture,
there was a decrease in viability in all conditions where PP-50 and PP-75 were used, including
significant decrease for the highest PP-75 concentration (Figure C.3C). It is noteworthy that
the viability in the DT6h condition without any polymer was exceptionally high in all three
replicates of the experiment; increasing this further would not be possible. However, the
addition of the polymer led to a decrease in viability in all concentrations and both variants.
Taken together, this data indicate that PP-50 and PP-75 do not improve cryopreservation
with neither trehalose alone nor the novel DMSO + trehalose protocol, although they were
used in non-toxic concentrations. This result was consistent with the data on the splenocyte
cryopreservation in Section 4.5.2 of Chapter 4. The lack of efficacy may stem from inability




Optimisation of in vitro functional assays
D.1 Measurements immediately versus 24h post-thaw
Pancreatic islets were cryopreserved in DMSO, no cryoprotectant agent (no CPA) or DMSO
+ trehalose with 3 h incubation time (DT3h). After thawing, ATP/ADP ratios and glucose-
stimulated insulin secretion (GSIS) were measured immediately or after 24 h post-thaw
culture (fresh islet used as controls).
ATP/ADP ratios obtained from islets immediately post-thaw were very low for all
cryopreservation conditions. The concentrations of ADP did not significantly differ from
fresh islets (data not shown) which suggests that immediately after thawing, the ATP stores
are depleted. In living and functioning islets, new ATP would be synthesised to re-establish
the balance and indeed, in the successful conditions, the ATP/ADP ratio rises again after the
post-thaw culture period. On the contrary, when no cryoprotectant was used (and all islets
presumably died during the freezing process), new ATP is not synthesised and ATP/ADP
ratio remained low (Figure D.1A). This data suggests that early measurement of ATP/ADP
is less informative and it may be more appropriate to measure the ATP/ADP ratio is after a
period of time needed for recovery of the ATP stores.
In the GSIS assay, a similar observation was made: none of the cryopreservation condi-
tions resulted in islets which would respond to high levels of glucose immediately post-thaw.
In addition, relatively high insulin concentrations were measured in all cryopreserved islets
even in 3.3 mM glucose concentration (Figure D.1B). This could point to the release of
insulin which was already present in the islets (as opposed to newly formed and actively
secreted) and is released due to cryopreservation-induced damage regardless of the glucose
concentration. After 24 h culture period, partial recovery of islets in the successful cryopreser-
vation conditions occurred, with decreased secretion of insulin at low glucose concentration
and stimulation-dependent release of insulin in high glucose (Figure D.1C). Conversely, the
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Fig. D.1 Optimisation of in vitro functional assays for pancreatic islets and their analysis.
(A) ATP/ADP ratios in fresh and cryopreserved islets (n = 2 – 3). (B) Insulin secretion of fresh
and cryopreserved islets stimulated with 3.3 mM and 16.7 mM glucose measured immediately post-
thaw (n = 2 – 3). (C) Insulin secretion of fresh and cryopreserved islets stimulated with 3.3 mM
and 16.7 mM glucose measured 24 h post-thaw (n = 2 – 3). (D) Stimulation index (ratio of insulin
concentration secreted in 16.7 mM glucose and in 3.3 mM glucose) of fresh and cryopreserved
islets stimulated with 3.3 mM and 16.7 mM glucose (n = 2 – 3). (E) Insulin secretion of fresh and
cryopreserved islets stimulated with 3.3 mM and 16.7 mM glucose measured 24 h post-thaw, not
normalised (n = 2 – 3). (F) Insulin secretion of fresh and cryopreserved islets stimulated with 3.3 mM
and 16.7 mM glucose measured 24 h post-thaw, normalised to DNA content (n = 2 – 3). Bars repre-
sent mean ± SD, triangles represent individual measurements from each replicate, horizontal lines
represent mean. Differences in (A) were measured by repeated measures one-way ANOVA, statistical
differences (p  0.05) are marked by an asterisk. no CPA = no cryoprotectant; DT3h = DMSO +
trehalose with 3 h incubation time.
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unsuccessfully cryopreserved islets in no CPA condition still released high levels of insulin
in 3.3 mM glucose and decrease in insulin secretion in 16.7 mM glucose (potentially because
the stores of insulin were already depleted after the stimulation in low glucose). Because of
the dysregulated release of insulin immediately after thawing, a period of recovery should
therefore elapse to enable reliable measurement of post-thaw function of islets.
D.2 Insulin concentration versus stimulation index
GSIS assay data is typically presented in the literature in the form of a stimulation index.
This is the ratio of the insulin concentration released in high glucose compared to low glucose
concentration. Higher ratios are often associated with improved performance of islets. These
ratios were calculated for the data in Figures D.1B and C and are shown in Figure D.1D.
Because the concentration of insulin released by fresh islets stimulated with 3.3 mM
glucose were very small (below 1), calculating the ratios introduced high variability in this
group. In all cryopreserved conditions, the calculated stimulation index was very small both
immediately and 24 h post-thaw. This was because insulin release in 3.3 mM glucose was
much higher than in fresh islets. In one replicate of no CPA islets measured immediately
post-thaw, the ratio measured was similar to that of fresh islets, presumably because of the
high variability in insulin release. It is clear, however, that this is not indicative of improved
islet function in the sample because it contained only dead islets.
This data suggest that displaying the GSIS data only as stimulation indices would
disregard some of the important information generated by the assay. It can be reliably used
to compare islet function if the insulin release in basal glucose concentration (in this case,
3.3 mM) is similar for all the measured conditions. However, in the case of cryopreservation,
this cannot be assumed and results should be displayed as the measured concentrations in
low and high glucose concentrations.
D.3 Normalisation of GSIS data
Significant variability between the replicates was observed in the GSIS assay (Figure D.1E),
possibly due to the variability in islet size. To test whether normalisation could remove some
of this variability, islet pellets were kept from all GSIS samples and DNA extracted and
quantified. Insulin concentrations of each sample were then normalised to its DNA content
(Figure D.1F).
While the normalisation reduced variability very well for fresh islets, the variability
persisted in the cryopreservation groups even after normalisation. These observations may
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be a consequence of the loss of viable islet mass during the cryopreservation and post-thaw
culture. At the beginning of the assay, 8 – 10 islets per sample were randomly selected and the
assay performed in triplicates for all conditions. The results in Chapter 5.5.1 demonstrated
that some of the islets at 24 h after thawing are entirely dead and some entirely alive. It
may be expected that the presence of dead islets does not increase the insulin concentration
(other than perhaps through leakage) but will increase the DNA content. Because only
8 – 10 islets were used for each group, this may result in significant variation between
replicates. This variance would theoretically have more impact on conditions which contain
large proportion of dead islets. Indeed, as shown for the no CPA condition in Figures D.1E
and F, normalisation to DNA content actually increased, rather than decreased variability.
One option to eliminate this variability would be to perform the assay only on the
surviving islets. However, it is currently not possible to visually distinguish between live
and dead islets at 24 h after thawing without viability staining. Moreover, this would
provide limited information about the overall performance of the particular cryopreservation
method. Another solution would be to increase the number of replicates per experimental
sample with implication on the cost of the assay. From the available results, normalised
and non-normalised data still provided the same conclusion about a performance of the
cryopreservation condition. It is therefore not convincing that DNA normalisation adds value
to the data obtained from cryopreserved pancreatic islets and for the purposes of this thesis,
non-normalised data were presented.
In conclusion, the stress during cryopreservation appears to cause a transient decrease
in function immediately after cryopreservation which recovers after a period of culture.
Obtaining functional data from cryopreserved pancreatic islets should therefore be performed
at a later time point, as demonstrated here on the examples of ATP/ADP ratio assay and
GSIS assay. Furthermore, for cryopreservation data, it is necessary to display the GSIS
results as the insulin concentrations in both low and high glucose concentrations instead of
the stimulation index which could disregard the increase of insulin release in non-stimulated
islets for unsuccessful cryopreservation conditions. Normalisation of the GSIS data to the
amount of DNA introduced an additional source of variability. A future approach to reduce
variability would therefore be to increase the number of replicates instead of normalisation.
Appendix E
STZ-induced diabetes in NSG mice
E.1 Dose of STZ
There are no standardised protocols for induction of diabetes with STZ. Different research
groups use different route for administration of STZ (intraperitoneal versus intravenous)
or preparation of the STZ solution. Different mouse strains and genders also require very
different doses of STZ for safe but effective induction of diabetes. For example, male BALB/c
mice require five injections of 60 – 70 mg/kg of STZ while CD-1 Nude mice only 30 mg/kg.
Moreover, it is possible to induce diabetes with a single high dose of STZ to achieve severe
injury with no remaining insulin production or use multiple smaller doses of STZ for milder
diabetes with some residual b -cell function [238]. Choosing the right amount of injury is
critical to ensure that it can be rescued by the intended dose of the treatment (in this case fresh
and cryopreserved islets) but at the same time, the animals should not recover spontaneously.
For this reason, the model using multiple low doses of STZ was chosen in this project.
Because one of the future aims of this project is to test the function of cryopreserved
human islets in vivo, the choice of an immunodeficient mouse strain was important. The
NSG immunodeficient mouse strain is well established and was previously used to study
survival of fresh and cryopreserved mouse or human pancreatic islets and was also used for
the STZ-induced diabetes experiments. However, protocols for this mouse strain have not
been published and protocols for generation of STZ-induced diabetic NSG mice required
optimisation.
The first dose tested was 75 mg/kg intraperitoneally for three consecutive days. This
dose was used to induce diabetes in another strain of immunodeficient mice, Scid/Beige
mice, in a publication by Lima et al. [239]. Using this dose, rapid onset of diabetes was
observed, reaching severe levels in less than one week after the first injection. This resulted
in rapid weight loss, indicating toxic effect of this high dose of STZ. The experiment had to
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Fig. E.1 Optimisation of STZ dose in the in vivo diabetes model using NSG mice. (A) Blood glucose
levels and weight losses of individual NSG mice injected with 75 mg/kg STZ for 3 consecutive days
(n = 6). (B) Blood glucose levels and weight losses of individual NSG mice injected with 50 mg/kg
STZ for 5 consecutive days (n = 8). (C) Blood glucose levels and weight losses of individual NSG
mice injected with 40 mg/kg STZ for 5 consecutive days (n = 9). Three separate experiments are
shown in figures (A), (B) and (C), all experimental animals shown in a single graph were tested
concurrently. Each line connects the measured values from an individual animal. Days of STZ
injections (STZ) and islet transplantations under kidney capsule (Tx) are indicated in the graphs by
vertical lines. STZ = streptozotocin; Tx = transplantation.
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be terminated for two out of six mice (day 9 and 12) because the mice approached the 20 %
weight loss, which is an endpoint stipulated by the Home Office (Figure E.1A).
Two lower doses of STZ were therefore tested: i.p. injections of 50 mg/kg in five
consecutive days and 40 mg/kg in five consecutive days. These doses work well for variety of
mouse strains [238]. In NSG mice, five 50 mg/kg injection caused slower onset of diabetes
but still resulted in weight loss in all of the animals (two out of eight terminated due to
20 % weight loss on day 17, Figure E.1B). Five injections of 40 mg/kg did not result in any
significant weight loss but there was high variability between the glucose levels in individual
mice. Three out of 9 animals did not develop diabetes at all while some have reached severe
levels of glucose in about two weeks after the first injection (Figure E.1C). The dose used by
The Jackson Laboratory in commercially available mice is also 40 mg/kg for five consecutive
days [240].
To conclude, the two higher doses tested (75 mg/kg for 3 consecutive days and 50 mg/kg
for five consecutive days intraperitoneally) caused rapid weight loss in most of the injected
animals. Lower, non-toxic dose must therefore be used in further experiments. Although
significant variability in glucose levels was observed with the lowest dose (40 mg/kg for
5 consecutive days), there was no weight loss associated with this. This dose was therefore
chosen for the future experiments. Experiments included larger groups of animals so that
non-diabetic animals can potentially be excluded from the group before the transplantation.
E.2 Dose of pancreatic islets for transplantation
In the initial experiments, 300 fresh islets were transplanted under the kidney capsule of each
diabetic NSG mice (based on a recommendation by Dr. Maja Wallberg for a minimum islet
dose to reverse diabetes) but in only 3 out of 6 animals this led to a decrease in blood glucose
levels after the transplantation (data not shown). The possible reasons include low dose of
transplanted pancreatic islets or variations introduced by the technique of the surgeon.
Male NSG mice were next rendered diabetic using i.p. injections of 50 mg/kg STZ
for five consecutive days (Figure E.1B) and transplanted with 300 or 400 freshly isolated
pancreatic islets from male C57BL/6JAX mice under the kidney capsule (3 mice per group).
Body weight and blood glucose was measured regularly and the experiment was terminated
4 weeks after the transplantation.
The body weights and blood glucose levels were well matched in the two groups before
transplantation. After transplantation, there was an increase in body weight for both groups
but it was more pronounced in the group transplanted with higher dose of islets (Figure E.2A).
There was high variability in the blood glucose level within the groups (Figure E.2B).
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Fig. E.2 Optimisation of pancreatic islet dose for transplantation under the kidney capsule of diabetic
NSG mice. (A) Average weight losses of animals injected with 50 mg/kg STZ for 5 consecutive days
and transplanted with 300 or 400 fresh mouse islets under the kidney capsule (n = 3 animals per group).
(B) Average blood glucose levels of animals injected with 50 mg/kg STZ for 5 consecutive days and
transplanted with 300 or 400 fresh mouse islets under the kidney capsule (n = 3 animals per group).
(C) Blood glucose levels of individual NSG mice injected with 50 mg/kg STZ for 5 consecutive days
and transplanted with 300 or 400 fresh mouse pancreatic islets under the kidney capsule (n = 6). All
experimental animals shown were tested concurrently. In (A) to (C), days of STZ injections (STZ),
islet transplantations under kidney capsule (Tx) and the end of the experiment (Cull) are indicated
in the graphs by vertical lines. STZ = streptozotocin; Tx = transplantation. (D) Correlation between
measurements from the portable glucometer and biochemical assay measured by the CBAL laboratory
(n = 38). Line of identity (slope = 1) is displayed on the graph (solid line), as well as the limit of the
portable glucose meter (horizontal dashed line). Nonparametric Spearman’s correlation coefficient
(rs) was calculated and is displayed together with the p-value.
E.3 Validation of the portable glucometer 227
Inspection of the data from the individual animals reveals that in both groups, there were
animals in which the diabetes was reversed and animals in which there was only slight (or
temporary) decrease in blood glucose levels. Specifically, only one out of three animals
transplanted with 300 islets and two out of three animals transplanted with 400 islets were
not diabetic at the end of the experiment (Figure E.2C). When the transplanted kidneys were
excised at the end of the experiment, very little or no visible islets were present in the graft
under the kidney capsule of mice in which the diabetes was not reversed (data not shown).
The animals did not differ significantly in age, weight and were not housed in different
cages. The animals were all transplanted by one surgeon on the same day within the minimal
time possible (2 h). No technical errors or differences between individual transplantations
were observed and the islets were clearly visible under the kidney capsule at the time of
injection in all animals.
In conclusion, there is inherent biological variation in these experiments, the cause of
which was not identified. Increasing the dose of fresh pancreatic islets from 300 to 400 per
animal still did not guarantee the reversal of diabetes in all animals.
E.3 Validation of the portable glucometer
A comprehensive testing or glucometers was conducted by Togashi et al. where they reported
that most glucometers record higher values than the biochemical test but the values generally
correlated with the biochemistry results [241]. To evaluate the particular model of glucometer
used in this project (iHealth Smart), multiple blood serum samples were taken over the course
of the in vivo experiments at the same time as measurements by the portable glucose meter
and sent for a biochemical analysis to the CBAL laboratory. Measurements which were over
the limit of the portable glucose meter (> 33.3 mmol/L) were excluded from the analysis
and data from the matched measurements were then correlated.
The result suggested a strong correlation of the two measurements (p  0.0001), although
low glucose concentrations were slightly overestimated and high values slightly underes-
timated by the iHealth Smart glucose meter, as can be seen in Figure E.2D. The biggest
error of the glucose meter was observed for values close to the limit (33.3 mmol/L). In the
available publication, only 1 out of 11 glucometers recorder lower values than biochemical
test, the rest showed higher values, across the range of glucose concentrations [241].
